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Abstract 
The primary objective of this research was to examine the e:-.:tent of adverse drug 
events (A DEs) in three age-related subgrmzps ofpaticms (children aged 5 17 years. adults 
aged 2: 18 years and elderly aged :;::65 years) either presenting to emergency departments 
(EDs) or admitted to hospitals in the Canadian province of Newfoundland and Labrador 
(NL). As secondary objectives. this research classified A DEs according to severity and 
preventability (wherever possible) and identified patients' demographic and clinical 
characteristics that can predict occurrence of A DEs. 
This dissertation research was comprised of three empirical studies. each of which 
led to a manuscript for publication. The first and second studies used retrospective 
reviews of patients· ED charts to determine prevalence. severity. and preventability of 
A DEs among children and adults presenting to EDs. The third study used a population-
based retrospective coho11 design over a 12-year period to detect adverse drug reactions 
(A DRs) using diagnosis codes in the hospital d ischarge abstract. The aim of this study 
was to determine the incidence of A DRs among elderly hospitalized patients and to 
assess patient-related risk of A DRs. 
We found that 2.1 % (95% Cl: 1.6-2.6) of pediatric ED visits and 2.4% (95% Cl: 
1.8-3.0) of adult ED visits were due to serious A DEs. of which 20% and 29%. 
respectively. were considered preventable. In the cohort of elderly hospitalized patients. 
the incidence of ADRs was 15.2 per 1.000 person·years {95% CJ: 14.8- 15.7). Children 
with and without ADE·rcla!Cd ED visits were similar with respect to mean age and mean 
number of medications. whereas adults with ADE·related ED visits were older. 
prescribed more medications and had a higher number of comorbidities compared to their 
non-A DE counterparts. In elderly hospitalized patients. comorbidity from chronic 
diseases and the severity ofpaticnr"s underlying illness. rather than advancing age and 
sex. increased the likelihood of recurrent events. The drug classes.associated with or 
implicated to A DEs were dissimilar among the three age-related subgroups of patients. 
I3y comprising the findings of the three studies together. we concluded that an 
ADE prevention strategy should be targeted at patient-specific physiologic and functional 
characteristics, and high-risk medications. as opposed to focusing individual's 
chronological age. 
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CHAPTER 1 
Introduction and Overview 
1.1 The context of Patient Safety: Driving Forces and Policy 
Implementation 
Patient safety is a major issue for everyone- healthcare professionals. providers 
and patients. The potential for medical care to cause hann has long been recognized 
throughout the history of medicine. However. the awareness of the problem of patient 
safety \\as stimulated follO\\ing the rising rate of litigation in the 1970s and 1980s. which 
led to the development of risk·management programs in the United States. and later 
elsewhere 1 • Starting from almost exclusively a legal and financial focus to protect 
institutional concerns. the error prevention movement has accelerated through addressing 
clinical issues and acting as a gateway to the underlying problem of patient safety. 
The topic of patient safety has become a focus of clinical care and research in 
recent years. Several studies have revealed the scale of harm to patients from healthcare 
management rather than disease. In the United States. the Harvard Medical Practice 
Study ~ reported that patients were unintemionally harmed by treatment in almost 4% of 
admissions in New York State. The resulting disability was slight or temporary for 70% 
of these patients. but in 7% it was pennanent and I-I.% of these patients died. panly as a 
result of their treatment. In the United Kingdom. a review of patient records indicated a 
\0.8% adverse event rate. of which about half were judged to be preventable 3. The 
Bristol inquiry was one of the few high-profile cases in Britain that painted a picture of a 
flawed system of care with poor teamwork between professionals by providing 
inadequacies at every point. from referral to diagnosis. surgery. and intensive care. The 
inquiry has continued to focus professional and public al\e!llion on patient safety in a 
manner unprecedented in both its depth and for the extent of professional involvement"· 
Patient safety practices include scientitic knowledge thai continually informs 
improvement of efforts and reduces risk of adverse events related to exposure to medical 
care 0 . The increasing incidence of adverse events in health care has led to a gro\\ ing 
concern in a number of countries about patient safety. and thus this issue remains a 
fundamental principle of patient care and a critical component of quality management 1• 
Among the recent works on patient safety. the Inst itute of Medicine's (!OM) landmark 
report "To err is human: building a M!fer healrh -\YS!em". a publication based·on a 
systematic review of patient safety·related medical literature. has aroused an enonnous 
response 7. Having fOcused on the potential tOr hann in modern medicine. the !OM repon 
investigated preventable adverse drug events. the role of systems failures in the aetiology 
of medical errors. and the effects oft he healthcare workforce on safety 2· 8· 9. The repo11 
estimated that 44.000 to 98.000 patients die every year because of medical error in the 
Unitt'd States alont'. Medical errors included all problems that commonly occur during 
the course of providing health care such as adverse drug events and improper 
transfusions. surgical inj uries and wrong-site surgery. suicides. and mistaken patient 
identities. Because reducing medical errors can save human lives and health care costs. 
the IOM repo11 called for a broad national ef!011 to include establishment of a Centre tOr 
Patient Safety. expanded reporting of adverse events. development of safety programs in 
health care organizations. and attention by regulators. health care purchasers, and 
professional societies 7. A number of legislative and regulatory initiatives to document 
medical errors and to search tOr solutions have been staned based on the strong 
recommendation of the report to set a goa l of reducing error related mo11ality in the 
Un ited States by 50% over a 5-year period 6. 
Several important new initiatives in the last few decades have been undertaken. 
especially by developed nations to build and advance safe r health ca re systems for their 
populations. These initiatives underline the increasing attention paid to patient safety. 
The U.S. government establ ished the National Patient Safety Foundation aimed at 
making health care safer for patients through an unprecedented partnership of health ca re 
practitioners. institutional providers. health product providers. health product 
manufacturers. researchers. legal advisors. patien t/consumer advocates. regulators. and 
policy makers 10. The Australian Patient Safety Foundat ion pioneered a sophisticated 
approach to patient safety by providing leadership in the reduction of harm to patients in 
all hcalthcarc environments since 1988 11 · 1 ~. The National Patient Safety Agency in 
England contributes to improving the safety of patient care by informing. supporting and 
influencing organi7ations and people working in the h~alth sector 10. Following numerous 
legal cases and media stories that highlighted the consequence of unintentional adverse 
events. patient safety is receiving growing attention in Canada as well 14 . The Winnipeg 
inquiry in Canada was a notably high-profile case that played a part in raising public 
awareness and driving policy changes 11 ln 2002, the Canadian government budgeted 
$50 million over 5 years for the creation of the Canadian Patient Safety lnstilllte (CPS [) 
that operated collaborativcly with many health care organintions and regulatory bodies 
to improve patient safety 14. The mandate of the CPS! is to provide a leadership role with 
respect to patient safety issues in the context of improving health care quality. CPS! 
facilitates collaboration between governments and stakt·holders to enhance patient satety 
initiatives to share best practices. and recognize the role of research, knmvledge transfer 
and evaluation to ensure patient safety 15• 
1.2 Overview of Drug-rela ted Problems 
Drug·related problems (DRPs) are a critical component ofpmient safety since 
these arc the events or circumstances involving drug therapy that actually or potentially 
interferes with desired health outcomes. Drugs are prescribed for patients to achieve an 
optimal therapeutic outcome in treating various medical conditions. Despite the fact that 
the therapeutic benefits of medications have resulted in hundreds of mi ll ions of people 
living healthier and longer lives everyday. medications arc not risk·frcc. As the number 
and strength of available drugs increase over time. prescription and util ization of drugs 
become more complex. leading to a variety of DRPs H'> . A DRP occurs when a patient 
experiences. or is lihely to experience. either a disease or symptom having an actual or 
suspected relationship with drug therapy- meaning that an optimal therapeutic outcome 
could not be achieved 17• In the existing literature 17' 18• eight different categories of 
DR.Ps have been described: untreated indication. improper drug selection. subtherapeutic 
dosage. failure to receive drugs (includes patient noncompliance). overdosage. adverse 
drug reaction. drug interaction. and drug used \\it bout an indication. Although many 
DRPs can be resolved without a major impact on patient health. some of these are a 
signiticant cause of hospitalization. emergency department visits and subsequent resource 
utilization. A US study reported that morbidity and mortality associated with drug-related 
problems accounted tOr $76.6 billion in health care costs. 17 million emergency 
department visits. and 8.7 million hospital admissions every year 19 Bates and colleagues 
reported that 76.000 deaths were due to adverse drug reactions mmually in the United 
States 20. Using the I: 10 ratio of the population of Canada to that of the US. it has been 
reported that adverse drug reaction fatalities would be ranked as the th leading cause of 
death in Canada. alter cancer. heart disease. stroke. pulmonary disease and accidents 21 
An adverse event (AE) is an injury resulting from medical management rather 
than the underlying disease 21 A great deal of research has been carried out in an a11empt 
to identify rates of serious AEs in USA and Australia 20· 2-'"26• llowcvcr. much less 
information is avai lable about these events in the Canadian population. This has been 
acknowledged in the National Steering Committee on Patient Safety report ... Buildin:< a 
Safer Health Sysrem- A National Integrated Slmtegyfor Improving Patient Sc{(ery in 
Canadian Health Care"" 21. This report highlighted that Canada is s igni ticantly behind the 
United States. the United Kingdom and Australia in accepting that patients are at 
signiticam risk. in \\atlling to leam about the relevant issue of patient safety. and in 
investing in the creation of a culture of safety. One of a series of recommendations 
provided by the Steering Committee was to improve measurement and evaluation 
processes and adopt designated areas of research. A study by Baker et al. I J provided the 
tirst national estimate of the incidence of adverse events among Canadian adult patients. 
The estimated rate of adverse events was found to be 7.5 per 100 hospital admissions 
and. after extrapolation. the number of hospital admissions attributed to adverse events 
was estimated between 141 ,250 and 232.250. As noted by the authors. the study provided 
a stm1ing point tOr understanding the incidence of adverse events and the burden of injury 
resulting from adverse events in Canadian acute care hospitals. Referring to the lack of 
Canadian data on adverse events. the study strongly recommended fu11her research to 
explore the types of these events and their contributing factors. Medications are the most 
frequent cause of adverse events. and SLICh injuries are referred as adverse drug events 
(ADEs) ~ . ~S ·ltl. Given that there has been a signiticant investment in the creation of a 
culture of patient safety in the Canadian Health System tOIIo\\ ing the recommendation of 
the National Steering Comminee on Patient Safety. it is important to carry out further 
research to quantify the magnitude of A DEs in the Canadian context. and examine 
whether there is any association between ADEs and patienHelated factors. Identification 
of drug·related problems. in particular. those causing hann to patients (e.g .. adverse drug 
events) and associated risk factors would allow providers to identify early symptoms of 
A DEs. and to respond to the patients quickly 31 
1.3 Adverse Drug Events 
1.3.1 Adverse Drug Event Terminology 
An adverse event is defined as '·any untO\\ard medical occurrence that may 
present during treatment with a pharmnceutical product but which does not necessarily 
June a causal relationship with this treatment" l J In other \\Ords. an AE may cause hann 
in a patient administered a drug but the event may not necessarily be caused by the drug. 
When an adverse event refers to ··circumstances that involve a patient 's drug treatment 
that actual!)'. or potentially. interfere with the achievement of an optimal outcome". this 
problem is termed as a drug.related problem I ':I n _ Drug-related problems include all 
issues that can potentially am:-ct the success ofphannacotherapy in a given patient. These 
issues are described by several commonly used tem1s to denote a non·beneficial effect 
from a drug: adverse drug events. adverse drug reactions. medication errors. drug 
toxicities and side effects. etc. 
The term "adverse drug event" (ADE) is delined as any undesirable etlt:-ct caused 
by the interaction of a drug (prescription or nonprescription) with a patient 1R Events may 
be the result of nomwl or inappropriate use of a medication. and could range from minor 
reactions such as a skin rash to serious and life·threatening events. and even death. A DEs 
can arise from inappropriate prescribing of a medication (e.g .. misdiagnosis. 
inappropriate medication. inappropriate dose. inappropriate regimen. etc.). medication 
errors. self-medication. side effects. allergies. genetic predispositions. drug·drug 
interaction. drug·disease interaction. or patient non-compliance (taking more or less of a 
drug than the prescribed amount). 
Adverse drug reaction (/\DR) is a tenn used to describe the undesirable effects of 
medications. According to the World llca!th Organization, an ADR is "Any response to 
a drug ''hich is noxious and unintended. and which occurs at doses nomwlly LlSed in 
humans for prophylaxis. diagnosis. or therapy of disease. or for the modification of 
physiological function" 34 Clearly. this definition of ADR requires a judgment as to 
noxiousness of the response as well as to the intention of an unspecified party. Kramer 
( 1981 ) 1 ' argued that whether an e\ ent is ad\erse or no'<ious depends on the clinil..:a1 
setting and the intentions of the treating physician. and that his or her judgment should be 
made separately for each case. 
The term ··Medication errors·· (M E) include mishaps that occur during 
prescribing. transcribing. dispensing. administering. adherence. or monitoring a drug. 
Examples of medication errors include misreading or miswriting a prescription. 
Medication errors thai are stopped before hann can occur are sometimes called ··near 
misses"". ··close calls"" or more fonnally. a potential adverse drug event (Figure 1.1 ). Not 
all prescribing enors lead to adverse outcomes. Medication enors are more common than 
adverse drug events. but result in harmful events less than I% of the time; about 25% of 
adverse drug events are due to medication errors 12. Figure 1.1 adapted with permission 
(Appendix B.3) from Morimoto et. a1. ~8 and Nebc:ker et al. 3~ demonstrates the 
relationship among medication errors. A DRs. A DEs and potential A DEs. 
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Potential Adverse Drug E\'ents 
Adverse Drug Events 
(all gray areas) 
Figure 1.1: Relationship between A DEs, ADRs, Potential Adverse Drug Events, a nd 
MEs 
Although A DEs and A DRs arc sometimes used interchangeably. they do not have 
the same meaning. An /\OR refers to adverse effects of medications when they are used 
appropriately at normal doses, either for prophylaxis. diagnosis or trcauncnt .lb. The term 
ADE includes A DRs in which no error occurred and/or complications that result from 
medication errors. The term ADR implies that drugs arc properly prescribed and 
administered. and thus the reactions are difficult to prevent. their reduction mostly 
depends on development of new and safer agents. HO\\Cver. A DEs due to medication 
errors are preventable and developing strategies to prevent these reactions me relatively 
easy 37. The tenn ADE has been broadened by Nebeker et al. 12. in which it refers to as 
··any undesirable effect related to the use or misuse of a drug (prescription or 
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nonprescription)"'. and is considered to be a relatively better definition given that it 
includes errors of omission. An error of omission involving the fa ilure to provide an 
effective treatment in the setting of a severe disease poses \ery substantial risks for 
patient safety and outcome. 
A ··possible adverse dmg event" (PADE) is defined as an event that may have 
been related to a cmTent medication: however. it may also have been due to another cause 
(e.g., viral infection), and therefore. confim1ation of ADE is not possible. When ADE 
studies were carried out based on retrospective study design. in particular reviewing 
patients' medical charts. the term of possible ADE was found favorable over potential 
ADE due to the fact that necessary information may not have been available in patient 
charts to identify a confirmed reason leading to adverse event. 
Dutchman Mcyler was the first who provided a systematic overview of ·side 
effect of drugs. in \951 JU~,~ _ The term "side effect·· does not imply that the response is 
adverse. A side effect usually includes any response other than the main therapeutic 
effect of the drug and may be desirable. undesirable. or inconsequential .13 An event of 
side effect rnight also irnply that the effect can be beneficial. These events can range from 
hannless epiphenomena to innocuous m1isances to harmthl and possibly irreversible 
injuries to death. Both tenns ··side effect" and ··A oR·· imply that the observed effect is 
caused by a particular drug. Because A DRs are often erroneously classified as ··side 
12 
effects··, it has been reconunended the term ··side etlfcts·· no longer be LlSed as this tends 
to minimize the injury from drugs P 40. 
1.3.2 Severity and Preventability of Adverse Drug Events 
The severity of A DEs is usually detennined \\hen detection of A DEs involve 
prospective follow-up of sllldy patients or manual review of medical charts. Previous 
studies ~0 ~ 1 -4 1 have classified A DEs into tOur categories: I) lfltal. 2) life threatening. 3) 
serious and 4) significant. An ADE was considered to be significant if the event caused 
symptoms that whi le harmful to the patient pose little or no threat to the patient's life 
function. An event is referred as a serious ADE if it caused symptoms associated with a 
serious level of risk while it was not high enough to be lite threatening. An ADE is also 
serious if it caused persistent alteration of life function. An ADE is considered to be li fe 
threatening \\hen an event caused symptoms that if not treated. \\Ould put the patient at 
risk of death. An ADE is fatal when the event results in death of a patient ~ 1 • 
Classilication of the severity of A DEs usually takes into consideration several pieces of 
infonnation such as the impairment of the patient's quality of life: hospitalization or 
prolonged hospital stay: temporary or pennanent mal function of an organ system: 
temporary or pennanent inability to work: elevated or depressed lab values resulting in 
medical interventions: life threatening: and discontinuation or substitution of the drug 44. 
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Gun\ itz eta\. J~ noted examples in darit'ying severity of A DEs. A nonw1icarial skin rash. 
a fall without associated fracture. hemorrhage not requiring transfusion or hospitalization. 
and oversedation were examples of significant A DEs. Serious A DEs included urticaria. a 
fall with an associated fracture. hemorrhage requiring transfusion or hospitalization but 
without hypotension. and delirium. Any harm such as hemorrhage with associated 
hypotension. hypoglycemic encephalopathy. profound hyponatremia. and acute renal 
tflihu·e requiring hospitalization \\ere given as examples of life-threatening A DEs. 
Preventable A DEs \\ere those due to error that could have been prevented by any 
means available 40 Preventability was categorized as definitely preventable. probably 
preventable. probably not preventable. or delinitely not preventable. When the data 
collection involves a physician and/or pharmacist reviewer. the determination of 
preventability is usually based on the reviewer"s presumed knowledge at the time the 
drug was prescribed. This infom1ation was used in conducting subjective assessment of 
categorization following consensus between reviewers "' 1• Although the data collection 
and recording in this thesis follows these categories. results were often collapsed into 
preventable and non-preventable categories to reduce sampling error associated\\ ith 
small number of events"'~ . A preventable ADE is an adverse event attributable to a 
medication error. whereas an event causing injury. with no error involved. is known as a 
non-preventable AD E. An example of a preventable ADE includes allergic reaction in a 
patient known to be an allergic to a pm1icular drug. On the contrary. allergic reaction in a 
patient not known to have dmg allergy is an example of a non-pre\'entable ADE 4~. 
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1.3.3 Detection of Adverse Drug Event 
Multiple epidemiological methods exist for the detection of acherse drug events. 
Different methods of ADE identification include voluntary reporting. chart review. direct 
observation. patient interview and electronic Sltrveillance. The methodology used 
depends on the research questions, study design and scope of the study based on available 
resources. 
In voluntary reporting. healthcare professionals. drug manufacturers and drug 
consumers are prO\ ided a pre-designed form by '' hich the) can report an) suspected 
drug-related incidents. In the context of ADE reporting. the tenn ·voluntary' reporting is 
also refetTed to as 'spontaneous· or ·incident' rep011ing. "hicb means reporting is not 
compulsory JR . Voluntary reporting depends on the ability of health professionals to 
recognize errors and their willingness to disclose them in error repot1S "0. Although this 
method remains an attractive source of infonnat ion for researchers. because the 
infonnation is generally readily available. the problem of under rep011ing greatly limits 
its utility for patient safety research. Studies have shown that voluntary reports identify 
only 5% of A DEs "7'49. Daily chart review and solicited repot1ing have detected tive 
times as many A DEs as voluntary coding in hospital separation or mortality records ~u . .: 1 
Intem1ption in work !low. perception that completing a tOm1 does not result in any 
improvement. lack ofkno\\'ledge that an ADE has occurred, and fear of exposing oneself 
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to litigation have been identified as possible reasons why incident repot1S are 
underutilized ~0 
Medical cha1  reviews have been employed in retrospective coho11 studies and 
case~control studies to detect A DEs. Murff eta\ ~0 summarized chart review studies citing 
Se\eral high quality studies. including the California Mt'dical Insurance Feasibility Study 
'
1
• the Harvard Medical Practice Study ~2• and the Colorado~ Utah Study 53 In this method 
of ADE detection. patient charts usually undergo a two~phase screening process. Initially 
a trained reviewer. usually a research nurse at the first phase. examines charts using a set 
of pre-defined screening criteria. Charts identified wi th at least one of the screening 
criteria then undergo physician review in the next phase to judge whether physician 
revievvers believe an adverse event had occurred based on the infom1ation in the chart. 
Usually two physicians independently review each chart flagged at the first phase. and if 
the physician reviewers disagree on whether an adverse event occurred. the physicians 
come to a consensus or involve a third pat1y to resolve the disagreement 50 
There are several limitations with the use of patient chart review to identify 
ADEs. First. identifying and classifying ADEs tlu·ough chart review requires implicit 
judgment by the researchers: this process may introduce bias 54• Second. this method for 
ADE identification has been predominantly used in retrospective studies. where 
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supplemental information cannot be obtained and this may cause underestimation of 
A DEs 5-J 55• Third, there is a tendency of the nurse reviewer at the first phase to flag a 
large number of charts as a probable ADE even if there may be very linle documentation 
of having an ADE. A study focusing on reliability and validity of judgment conceming 
adverse events repo11ed that the positive predictive value of the initial screening process 
was as !ow as 21%. and as a result physicians reviewed a high number of false positi ve 
charts,, A tina!. but possibly the greatest limitation to this methodology. is the overall 
resources required. '>vhich can be significall! when compared to other screening 
modalities ~n Since chart re' ie,, s are very costly and time consuming. some investigators 
have used fewer screening criteria to help reduce the overall resource burden 51• 
TheretOre. medical chart review. in general. remains an impractical means tOr routine 
adverse event detection. 
Patient inten iew is another method of ADE detection. A study by Forster eta!. 12 
utilized patient interviews as well as information from sign-out notes. discharge 
summaries. and laboratory results to prepare case summaries tOr physician reviewers. 
A DEs were determined based on review of these case summaries. The study reported that 
nearly one in five patients experienced an ADE during the transition from the hospital to 
home. A review paper 50 citing studies that used patient interview data reported that 10% 
to 42% of patients experienced and ''ere aware of an error occurring \\ ith their medical 
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care. The major limitation of patient interview is that it requires a substantial reSOllrce 
commitment. 
Computer-based approaches (i.e .. computer-based monitoring programs) have 
recently been incorporated in research to identify A DEs. This program identifies ·nlcrts'. 
which are situations suggesting that an ADE might be present. Following these alerts. a 
trained reviewer examines patients' hospital records to dctcnninc whether an ADE had 
occurred ~M. This approach has an advantage over chart review in that it is a more cost-
effective method~-~. Computer-based programs have been shown to identify more cvcms 
than spontaneous reporting ~~~. However. there is limited use of this method to identify 
A DEs because of the huge cost for institutions to develop this system and the uncertainty 
regarding its effectiveness. Previous studies have used medical chart review and 
compared the results to computer based programs and other methods to identify A DEs ~s-
5'~. A study by .lha eta\ Sll reported that more events were identified through chart review 
compared to the computer-based monitoring strategy and voluntary reporting (13.3 vs. 
9.6 vs 0.7 /\DEs per \.000 patient-days. respectively). In a study with nursing home 
residents. Gur\\'itz et al ~Q ascertained A DEs by utili7ing both chart review and incident 
reporting by health care providers. It was reported that the method of chart review 
identified many more A DEs than using health care provider reporting (83% vs. 17%. 
respectively). 
18 
While each method illustrated Jbove has its own strengths and limitations. the 
scope of available resources etten dictates which methodology is used for detecting 
ADEs. In Newfoundland and Labrador (NL). having a sample frame through an 
electronically available Emergency Depm1ment (ED) triage database allowed for 
sekction of a representative sample to carry out two of the studies (described in the next 
sections) included in this dissertation. The step-wise chart review method that used a 
trigger assessment tool and subsequently a data collection tool. illustrated in chapters 2 
and 3. greatly simplified the chart review process by allowing relatively rapid and 
systematic examination of charts to extract relevant data for the detection of A DEs. 
Additionally. in NL. there is a unique opportunity to study a large. geographically 
isolated population using pre-existing daw sources. Utilization of the hospital discharge 
abstract database for assessing ADRs and its linkabil ity with other administrative data 
was found to be a cost effective method that offered a potential to capture a large 
population of patients. This method -.vas also employed in detecting A DRs used for this 
disse11ation. A brief description is provided in the next sections of this chapter. along 
with further detail in chapter 4. 
1.3.4 Measurement of Adverse Drug Event Occurrences 
A central task in adverse drug eve111 epidemiology is to quantify the occurrence of 
A DEs in study populations. In order to express the extent of the problem resulting from 
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ADE occurrence. we need to be able to measure the frequency of ADE occurrences. 
Incidence rate. cwnulativc incidence and prevalence arc the three basic measures of 
.. disease .. or .. incident" occurrence. Although A DEs are tenned as an incident rather than 
a disease. definitions of tenninologies to measure the frequencies discussed in this 
section mostly with reference to a disease. This is just to be consistent with the 
epidemiology and public health literature in defining and illustrating tenninologies. 
1-JO\\ever. a concluding paragraph was given with respect to ADE occurrence to claritY 
the fact that these tenns can be used to express the extent of an incident as well. 
The incide11Ce rate is the number of new cases of disease of interest that occur 
during a specified period of time in a population at risk for developing the disease. In 
estimating incidence rate. the number ol· ne\v cases of disease is divided by the sum of the 
time periods of observations for all individuals in the population. Because the 
denominator of the incidence rate is the sum of the persOJHimc of the at risk population. 
it is also known as the incidence density mre or person-time incidence rare OO.b l The 
cumulatil·e incidence refers to the proportion of people who convert. during a specilied 
period of time. from non-disease to disease. If risk is defined as the probability of an 
individual de\'eloping a disease in a specified time interval. then cumulative incidence is 
a measure of average risk. Cumulative incidence is calculated as the nmnber of new 
disease cases divided by the number of persons at risk of developing the disease during 
that period of time. The critical element in the detinition of incidence density or 
cumulative incidence is new cases of disease. These two terms arc a mcaSllrC of events 
for which the disease is identified in a person who develops th~ disease and did not have 
the disease previously. 
Prewilence measures the proportion of a population that is affected by disease or 
incident at a specitied time. Prevalence is calculated as the number of disease cases 
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present in the population at a specified time divided by the number of persons in the 
population at that specific time. As a measure of disease occurrence, prevalence can be 
viewed as a slice through the population at a point in time at which it is detem1incd who 
has the disease and who docs not (- ~. Prevalence can be used in two ways- point 
prevalence and period prevalence. The tenn poim prevalence refers to prevalence of the 
disease measured at a point in time. The other term period prero!ence measures 
prevalence of the disease at any time during a certain period. such as during a single 
calendar year. When we think of a survey as the source of obtaining data. it is vi11ually 
impossible to survey an entire city on a single day. Therefore. prevalence measured from 
survey data often conceptually think of in terms of sing le point in time, but in reality. the 
survey would take much longer. This is why. in some situations researchers arc to choose 
prevalence that measures how many people have had the disease at any time during a 
given period. In estimating period prevalence. it is considered that some people may have 
developed the disease during that period. and others may have had the disease before and 
died or been cured during that period. 
The numerator of prevalence includes a mix of people with different durations of 
disease or incident, and the denominator includes the number of population at that 
specified time as opposed to population at risk. Thus. prevalence is not a measure or risk. 
If the aim is to measure risk. the term incidence must be used. because in contrast to 
prevalence. it includes only new cases and a specific time period during which these 
events occurred I'l L 6~ . 
Similar to any disease occurrence. the frequency of A DEs can be measured using 
rates or proportions. Incidence density or cumulative incidence can be treated as rates 
and are used to comprehend how fast the ADE is occurring in a population. whereas 
21 
pre' alence is a proportion which is used to tell us whm fraction oft he population is 
affected 61. When an ADE is an outcome of interest. these events are not inevitable or 
may not occur during the period of observation. In this situation. prevalence is considered 
as the measure of ADE frequency. However. in an attempt to measure the frequency of 
ADE occurrence in a population. it is insutlicient merely to record the number of A DEs 
occurred in that population. It is also necessary to take into account the length of time 
contributed by all persons during the period they were in the population 61 • whichjustities 
the importance of incidence. Although the tem1inologies discussed in this section have 
importance to express the magnitude of a disease or incident of interest. which measures 
to be used to express the frequency of an event depends on the study design that permits 
identitication of the event through clearly defining when the event occurred. The sources 
of data from which cases are identified influence how we use measures of occurrence to 
express the extent of disease or incident. 
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1.4 Research Engagement 
Over the last decade. the province of Newfoundland and Labrador has undertaken 
an initiative to develop a province-wide Electronic llcalth Record (EIIR). The EIIR will 
allow data linkage of major clinical and administrative information systems together to 
allow authori7cd health care providers secure access to a paticnt"s key health history and 
care within the heath system. One of the systems under the anns of EI-IR is the 
Newfoundland and Labrador Phannacy Network. This system is undergoing a benefit 
evaluation using pre and post comparative study designs. The pre-implementation 
evaluation of the Phannacy Network included several studies aimed at gathering baseline 
data on drug related problems. including the occurrence of serious A DEs. which has 
fonned the bas is of this dissertation research. This involved two separate studies that used 
retrospective review of patient ED charts to determine prevalence. severity and 
preventability of A DEs occurring in children and adults in the community setting and 
resulting in ED visits. In addition to these studies. a third study. which is not part of the 
bene fit evaluation of Pharmacy Network. involved the detection and analysis of A DEs 
among elderly hospitaliLed patients using a population-based retrospective cohort study. 
This dissertation research was comprised of these three studies. 
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The EHR initiatives in Newfoundland and Labrador included several infOnnation 
systems. While other information systems (e.g .. Telehealth. Laboratory. Picture 
Archiving and Communication Systems) considered pa11 of the EHR are out of scope tOr 
this dissertation. the project ideas illustrating how the Phannacy Network fits in with the 
overall EIIR implementation plan deserve elaboration. 
1.4.1 Electronic Health Record Initiatives in Newfoundland and 
Labrador 
An electronic health record provides health care professionals with online real-
time ac(.;ess to their patient's complete medical protilt.". It holds key health information 
about every person in the province through building a secure and private lifetime record 
of a person's health and healthcare history. It shares selected aspects of patients' health 
information. from medications or x-rays to blood tests or vaccines. with all authorized 
health care professionals 03 Recognizing the impot1ance of the EHR in improving the 
quality and etliciency of health care. the federal govemment of Canada established 
Canada Health lntOway (/l!{oway) in 2001 to accelerate the deYe]opment and adoption of 
Electronic Health Records across the coumry. 11!/0II'ay was provided with $1.2 bill ion in 
funding and a 7-year mandate to \\Ork with all jurisdictions in Canada in both planning 
and implementing their EHR initiatives. With an aim to have 50% of Canadians 
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connected to an EHR by the end of2010. hrfoway identified core components of an EHR 
in their 2003/04 Business Plan M-n_,_ 
The Newfoundland and Labrador Centre for Health lnfonnation (NLCHI) has 
received funding from ln}Oway to implement six key building blocks of the 1-::IIR: (I) a 
unique personal identifier/client registry. (2) a pharmacy network. (3) a laboratory 
network. (4) tclchcalth. (5) a provider registry and (6) a diagnostic imaging network b5-ot:.. 
To determine the benefits of the EHR. a number of research initiatives have been 
lllldertaken to establish baseline data on the delivery of various aspects of health care in 
r\ewfoundland and Labrador. Once the EHR is in full operation. these studies will be 
repeated as a means to assess benefi ts to health care delivery using a pre/post-
comparative design. 
1.4.2 The Newfoundland and Labrador Pha rmacy Network 
The Newfoundland and Labrador Pharmacy Network is a provincial drug 
infonnation system that will offer province wide on line. real-time medication profiles. as 
well as comprehensive drug infonnation. A personal medication dispensing history built 
up within the Pharmacy Network involves linking community and hospital pharmacies 
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and physician oflices. so that a patient"s historical and cuiTent medication protile is 
available to health professionals at the point of care. Once all pharmacies in the province 
are connected to the Pharmacy Network. medication information of a patient will be 
stored in one record- the patient's profile. It is expected that giving health professionals 
access to that record will provide many benefits to the patient. as well as the patient's 
health care providers 63. Health professionals· access to infonnation about the 
medications a patient takes is expected to improve the quality of the patient\ healthcare. 
The information will support better decision making about medications. diagnosis and 
treatments. and therefore it will be easier and quicker for health professionals to decide 
whether a patient' s new medication will react with others the patient is taking. One of the 
many expected benefits of the Pham1acy Network in Newfoundland and Labrador is the 
reduction of serious adverse drug events occurring in the community. With a drug 
information system and an interactive database alTering accurate real-time prescription 
protiles. health professionals would be able to interYene before and after an adverse eYent 
occurs. This system can help avoid hannful drug interactions and lead to a decrease in the 
cost of doctor visits. emergency department visits. and hospitalizations 6l 65 The personal 
medication dispensing history ''ould also result in more appropriate prescribing and 
dispensing. recognition of contraindication. improved counseling. improved compliance 
monitoring and reduced abuse of prescription dwgs. A Benetit Driven Business Case 
(BOBC) submitted by the NLCH! to the Govemment of NL in 1998 suggested the 
Personal Medication Dispensing History would deliver savings to the health system by 
reducing ADEs, both in the community and the hospital settings 6.1 The BDBC predicted 
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approximately $4. 1 million in annual savings to the health system following the 
implementation of the provincial Phannacy Network. 
The provincial EIIR. including the Pharmacy Network. is a collaborative initiative 
between the Newfoundland and Labrador Centre for Health Information. the Government 
ofNev.-foundland and Labrador. Canada 1 lealth lnfoway. and the Regional I lealth 
Authorities. along with many supporting stakeholders. The Provincial Government and 
ll~foway have commincd $8.6 million and $17.9 million. respectively in its development 
and implementation. The provincial government has committed necessary funding for the 
ongoing operation of the Phannacy Net\\Ork. In May 2002. NLCHl received approval 
from the provincial government to carry out a Pharmacy Network project scoping 
involving a high level analysis to determine the required functional ity of the system. and 
the resources needed for its implementation. following the completion of the project 
scoping and subsequent dialogue and clarification, the government granted approval lOr 
NLCHJ to move forward with issuing a Request for Proposals (RFP) for the 
implementation of the Phannacy Nel\\,ork in October 2004. In June 2006. the provincial 
government and 11!f011"ay signed an agreement to partner on the implementation of the 
Pharmacy Network. N~wfoundland and Labrador began connecting community 
pbannacies to the provincial Pharmacy Network in May 2010. Implementation in more 
than 190 community pharmacies province wide will continue in a phased·in approach 
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throughout 20 I 0 and 20 II. After community pharmacies. the next step is connecting 
health care fac ilities in the four regional health authorities to the Pharmacy Network 67. 
As previously stated. the Newfoundland and Labrador Phannacy Network is 
undergoing a benefit evaluation using a pre- and post-comparative study design. The pre-
implementation evaluation of the Pharmacy Network encompasses several studies to 
gather baseline data on drug-related problems. Two of the studies were carried out to 
gather infom1ation on serious A DEs occurring in the community setting and resulting in 
Emergency Department visits. Given that children and adults have very different drug 
utilization and in many other ways with regard to medical care. two separate studies were 
carried out- one in children and the other in the adult population. The overall objectives 
of these two studies were: 
I) To estimate the prevalence of A DEs separately in children and adul ts presenting 
at Emergency Departments in St. John' s over a one year period. and to classify 
these ADEs with respect to severity and prevemability. 
2) To use the results of these studies as a baseline; which then will be compared to 
the results of the repetition of the same studies to be carried out post-Pharmacy 
Network implementation. Comparisons of pre-post Phannacy Network will be 
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made on the overall prevalence of A DEs presenting at EDs. as well as the severity 
and preventability of the /\DEs, 
3) To build research capacity in the province of Newfoundland and Labrador in the 
area of optimal drug utilization through enhanced infonnation systems. 
1.5 Progra m of Research for Dissertation 
The objectives of the two pre-Pharmacy Network studies noted above provided 
the basis for this doctoral dissertation. While the second and third objectives arc more in 
line with the larger program of benefit evaluation and achievable following the post-
implementation of Phamwcy Network studies. attainment of the first objective was 
possible based solely on existing data of the two pre-Pham1acy Network studies. 
Although. the focus of the benefit evaluation initiatives through these two studies was to 
determine the frequency of ADEs and their distribution with respect to severity and 
preventability. investigating how these A DEs differ by patients' demographic and clinical 
characteristics was one of the primary focuses of this dissertation research. Serious A DEs 
also have great impact on inpatient admission and length of stay. which is especially 
more common in elderly patients who usually take multiple drugs to control multiple 
comorbidities. l-Ienee. considering this high risk group as another subpopu!ation. ADF:s 
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have been identified using diagnosis codes in the hospital d ischarge abstracts and 
included as a third study in this dissertation. 
A majority of patients with mild or non-serious A DEs typically seck care from 
primary health care providers (e.g .. pharmacists. family physicians. etc.) rather than 
present to EDs or be admitted to hospitals 68 Therefore, this research examines serious 
ADEs only requiring utilization of health care resources such as ED visits. hospital 
admission or prolonged hospital stay for an existing patient. Although studying A DEs in 
hospitalized patients was not part of the benefit evaluation. this has been included for the 
following two reasons: 
I) Serious A DEs are clinically significant dwg-related problems that reslllt in 
increased health care resource utilization and may either lead to ED\ is its or 
hospital admissions. A more thorough study including A DEs in the hospital 
setting was chosen to make this doctoral research more comprehensive 
concerning serious ADEs in NL. which could lead to more rational interventions 
to improve quality and safety. 
2) Since the small number of events in the two prc-Phannacy Network studies would 
potentially introduce high sampling error. a more robust study. investigating 
A DEs in elderly hospitalized patients. with a strong retrospective cohort design 
that made us of fairly recent statistical advances. allowed for the identification of 
patient-related factors that can predict rare events such as serious A DEs. 
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This disse11ation was comprised of these three studies. each of which was carried 
out as a distinct study and led to a .. stand-alone .. chapter (Chapters 2. 3 and 4). However. 
the three studies complement each other by focus ing attention on serious ADEs which 
represent important aspects of quality of care. and drawing attention to the need for 
increased eftOrts to improve patient safety. Of the three studies. the two pre-Pharmacy 
Network studies were carried out for the first time in NL. The third study is considered 
one o f the most comprehensive studies on recurrent event of serious A DRs undertaken to 
date. 
1.6 Research Questions 
The key research qlJCSt ions for this dissertation arc given below: 
1) What is the prevalence of A DEs in (a) chi ldren aged less than 18 years. (b) adults 
aged 18 years and older presenting to EDs over a one year period? 
2) What \\as the proportion of A DEs in these 1\\0 groups of population (children and 
adults presenting to EDs) severe and preventable? 
3) How does the occurrence of A DEs in these two groups of population (children 
and adults presenting to EDs) relate to the patients· demographic and clinical 
characteristics? 
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4) What is the incidence of ADR occurrences in the elderly population aged 65 years 
and older admitted to hospitals? 
5) What does the impact. if any. age. comorbidity and other covariates have on the 
number of ADRs in elderly hospitalized patients? 
The events identified from the !irst two studies were tenned as 'adverse drug 
events·. which was the focus of the research question 1. 2 and 3 as the primary outcome 
,·ariable. The e'ent that \vas detected from the third study was referred to as ·adverse 
drug reactions'. This ADR ''as used as a primary outcome variable to answer research 
questions 4 and 5. As evident in the research questions above. this dissertation tOcused on 
the unified goal of detecting and characterizing serious A DEs requiring utili zation of 
health care resources. llowcvcr. due to the differences in study design and data sources 
among the three studies. there is a subtle difference in the primary outcome variables 
(ADE vs. ADR) and measures of occurrences considered (prevalence vs. incidence). 
These differences h3\e been renected in the research questions given above. To answer 
question \. a measure of period prevalence was considered that indicated how many 
people of the specilied age groups had ADEs leading to an ED visit during the one-year 
period. However. for research question 4. a measure of incidence was computed which 
referred to the incidence rate (or. incidence density) at which the number of new events 
occurred in the population at risk during a specified time period (e.g .. annual ly). 
Consideration of estimating period prevalence for the tirst two studies and incidence rate 
for the third study to measure the extent ADE occurrence is just a reflection of 
recognizing the study designs and sources of data from which ADE were identified. 
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The incidence of A DEs in the elderly hospitalized patients referrers to the 
incidence of ADRs. which is a conservative estimate of A DEs as defined in section 1.3.1. 
Research questions I. 2 and 4 generated knowledgeable data about the magnitude of the 
problem of ADE occurrence in EDs and in high risk hospitalized patients. This 
information is necessary prior to the investment of resources to tind ways to reduce 
preventable discomfon. disability. and death directly attributable to adverse outcomes 
associated with drugs. Although knowledge of t he proponion of A DEs in elderly 
hospitalized patients that could have been prevented and their level of severity is an 
impot1ant concern. this was not included as part of the research questions since the 
administrative database used to answer these questions could not classify A DEs with 
respect to se\ erity and pre\ entability. Given that EDs and in-hospital are two dift'erent 
settings with distinct level of care. these are sepamted into t\\·o distinct studies and thus 
research questions are separated by study setting. It has been illustrated that the 
epidemiology of adverse events and preventable adverse events in children is ditferent 
than in aciLllts since children diJl'er from adults in many ways with regard to medical care 
6Q Therefore. prevalence of ADEs was measured separately in children and adults. 
Research questions 3 and 5 are imponant to direct ho\\ patient saf'ety initiatives should be 
focused in different pans of the population. Patient-related factors associated with serious 
A DEs need to be better understood in order to implement interventions that can reduce 
the incidence and burden of dmg-related problems in the population. 
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I. 7 Ethics Approval and Copyright Permissions 
Ethics approval for this doctoral dissertation was obtained from the Human 
Investigation Committee of Memorial University of Newfoundland (Appendix A). The 
two papers were written based on the fi ndings of the first two studies and subsequently 
published in the Journal of Plwrmacoepidemiofogr and Drug Sa.fi!fy and 1/te Annals o.f 
Pharmac01herapy. The both journals granted wrillen permission to include the papers in 
my doctoral thesis (Appendices B.! and 8.2). As noted earlier. the written pcm1issions 
were also obtained from the original authors regarding the adoption of Figure I .I in the 
thesis (Appendix 8.3). 
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Abstract 
Objectives: The aim of this study was to examine epidemiologic characteristics of 
Adverse Drug Events (ADEs) among children and adolescents presenting to an 
Emergency Department (ED) in Newfoundland and Labrador (NL). Canada. 
Materials and Methods: This study was conducted in three phases and included an ED 
chart review of visits to the Janeway llospital in St. John' s. NL. between April 27th. 
2006 and April 26th. 2007. The first phase narrowed the sampling frame by excluding 
visits highly unlikely to be drug-related. In the second phase. a random sample of ED 
charts was selected for review by two research nurses using a Trigger Assessment Tool 
that classified ED visits according to their likelihood of being drug related (""high ... 
··moderate··. ··[ow··. ··very low·· or ··no·· probability). The third phase included a full chart 
review of all ""high··. ··moderate··. ··tow··. and ··very low·· probability AD!: charts. carried 
out independently by two ED pediatricians and two clinical phan11acists. Each ADE was 
also scored for severity and preventability. and consensus was reached among all four 
re' iewers during meetings held at the end of this phase. 
Results: In this study. 69 patients presented to the ED either due to an ADE or a possible 
ADE (PADE). After a sample-weight adjustment. the prevalence of ADEs/PADEs was 
tOund to be 2. I%. The number of comorbidities was inversely assodated v. ith 
medication-related visits. There was no significant difference found between patients 
with and without medication related visits with respect to mean age of the patient and the 
mean number of current medications being taken. Of the 69 confim1ed ADE/PADEs. 
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none were fataL six (8.7%) wer~ serious/life-threatening. and 63 (91.3%) were 
considered significant. Antimicrobia l agents (45.0%) were the most common drug classes 
associated with ADEs/PADEs. Approximately 20% of the 69 ADEs/PADEs identitied 
were considered preventable. 
Conclusions: In St. John' s NL. emergency department visit s as a result of A DEs are 
common among the pediatri c population and in many cases preventable. Age and num ber 
or current med ications do not appear to be associated with ED visits related with ADE. 
Antimicrobial agents were found to be to the cause of most ADEs/PADEs. 
Keywords: Adverse Drug Event (i\DE), Pediatrics. Emergency Department. 
Newfoundland. Canada 
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Introduction 
An Adverse Drug Event (ADE) is defined as any undesirable effect related to the 
usc or misuse of a drug (prescription or nonprescription) 1 II has been estimated that such 
events account for 17 million emergency department (ED) visits and 8.7 million hospiial 
admissions annually in the United States~- 3. Studies of A DEs among children and 
adolescents is not well understood. mainly because research regarding drug usage in 
pediatric populations is generally lacking.~ To date. pediatric A DEs have been evaluated 
mostly in hospital settings 5' 10 . It has been estimated that 70.000 children hospitalized in 
the United States experience an ADE each year. and that 60% of these events arc 
preventable~- Considering the limited research on A DEs among pediatric ambulatory 
care visits and particularly ED visi ts. this study was conducted to examine the 
epidemiologic characteristics of A DEs presenting to a pediatric ED in the city of St. 
John's. the capital of Newfoundland and Labrador (NL). Canada. 
Methods 
This study was conducted at the Janeway Children's Health Care Centre (the 
Janeway) in St. John's. NL. Canada (the only te11iary care centre for children in the 
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________________ ) ________________ _ 
: Phase-1 U$Ulg scree!Ungtoc>l on EmergencyT~ Diii.&b-.se 1 
I Random Sample ofN=2,57!1 I 
________ ________ ] _______ _________ _ 
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utJ 
Figure 2.1: lllustrati\'e flow-chart for identification of pediatric patients with ADEs 
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province) in three phases from April 2th. 2006 to Apri l 261h. 2007 (Figure 2. 1 ). 
The inclusion criteria v .. ere: 1) patients aged~ 17 years. and 2) resident ofNL. 
Exclusion criteria included: 1) patients whose reason for the ED visit was unlikely to be 
the result of an ADE (e.g .. alcohol-related. cut-related injuries. bLln1. WOLltld dressing. 
drug abuse. attempted suicide. etc.). and 2) visi ts where the EO charts were found to lack 
documentation or had missing inforn1ation. The main reasons we excluded visits due to 
drug abuse or intentional overdose was to avoid overestimating the true frcqL1ency of 
ADE-related visits to the EDs. given such events would not constitute a drug-related 
problem (DRP) according to widely accepted criteria of DRPs. These criteria can be 
broken out into 8 categories: I) untreated indication. 2) improper drug selection, 3) sub-
therapeutic dosage. 4) failure to receive drugs (includes patient non-compliance). 5) 
overdosage. 6) adverse drug reaction. 7) drug interaction. and 8) drugs used without an 
indication 11• 
In the first phase, the Janeway ED triage data file containing all ED visits during 
the study period was examined based on the inclusion/exclusion criteria. This data fi le 
included patient demographic infonnation. hospital chart number. date and time of the 
ED visit. and self-assessed reason for the visit. In order to obtain the sampling frame. a 
screening tool was developed to exclude those ED visits having a high probability of not 
being auributed to A DEs (e.g .. alcohol-related, cut. burn. wound dressing, etc.). 
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Recognizing that conditions such as attempted suicide and drug abuse would not likely be 
the complaint of the preseming patient (i.e., adolescents). these ED visits may not have 
been excluded at this phase of the study: rather. they were excluded case by case at a later 
phase when the actual chart reviews were conducted. 
I o permit identification of an estimated prevalence of 1.7% for A DEs with a 95~o 
confidence interval half width of0.5%. a sample size of 2.575 (including a I 0% over 
sample) were selected from the sample frame for initial review. The estimate of 1.7% was 
the average ADE prevalence reported in the published literature for pediatric settings 1 ~-
1-t. The initial review was carried out by two research nurses. who classified the visits 
according to their likelihood of being ADE-relmed ("high". "moderate". "low". "very 
lo" .. and "no" probability). In this phase. a Trigger Assessment Tool (Appendix C.!) ''as 
used. which listed 38 screening criteria (triggers) known to be sensitive to the occurrence 
of ADEs among the pediatric population. Charts were selected from the sampling frame 
using a simple random sampling design. Recognizing that a patient may have had more 
than one ED' isit during the study period. only one ' isit per patient was randomly 
selected during the sampling process. 
Following the screening of visits for their likelihood of being A DE-related. a fu ll 
review of ED charts was carried out by two ED pediatricians and two clinical pharmacists 
on all those identified as having "high", ··moderate" ... low". and "very low" probability of 
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being A DEs. A validation exercise was considered to assess how good the trigger 
assessment tool was in separating the sampled visits with respect to probable ADE 
classes. As pan of the \alidation exercise of the Trigger Assessment Tool. a full revie\\ 
was also carried out on a sample of charts for visits classified as having "no·· probabi lity 
of being due to an ADE. A random sample of 344 patients from the "no·· probability 
group was selected by assuming that. at most. 1.5% of the visits in the "no" probabil ity 
ADE category were actually the result of an ADE. and by using a 95% confidence level 
with a one-sided error of 1.0%. 
A data collection tool de\ eloped by the research team \\aS used by the revie'' 
team to collect relevant information and assess whether the ED visit was due to an ADE 
(Appendix C.2). The data collection tool was developed based on the tool used by 
Gandhi eta\. 15• was piloted and minor revisions were made prior to the chart review. 
Using the data collection tool. the reviewers recorded demographic and clinical 
information including presenting complaint. past medical history, dmg history. history of 
allergy. medication dose. frequency. and reaction to the event. as well as the patient's 
most recent laboratory results. This infonnation was used 10 assess whether the ED visit 
was the result of an ADE. a possible ADE (PADE). or a medication enor (ME). In this 
study. an ADE was defined as any undesirable effect caused by the interaction of a drug 
''ith a patient. The term ·possible adverse drug event' (PADE). was defined as an event 
that may have been related to a current medication. however it may also have been due 10 
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another cause (e.g. viral infection). and therefore continnation of the ADE was not 
possible. A medication error was defined as a mishap that occurred during prescribing. 
transcribing. dispensing. administering. adherence. or monitoring a drug. Only a small 
proportion of medication errors lead to adverse outcome I. 10 A medication error that did 
not cause harm or was stopped betOre hann occur (i.e .. near misses or close calls) was 
included as a potential outcome in the data collection sheet: however because of the 
retrospective nature of our study. and the limited documented clinical information in the 
patient charts. we did not expect. nor did we find any medication errors that could be 
considered "ncar misses" or "close calls". 
Each reviewer classilied the events (i.e. ADE or a PADE) according to their 
se,erity and preventability. Severi ty was classified as ··fatal" (resulted in death). '·life 
threatening" (the event caused symptoms that. if not treated. would have put the patient at 
risk of death). "serious·· (the event caused symptoms that were associated with a serious 
level of risk. but was not high enough to be life threatening). or "significant" (the event 
caused symptoms that. while hannful to the patient. posed little or no tlu-eat to the 
patient's life). Preventabili ty was classified as ··error intercepted". "definitely 
preventable", "probably preventable". ''probably not preventable··. or "definitely not 
preventable" 1 ' . Each member of the review team reviewed each chart independently and 
consensus was reached among all four reviev.-ers during meetings held at the end of this 
phase. Because disagreement about classification of ADEs. and the ir severity and 
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preventability were resolved during consensus meetings. measuring inter-rater reliability 
was beyond the scope of the study. 
Due to small counts the primary outcome variables (i.e., ADE and PADE) were 
combined into a single variable (ADEIPADE). as we assumed that the causes of possible 
A DEs were quite s imilar to that of confirmed A DEs 17 The methodological benefit of 
pooling these two categories of events was to reduce the random error associated with 
small number of events. The estimation of prevalence of ADEs/PADEs was based on the 
sample reviewed in Phase 2 (rep011ed as per I 00 ED visits). To adjust for the sampling 
fraction in the study design. sampling weights were used to estimate the overall 
prevalence of ADEs/PADEs. The calculation of the sample weights were based on the 
inverse of the sampling fraction for Phase 2 and Phase 3. which resulted in an adjusted 
number of total visits to be studied (i.e .. the denominator). as well as an adjusted number 
of ADEs/PADEs identified (i.e .. the numerator). The rate of severity and preventabil ity of 
ADEs/PADEs was derived by dividing the number of events in the respective categories 
by the total number of ADEs!PADEs confirmed by the reviewers. Comparison of mean 
age. mean number of co-existing health conditions and current medications were 
perfonned bet\\een ADE and non-ADE related \isits using Student"s t-test. A similar 
analysis was carried out to compare percentage of female bel ween these two groups using 
Binomial prop011ion lest. The number of A DEs and PADEs was extrapolated 10 the study 
population by multiplying the weighted estimate of prevalence by the number of ED 
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visits in the study population. Events that were assessed as "definitely" or "probably'' 
preventable were merged into "preventable·. and those assessed to be definitely or 
probably not preventabl~ were merged into "not preventable·• Fisher's exact tests were 
used to determine whether there was any association between severity and preventabili ty 
of ADEs/PADEs. All data were entered and stored electronically using Microsoft Access 
and were analyzed using the SPSS 15.0 so thvare package (Statistical Package for Social 
Sciences. Chicago. IL). 
This study was approved by the Human Investigation Committee of Memoria l 
Universi ty ofNcwfoundland. 
Results 
During the study period. 33.819 ED visits to the Janeway were identified. Of 
these. 9.286 did not meet the inclusion criteria for continued review. resulting in 24.533 
ED visits ( l -L347 unique patients) eligible for the second phase of the study. The mean 
age (±SO) of this cohort was 6.8 (±5.3) years. wi th 51.2% of all visits being attributed to 
males. Oft he 2.575 patients thnt were sampled in the second phase. 158 (6.1 %) were 
identified by the research nurses as having a "high .. (n=28). "moderate" (n=86). "low" 
(n=37). or "very low" (n=7) probability of an ADE. Skin rashes and gastrointestinal 
symptoms (e.g .. nausea. vomiting. and abdomina l pain) were found to be the most 
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common manifestations of patients identitied as having .. high·· or ··moderate"' probability 
of ADE. Table ~.I presents the demographic and clinical characteristics of these \58 
patients identified for full chm1 review. Of the !58 patients identified for full chan 
review. 68 were confirmed by the review team to either have had an ADE (n 15) or a 
PADE (n=53). As pm1 of the \·a\idation process. a sample of 344 chans from 2.417 ED 
visits classified as ··no'" probability for ADE in phase 2 of the study was reviewed in the 
third phase. As a result of this review. one of the 344 (0.3%) visits was found to be the 
result of a PADE. making the total number of ADEs/PADEs identified in this study 69. 
This one event was weighted to the inverse of the sampling fraction (i.e .. I x 
1/(344/2.417)= 1 x 1/0. 142""7.03. or rounding. 7). yielding an estimated count among the 
random sample of2575 chans to 68+7=75 ADEs/PADEs (numerator). The denominator 
of the prevalence of ADE/PADE was set to 3.550 (i.e .. 2575 • 1 /(24533/33819)~3550) to 
account for the excluded ED visits at Phase I. with the assumption that none oft he visits 
were attribllled to an ADE/PADE. After accounting for the sample weight given above. 
the overall prevalence of ADEsn)ADEs was found to be 2.1 % (95% Cl: 1.6-2.6). 
Note that we only used this adjusted ADE number of 75 to calculate prevalence 
and for extrapolation. Informat ion related to those 69 AOEs/PAOEs acwally identified 
were used for further analysis given severity. preventability and drug related infom1ation 
was not available for these estimated 6 ADEs (75-69=6). 
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Table 2.1 : Demographic and clinical characteristics of pa tients se lected for chart 
rev iew (n = 158) 
Characteris tics No. of patients (%) 
Age. mean (±SO) 6.5 (±5.6) 
Age group. years 
< I 32 20.3 
1-4 37 23.4 
5-12 55 34.8 
13-17 34 21.5 
Sex 
Female 90 57.0 
Male 68 43.0 
Mean (±SO) of comorbidities 1.0(± I.\) 
Distribution of comorbidities 
71 44.9 
45 28.5 
24 15.2 
\3 8.2 
2:4 3.1 
Mean (:::SO) number of current 1.5 (± 0.9) 
Distribution of number of current 
0' \0 6.3 
79 51.3 
52 32.9 
5.7 
3.8 
• Nurse rev1ewers d1d not note that the pat1ent had not taken dmgs. 
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Of the 69 ADEIPADE cases. four were hospitalized. None of the 69 confi rmed 
ADE/PADE patients died. while six of the events (8.7%) were serious/life-threatening. 
and 63 (91.3%) were significant. Approximately 20% of the 69 ADEs/PADEs identified 
were considered preventable (Table 2.2). Extrapolating from our prevalence of2.1 %. it 
was estimated that during the year under study. approximately 710 patients (95% Cl: 
554-875) were treated for ADEs/PADEs at the Janeway ED. of which approximately 145 
visits were considered to be preventable. Further. we estimated that 41 of these 71 0 
patients were hospitali...:ed because of an ADE. 
Ta ble 2.2: Distribution of ADEs/PADEs by severity and preventability categories 
C:1tegory of preventability 
Preventable .Nor Preventable Total 
P-value 
Category of Severity 1'10. {%) No.(%} 
Signiticant 13 (20.6) 50 (79.4) 63 
Serious or life 
0.65' I (16.7) 5 (83.3) 6 
hreatening 
Total 14 (203) 55 (79.7) 69 
' Ftshet s exact test was used for companng two mdependent bmomml ptopotuons. 
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Table 2.3 presents factors associated\\ ith the ADEIPADE visits. Following the 
full review of the 158 patient charts. 90 were found to have no evidence of an ADE or 
PADE: these 90 visits were then considered the control group for the purpose of 
comparison to the 69 pat ients considered to have presented with an ADE/PADE. There 
was no statistically signilicant ditYerence found between the mean age, percentage of 
females/males. or the number of current medications. for patients with and without ADE· 
related visits. The number of comorbidities was inversely associated with ADE related 
visits (P < 0.0 I). 
Table 2.3: Compa rison of factors associated with drug·related olRd not drug· related 
vis its to E D 
Type of vis it ; no., (0A)) of visits 
Drug-related Not drug- P·vll lue 
II "" 69" 
related 
11 ""90 
Age. mean (:::SO) 6.2 (~5.2) 6 7 (±6.0) 0.57 
Female sex(%) 56.5 57.8 0.87' 
No. of comorbiditics. mean (±SD) 0.7 (±0.9) 1.2 (±\.2) < 0.01 
No. of current medications. mean 
1.6(±0.8) 1.4 (±1.0) 0.16 b (±SD) 
• 69 ADE'PADE mcludes 68 tound durmg Phase 3 and one as a result ofvahdat1on cxcrCISC. Student's 
t-test was used for comparing two means:~ Binomial proportion test was used for 
comparing two independent proportions/percentages: 
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Table 2.4 presents the distribution of medication classes associated with the 69 
ADE-related visits and the 90 non-A DE related visits. The percentage of antimicrobial 
medication was significantly higher among patients\\ ith ADEs compared to those 
without A DEs (45.1% vs 23A%. p<O.Ol ). The medications most frequently associated 
'' ith ADEs/PADEs. either on their own or in combination with other agents. were 
macrolide antibiotics (e.g . azithromycin. clarithromycin) (26.1 %. 18/69) and amoxicillin 
(23.2%. 16/69). 
Table 2. 4: Medica tion class llSSoci:tted with drug-related a nd not drug-rela ted visits 
to ED 
Medication class Drug-related Not drug-r·elated 
n(%) n (%) P-value 11 
Antimicrobial agents 51 (45.1) 30 (23.4) <0.01 
Musculoskeletal agents 13 (11.5) 21 (16.4) 0.28 
Central nervous system 0.47 
agents 4 (3.5) 7 (5.5) 
l lorn1onc-modifying agents 3 (2 .7) 4 (3.1) 0.83 
Cardiovascular agents I (0.9) 2 (1.6) 0.64 
Other 41 (36.3) 64 (50.0) <0.05 
Bmonual proportton test was used for companng two tndependent bmonual proporttons 
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Discussion 
The extent of ADEs presenting to EDs among the pediatric popu!a1ion has not 
been previously studied in NL. This study found that drug-related events accounted for 
2.1% of child and adolescents ED visits at the Janeway (the only tertiary pediatric care 
centre in NL). of which 20% were considered preventable. Comparisons with other 
studies. particularly in Canada. are challenging since there are limited Canadian studies 
that have investigated pediatric A DEs presenting to EDs. A Canadian study by Kozcr et 
al. 1 ~ at the Hospital for Sick Chi ldren in Toronto repm1ed prescribing errors in 10.1% 
and drug administration errors in 3.9% of al l ED pediatric charts reviewed. The most 
common types of prescribing errors were dosing errors. followed by drugs given'' ith 
incorrect frequency. An Australian nwlticentre study 19 showed 3.3% (95% Cl: 2.9-
3.7%) of pediatric EO visits were due to dmg-related problems over an 18 week-period. 
of which 51.3% were judged to be preventable. A prospective Italian study estimated the 
rate of A DEs to be 6.2% (95% Cl: 4.3- 8.1 %) among patients aged 0-19 years visiting 
EDs. The prevalence of ADEsiPADEs determined in our study may not be comparable 
with that of other studies because of differences in detinitions (e.g. ADE. PADE. ME. 
etc). and variations in methodological designs. It is worth n01ing that not only is there 
limited research conducted on pediatric visits to EDs due to ADEs. but most literature on 
ED visits focuses on MEs. dmg-rclatcd problems and adverse drug reactions. rather than 
60 
studying A DEs that encompass both A DRs in which no erro r occuned and complications 
that result from MEs 20. 
In a national surveillance study of ED visi ts for ADEs among children and 
adolescents in the USA. most children experiencing an ADE (88. 7%) were treated and 
released; 5.1% were admitted to the hospital. and 2.9% were held for extended 
observation in the ED 21 • Cohen et al. also reported that children aged 1-4 years had a rate 
of hospitalization for A DEs that was almost 10 times higher than other pediatric age 
groups. Selbst et al. ~2 reported that of33 children vis iting the ED at the Chi ldren's 
Hospital of Philadelphia, only one required admission to the hospital as a direct result of 
the medication enor. The Easton-Caner study l\l from Australia found that of the 280 
pediatric ADE patients. 62 (22%) were admitted to hospital. including three to the 
intensive care unit. Based on the findings of our study. \\'e estimate that approximately 
710 children \\ere treated for drug-related events at the Janeway ED O\er the 12-month 
study period. \Vith 41 (5.8%) requiring hospitalization. We extrapolated the prevalence of 
ADEs/PADEs found in this study to the study population by multiplying 2.1% by 33.819 
(total ED visits in the study population). 
In this study no significant difference was found between the mean age and 
number of current medications for patients with and without A DE-related visits. while 
the number of comorbiditics was foLmd to be inversely associated with A DE-related 
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visits. This may be due to the fact that children with higher numbers of comorbidities are 
prescribed multiple medications. and as such. receive a closer monitoring in the 
community. Moreover. drug exposure has been shown to be a predictor of A DEs in the 
inpatient pediatric settings. where patients are normally much sicker than those 
presenting to outpatient or ED settings ~3 . Overall. our study sample was found to have 
low drug exposure which explains why we observed no association between number of 
dn1gs and A DE-related ED visits. Nonetheless. funher imestigation is needed to explore 
this fi nding. 
In this study. antimicrobial agents were tOund to be the most commonly 
prescribed drugs and were most frequent ly associated with ADEs/PADEs. which is 
consistent with the tindings of other studies I\IJ 1q ~~.~~.Because antimicrobial drugs are 
prescribed frequently in children. and a number of chi ldren have allergies to some 
commonly used antimicrobial drugs. the Canadian Pediatric Society recommends that 
antimicrobial therapy should be limited to those situations in which there is a clear 
indication. and should only be administered for the shortest etTective dL1ration H ~~. 
Cohen et al. ~ 1 reported antimicrobial agents. analgesic medications. and respiratory 
medications accounted tOr almost half of all A DEs (:25.2%. 13.7% . and 1 0.6%. 
respectively) in a national surveillance study of ED visits among children in the USA. 
They also fOund that almost half of the antimicrobial agent A DEs ( 4 7%) ,,,ere caused by 
amoxicil\in, whereas more than half of the A DEs from analgesic medications (6:2.8%) 
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\\ere caused by acetaminophen and nonsteroidal anti·intlammatory medications~~. 
Similarly. in the Easton·Carter study 1 '~. the most ti·equently occurring drugs were 
antimicrobial agents and analgesic medications such as amoxicillin. paracetamol 
(acetaminophen). cefaclor. amoxicillin and clavulanic acid. erythromycin. and penicillin 
V. Since antibiotics seem to be the most common medications causing A DEs among 
children. educational interventions need to focus on both the optimal approach to 
diagnosis and management of infection. and the negative consequences of unnecessary 
antibiotic use. 
This study t8ced several limitations. First. there is a lack of a ··gold standard" 
approach for accurately determining the prevalence of A DEs in the community setting. 
perhaps due to the cost involved and time needed to carry Olll SliCh a study. For this 
reason. researchers have used both prospective and retrospective methods. as well as 
ditl'erent data sources such as administrative systems and medical charts. to study the 
magnitude of ADE prevalence among the pediatric population. Secondly. using a 
retrospective chart review design limited the accuracy with which we could determine an 
ED visit as being caused by an ADE. Ideally, a prospective design with a large sample 
including patient/physician inten iews and obtaining key information could have 
increased the accuracy of estimates of ADE-related visits and their preventability. 
Thirdly. this study attempted to identify A DEs treated in EDs. and did not consider ADEs 
treated in outpatient clinics. physician offices. or those patients who did not seek medical 
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care. However, the ED is likely the most appropriate setting to capture severe. acute 
outpatient ADEs. 
Fourthly. in ou r analysis A DEs and PADF:s were combined into a single variable 
(ADE/PADE). which may result in an overestimate of the true prevalence of ADE. 
although we assumed that the causes of poss ible A DEs were simi lar to that of con finned 
ADEs. Fifthly. during Phase 2 of the study we used a Trigger Assessment Tool that was 
developed for the study to identify ED visits based on their likelihood of being an ADE. 
Upon validation of the Trigger Assessment Too l we found that there was one visit (chart) 
identified initially as ··no" probability of being an ADE that was in fact a PADE. Th is 
suggests that the Trigger Assessment Tool may not have been as sensitive as we had 
hoped. and as such. \VC may be underestimating the true pre,a lence of A DEs in the 
community. although it is recognized this would be by a very small margin. The Janeway 
Hospital is a referral centre and is located in St. Jolm·s. the capital of Newfoundland and 
Labrador. Thus, find ings from our study cannot be considered representative of EDs 
treating children elsewhere in the province. Anot her limitation of this study may have 
been reviewer bias . A professional's ability to detec t an ADE from reviewing a medical 
chc~rt is based on his/her clinical experience and knowledge. Though this bias ''as 
minimized by having four reviewers independently review the charts and then reaching 
consensus. we were still limited to certain areas of clinical expertise with each of the 
reviewers. 
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Conclusion 
Emergency Department visits as a result of ADEs are not uncommon among the 
pediatric population in StJohn's. Newfoundland. and in many cases may be preventable. 
/\ge and number of current medications do not appear to be associated with pediatric 
ADE. although it is recognized that our study sample was not taking many different 
dmgs. Antimicrobial agents were found to be most frequently associated with 
ADEs!PADEs. Further education along with tools to rnakc health care professionals more 
aware of potential A DEs and their implications is needed. The optimal strategy may 
involve intcrvcrllions outside the hospital to improve prescribing practices and 
monitoring. particularly among high-risk patients or patients taking high·risk 
medications. 
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Abstract 
Background: Adverse drug e\'ents (A DEs) occurring in the community and treated in 
Emergency Departments (EDs) have not been well studied. 
Objective: To dctennine the prevalence. severity and preventability of A DEs presenting 
at EDs in two university-aniliated tertiary care hospitals in the Canadian province of 
Newfoundland and Labrador (NL). 
Methods: A retrospective chart review was conducted on a stratified random sample (n = 
I .-1.58) of adult patients (2: 18 years) that presented to EDs from January I to December 
31. 2005. Prior to the chart review. the sample frame was developed by first eliminaling 
visits that were clearly not the result of an ADE. The ED summary of each patient \\HS 
initially reviewed by two trained reviewers in order to identify probable ADEs. All 
eligible chm1s were subsequently reviewed by a clinical team. consisting of two 
pharmacists and two ED physicians. to identify ADEs and detern1ine their severity and 
preventability. 
Results: Of the 1 .458 patients presenting to the two EDs. 55 were detennined to be the 
result of an ADE. or a possible adverse drug event (PADE). After a sample-weight 
adjustment. the prevalence of ADE/PADE was found to be 2.4%. Prevalence increased 
v. ith age (0.7%. 18-44 )Cars; 1.9%. 45-64 years; 7.8%. ?:65 years) and the mean age for 
patients with A DEs was higher than those with no A DEs (69.9 vs. 63.8 years. P< 0.01 ). 
A higher number ofcomorbidities and medications were associated with drug-related 
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visits. Approximately 29% of the ADEs/PADEs identitied were considered to be 
preventable. with 42% requiring hospitalization. Cardiovascular agents (37.4%) were the 
most common medication class attribll!cd with ADEs/PADEs. 
Conclusions: Adult A DE-related ED visits arc frequent in NL and in many cases 
preventable. Further efforts are needed to reduce the occurrence of preventable ADEs 
leading to ED visits. 
Keywords: Adverse Omg Event (ADE). Prevalence. Severity. Preventability. Emergency 
Departments. 
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Introduction 
Prior research indicates that adverse drug events (ADEs) are a concern in both 
inpatient and outpatient settings I·~ These unfavorable occurrences arc a significant cause 
of morbidity and mortality 6· 7. and result in signilicant resource utilization. including 
increased emergency department (ED) and physician visits. diagnostic tests. medication 
use and hospital admissions li Such events account for 17 million ED visits and 8.7 
million hospital admissions in the United States each year 'l, 10 Between 1995 and 2000. 
costs associated with ADEs in the United States rose from US$76.6 billion to over 
US$ 177.4 billion 10 11 . 
An ADE is any injury resulting from medical in ten entions related to a drug 
whose outcome is unexpected and unacceptable to the patient and health care provider I! 
ll. A DEs ha\e been studied mostly among hospital patients. and it has been estimated 
that 5%--25% of hospital admissions are drug·related 1 ~ 1 ~. However. A DEs occurring in 
outpatient settings and treated in EDs receive less attention. even though more than 80% 
of community·dwelling adults use medications on a weekly basis. and approximately 
threefold more patients are treated in EDs for A DEs compared to those admitted to 
hospi tal~. 16 
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The Institute of Medicine report To Err Is Human. Building ll Sl!fi!r Health 
System concluded that the solution to preventing medical errors is ··building a safer health 
system"that identities patient safety as a pre·requisite to high quality care 17. Despite 
widespread recognition of the need for a safer health system. ADEs occurring in 
community settings remain a substantial cause of ED visits. The aims of this study ''ere: 
(I) to detennine the prevalence of A DEs presenting at adult EDs in Newfoundland and 
Labrador (NL). Canada. and to classify them according to severity and preventability: 
and (2) to describe demographic and clinical t:1ctors associated with A DEs. 
Methods 
Setting and study population 
The study setting was two adult acute care hospitals. the Health Science Center 
(HSC) and St. Clare's Mercy Hospital (SCMH). both of,,hich deliver te11iary care in St 
John's. NL. Canadu. These two hospitals serve a catchment area of approximately 
280.000 residents. and together have an average of28.000 admissions and 80.000 
emergency room visits per year. 
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Eligible subjects included all patients aged ~ 1 8 years who were residents of NL 
and presented to one of the two EDs between January I st and December 31st. 2005. ED 
visits with a high probability of not being due to an ADE (e.g .. motor-vehicle accident. 
substance abuse. drug abuse. anempted suicide. cut- or bum-related injuries. etc.) were 
excluded to narrow the sampling hame. The main reasons \\e excluded visits due to drug 
abuse or intentional overdose was to avoid overestimating the true frequency of A DE-
related visits to the EDs. given such events would not constitute a drug-related problem 
(DRP) according to widely accepted criteria of DRPs IR. Patients who presented to EDs 
through a referral process. and subsequent ly identified as a valid ED visit were included 
in this study. Ethics approval was obtained from the Human Investigation Committee of 
Memorial University of Newfoundland. 
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Figure 3.1: Illustrative flow-chart for identification of A DEs in adult )llltients 
presenting to EDs 
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Study sa mple 
Chans were selected using a stratified random sampling design (figure 3.1 ). 
There were six strata (Male 18-44 years. :v1ale 45-64 years. Male :::65 years. Female \8-
4~ years. Female 45-64 years. and Female 2:65 years) based on patients sex and age at ED 
visit Evidence in the literature regarding the prevalence of ADEs was found to be 
inconsistent, ranging from 2.5% to 35%. which can be mostly attributed to differences in 
study designs and patient demographics l\1· 2 ~ . To determine our study sample we 
estimated an average of I 0% of ED visits would be attributed to ADEs in patients aged 
2: 18 years. To achieve a 95% confidence interval (±4%). we initially calculated a sample 
size of 217 ED visits for each stratum. resulting in a total of 1.302 ED visits. To reduce 
the sampling error. and to compensate for the exc lusion of ED visits attributed to suicide 
attempts and drug abuse. we added a 10% over-sample. After the chart review was 
completed. the final sample size for the study was 1.458: resulting in a 12% over-sample. 
This difference of2% \.vas attributed to inclusion or ED visits through referrals as 
previously described. For patients with multiple ED visits during the study period, on ly 
one visit was selected at random for review. 
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Outcomes and definitions 
An ADE is defined as any undesirable effect caused by the use or misuse of a 
dmg (prescription or nonprescription) with a patient n. ~-· . Events may be the result of 
non11al or inappropriate usc of a medication. and range from minor reactions such as a 
skin rash to serious and life-threatening events. even death. In this st udy. we used another 
tenn ··possible adverse drug event .. ( PADE) was defined as an event that may have been 
related to a current medication. but could not be conlirmed using the patient chart. 
Medication errors arc mishaps that occur during prescribing. transcribing. dispensing. 
administering. compliance. or monitori ng of a drug. Example of medication errors 
includes misreading or miswriting a prescription. Medication errors arc more common 
than A DEs. but result in ham1 less than 1% of the time u . We studied ADEsfPADEs 
involving either prescription or over-the-counter drugs encompassing all traditional 
adverse e!Tects. We also included those medication errors that caused harm. 
Data Coll ection 
Data collection involved a 2-step review of ED chans using the Meditech system. 
a hospital intOnnation system whereby all e lectronic patient infom1ation. including ED 
summaries. is scanned and uploaded to the patient's protile (Figure 3.1 ). In the fi rst step. 
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the ED summaries of each chart were reviewed by a team consisting of a physician and a 
registered nurse using a manually enabled Trigger Assessment Tool developed by the 
research team (Appendix D.l ). This tool listed 39 screening criteria (triggers) known to 
be sensitive to the occurrence of AOEs among adults. The reviewers combined these 
triggers with the patient's history of medication use. as well as a subjective assessment. to 
determine whether an ADE was the reason for the ED visit. If it was classitied as being a 
probable ADE. the reviewers through a consensus process coded the reason for the visit 
as having either a high. moderate.low. or very low probability of being an ADE. 
The second step included a full review of all ED charts identified as having 
"high" and "moderate" probability A DEs. and a random sample of "low/very low'· 
probability A DEs. As part of the validation process. a full review was also carried out on 
a sample of those ED visits classified as having "no" probability of being an ADE. Two 
ED physicians and two clinical pharmacists independently reviewed each of the charts 
using a data collection tool that was a modi tied version of the tool developed by Gandhi 
ct a! 2~ (Appendix o.:n There\ ie\\ers were blinded to the lirst step review that identitied 
probable A DEs. The reviewers first obtained demographic and clinical infonnation. 
including presenting complaints. past medical history. drug history. history of allergy. 
medication dose. frequency. and reaction for the event. as well as the patient's most 
recent laboratory records. The re\ iewers used this iniOnnation to assess whether the ED 
visit was a result of an ADE. PADE or medication error. Each reviewer also classified the 
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event according to its severity and preventability. Using an adapted version of previously 
published criteria. severity was classified as being "fatal". "life threatening ... "serious or 
"signiticant ·:and preventability was classilied as '·definitely preventable ... "probably 
preventable··, "probably not preventable", or "definitely not preventable·· 2· ~~-15 . 
Disagreement about classification of A DEs. and their severity and preventability were 
resolved during consensus meetings. The principal invest igator of the study (Dr. Don 
MacDonald) was present dLlring all consensus meetings to ensure healthy discussion 
among all reviewers and to mitigate potential influences of any dominant personalities. 
As a result. consensus by all 4 reviewers was always reached. 
In this analysis we used 2 data sets: (I) summary data on all patients from the first 
review. and (2) detailed infonnation on the sub-sample of patients collected through the 
chm1 review. 
Sta tistica l Analys is 
We generated descriptive statistics including means. standard deviations and 
ranges. The primary outcome variables ADE and PADE were combined into a single 
variable ADE/PADE. as we assumed that the causes of possible A DEs were similar to 
confirmed ADEs 2 The methodological bene lit of pooling these two categories was to 
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reduce the random error associated with small number of events. The unit of analysis was 
the ED visit. Prevalence ofADEs/PADEs was calculated per 100 ED visits and presented 
with p-values using the binomial propo11ion test. We considered the inverse of the 
sampling fraction for step I and step 1to obtain an adjusted number oft01al visits to be 
studied (i.e .. the denominator). as \\ell as an adjusted number of ADEs/PADEs identified 
(i.e., the numerator). Each study subject was assigned a weight to represent the number of 
ED visits in the study population by each sampled ED visit. The prevalence of 
ADE/PADE was estimmed after sample weight adjustment to account for the sampling 
fraction and stratification in the sampling design (Appendix E). Events that \\ere assessed 
as definitely or probably preventable were merged into "preventable". and those assessed 
as definitely or probably not preventable were merged into ··not preventable". Rate of 
severity and preventability were derived by dividing the number of events in the 
respective categories by the total number of A DEs con tinned by the reviewers. Mantel-
Haenszel chi-square analysis was perfom1ed to determine whether there was an 
association between severity and preventability of A DEs. Factors (i.e .. age. sex. number 
of co-existing health conditions and current medications) associated with ADE/PADE-
related visits were tested using Student's !-test fOr mean and Binomial propottion test tOr 
proportion. The number of ADEs was extrapolated to the study population by multiplying 
the weighted estimate of prevalenct! by the number of ED visits in the study sample. 
Number of preventable ADEs and hospitalization due to ADEs were extrapolated to the 
study population in a similar manner. Data analysis \\8S carried out using SPSS fOr 
Windows versionl5.0 (SPSS Inc .. Chicago.IL). 
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Results 
During the study period. 82.516 adult ED visits were identified. Of these. 2. 749 
visits were excluded because they were by non-residents ofNL. and 12.076 were 
excluded since they did not meet the inclusion criteria. 1\ total of67.69l ED visi ts 
(41 .135 uniqw: patients) were available for the sample frame. The mean age (±SO) of this 
cohort was 46.9 (± 19.6) years" ith 54 A% (36.814/67.691) v.ere female. 
Of the \,458 ED visits sampled from the 67.691 visits. 653 (44.8%) were 
identitied as having a high (29). moderate ( \35). low (218). or very IO\\ (271) probability 
of being the result of an ADE. Gastrointestinal symptoms (e.g .. nausea. vomiting. and 
d iarrhea) and skin rashes were found to be the most common manifestations of patients 
identilied as high or moderate probability of having an /\DE. 
Patit.>nts identified as hm ing a ··high" (n=29) or "moderate" (n= 135) probabi lity 
of having A DEs. along with a random sample of 170 ED visits out of 489 classified as 
having a ·•[ow" or ··very low" probability of having A DEs. were independently reviewed 
by two ED physicians and t'''O clinical pharmacists. Table 3.1 presents demographic and 
clinical characteristics oft he 334 (29 + 135 + 170) patients selected fo r chart review. The 
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mean (±SO) number of comorbidities and Cllrrent medications for th is group ''ere 3.5 (± 
1.9) and 5.6 (± 3.6). respectively. 
Fifty-five of the 334 patients were identified by the team as having an ADE 
(n=29) or a PADE (n=26). Of the 55 ADEs/PADEs. 52 (31.7%) were identified from the 
16-J ED visits classified as .. high/moderate .. probability for ADE visi ts and the remaining 
3 (1.8%) were from the sample of 170 ED visits classified as " low/very low·· probability. 
As part of the validation process. a sample of 192 charts from 805 I::: I) visits classified as 
.. no'" probability for ADE visits were revie\\ed for validation of the trigger tool exercise. 
None of these 192 visits was found to be A DE-related. 
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Table 3. I : Demographic and clinical chantctcdstics of 334 patients selected for 
Characteristics 
Age. mean (±SD) 
Age group. years 
Sex 
18-././ 
./5-6./ 
65 -
Female 
Male 
Total no. of comorbidities. mean 
(±SD) 
\lo. ofcomorbidities 
0 
dtart revie" 
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No. of patients 
64.8 (±16.6) 
38 
105 
191 
199 
135 
3.5 (± 1.9) 
4 1 
58 
74 
68 
33 
(%) 
11.4 
31.4 
57.2 
59.6 
40.4 
2.7 
12.3 
17.4 
22.2 
20.4 
9.9 
>5 51 15.3 
Total no. of medications. mean (±SO) 5.6 (± 3.6) 
No. of medications 11 
Not m·ailable 0.6 
21 6.3 
35 10.5 
55 16.5 
51 15.3 
34 \0.2 
>5 136 40.7 
Previous history of allergy 101 30.2 
8 
··current medication·· means medication or medications (prescription or non-
prescription) that the patient had been taking prior to presenting to EDs. not those that 
may have been given after arriving at EDs. 
We have \\t:ighted to the inverse probability of the sampling fraction ((i.e .. 3 x 
1/( 170/489)- 8.6. rounding to 9). yielding an estimated count among the random sample 
of 1.458 charts to 52+9=61 ADEsfPADEs (numerator). The denominator of the 
prevalence of ADEs/PADEs was set to I ,777 (i.e .. 1458 x 1 /(6769 1 /82516)~1.777) to 
account for the excluded ED visits prior to the chart review. with the assumption that 
none of the visi ts was anriblllcd to an ADE/PADE. The age group and sex of the 6 
additional patients with an ADEIPADE in the numerator (61-55=6) were assigned in 
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proportion to the actual number of ADE/PADE (55) and those for 3 I 9 (I 777- 1458=3 I 9) 
patients in the denominator were in proportion to the study sample ( 1.458). with rounding 
to the nearest whole number. Atler a sample weight adjustment to account for the 
sampling fraction given above and stratification in our study. the overall prevalence of 
ADEs!PAOEs was 2.4% (95% Cl: 1.8-3.0). Note that we only used this adjusted ADE 
number of61 to calculate prevalence and for extrapolation. Information related to the 55 
ADEs/PADEs actually identitied was used for further analysis. given that severity. 
preventability. and dntg related infonnation was not available for the 6 estimated A DEs. 
We estimated the results of our validation exercise that the rates of ADEs/PADEs among 
high. moderate and low probability groups were 72.4% (2 1129). 22.2% (301135) and 
3.7% (3/82). None of those revie\\ed from the very low probability (88) and no 
probability ( 192) groups were found to be A DE-related. This suggests that the Trigger 
Assessment Tool was sensitive to trigger the true ADEs/PADEs in the ED charts. 
The mean (±SO) age for patients with an ADEIPADE was 69.9 (±14.2) years; 
71.6±9.9 years for males vs. 68.7± 16.5 years for tCmales. The distribution of 
ADEs/PADEs by age and sex is presented in Tab!~ 3.2. The prevalence of ADEs!PADEs 
among males ( 1.6%. 95% Cl 1.0-::!:.2) and tema1es (3.1 %. 95% Cl 2.1-4.2) \\as similar. 
and increased with age. peaking at 7.8% for patients aged :::65 years. Twenty-three 
(4 1.8%) oft he 55 patients with ADEs/PADEs required hospitalization. 
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Table 3.2: Prevalence of ADEs/PAOEs by age and gender 
All 
Sex 
Male 
Female 
Age (years) 
18-44 
45-64 
65-
No of patients with 
ADEII'ADE 
55 
22 
33 
10 
4 1 
Weighted prevalence of 
ADEIPADE, 'Yo (95% Cl) 
2.4(1.8. 30) 
1.6 (1.0, 2.2) 
3.1 (2.1. 4.2) 
0.7 (0.0. 1.4) 
1.9 (0.8. 2.9) 
7.8 (5.6. 9.9) 
• Point estimate~ and Cis \\ere v.eighted to account for stratification in the ~ampling design and sampling 
fraction associated with the selection of number of chans for revie\\ . 
Table 3.3 presents the analysis of factors associated ''ith ADE/PADE 'isits ( i.e .. 
number of comorbidities present and number of medication used). The mean age for 
patients with ADEs/PADEs ''as higher than for those having no drug-related visits (69.9 
vs. 63.8 years. P< 0.01). A higher number of comorbidities and medicat ions was 
associated with drug-related visits (p < 0.05 and p<O.Ol. respectively). Of the 55 
confirmed ADE/PADE patients. one (1.8%) case was t:1tal. 2 (3.6%) \\'ere life-
threatening. 25 (45.5% ) serious. and 27 (49.1 %) signiticant. Approximah:.'l) 29% (95% 
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CI: 17.1 - 41.1) of the 55 ADEs!PADEs identitied were considered to be preventable. Of 
the serious. life-threatening. and fatal events. 35.7% were identified as potentially 
preventable. compared with 22.2% of the signiticant e,·ents: however. the difference was 
not statistically significant (Table 3.-1.). Of the 23 hospitalizations due to ADE/PADEs. 8 
(3-L8%) were considered preventable. 
Based on the 55 ADEIPADE patients. we estimate that approximately 2.000 adul t 
patients (95% Cl: 1.458-2.495) were treated in the St. John·s region for ADEs/PADEs in 
the two EDs during the one-year study period: of these. an estimated 570 ADEs/PADEs 
would have been preventable. Further. it is estimated that 826 of the 2.000 would have 
been hospitalized. This estimate is based on the total ED visits in the swdy population 
(n=82.516). 
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Table 3.3: Factors associated with drug-related visits (ADEs/PADEs) to EDs 
Type of visit; no. ,(%) of visits 
Drug-related Not drug-related P-value 
n =55 n = 279 
Age. mean (±SO) 69.9 (±14.2) 63.8 (±16.9) < 0.01" 
Female sex(%) 60.0 59.5 0.94 b 
-;\lo. of comorbidities. mean (:::SO) 4.0 (±1.9) 3.4 (±1.8) < 0.05 u 
Total no. of medications c. mean 
7.4(±3.9) 5.2 (±3.5) < 0.01" 
(~SD) 
a Student's t-test was used for comparing two means: Binomial proportion test was used 
for comparing t\\0 independent binomial proportions:,. ··current medication" means 
medication or medications (prescription or non-prescription) that the patient had been 
taking prior to presenting to EDs, not those that were taking at the time of ED visi ts. 
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Table 3.4: Number :md rates of preventability of adverse drug cnnts by severity 
Category of preventability 
P-\'ltluc Total 
Preventable Not Preventable 
Category of 
Severity No.(%) No.(%) 
Significant 6 (22.2) 21 (77.8) 27 
Serious. life \8 (64.3) 0.43 a 10 (35.7) 28 
threatening or fatal 
Total 16 (29. 1) 39 (70.9) 55 
~ Mantei-Haenszel chi-square test \\aS used lOr comparing two independent bin~ 
propo11ions. 
The d istribution of clinical complications associated with ADEs/PADEs is 
presented in Table 3.5. Hematologic complications (43.6%) were the most common 
complications associated ''ith ADEs/PADEs. followed by gastrointestinal (32.7%). 
neurological ( 1-l-.5%). skin ( 12.7%). cardiovascular ( 12. 7%). metabolic (9.1 % ). 
respiratory (7.3%) and renal (5.5%) complications. 
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Table 3.5: Number and rates of clinical complications associated with ADEs/PADEs 
Cl inical complications No. of (%)' 
patients 
Hematological (including bleeding) 24 43.6 
Gastrointestinal 18 32.7 
Neurological 14.5 
Skin 12.7 
Cardiovascular 12.7 
Metabolic 9.1 
Respiratory 7.3 
Renal 5.5 
Other 10.9 
• A patient nta) have had more than one compl1cation a~ a result of ADE~PADEs. l"he total number of 
patient~\\ ith ADF:JPADEs bused as denominator. 
Table 3.6 presents the distribution of drug classes implicated in the 55 
ADE/PADE related visits. with cardiovascular (37.4%). honnonal ( 11.2%). and 
hematologic (9.8%) being the most common agents. Medications most frequently 
associated with ADEs/PADEs. either on their own or in combination with other agents. 
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were antiplatelets agents (24%). warfarin (18%). antibiotics ( 15%). antihypertensive 
agents (13%). and chemotherapy agents (I I%). Warfarin. divalproex, and chemotherapy 
agents. drugs with a nanow therapeutic index and high risk fo r toxicity. were found to be 
the cause of nearly one-third (31.7%) of EO-treated ADEs/PADEs in patients aged ~65 
years. 
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Table 3.6: Distribution of medication class implicated in the 55 ADEs/PADEs 
patients 
Medication class 
Cardio"ascular agents 
Diuretics 
Angiotensin·converting·enLyme inhibitors 
Cholesterol Agents 
b·Blockers 
Calcium Channel Blockers 
Other cardiovascular agents 
Nitrates 
Angiotensin II receptor blockers 
Combination blood pressure medications 
Hormone agents 
Oral hypoglyccmics 
Corticosteroids 
Thyroid Agent 
Insulin 
Other honnone-modifying agents 
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No. 
153 
30 
30 
28 
27 
16 
46 
22 
II 
% 
37.4 
7.3 
7.3 
6.8 
6.6 
3.9 
2.2 
1.5 
1.0 
0.7 
11.2 
5.4 
2.7 
1.5 
0.7 
0.7 
Estrogen 0.2 
Hematologic ngents 40 9.8 
Platelet inhibitors 25 6.1 
Oral anticoagulants 13 3.2 
Other Hematological Agents 0.5 
Gastrointestinal drugs 39 9.5 
Central nervous system agents 31 7.6 
Benzodiazepines 14 3.4 
Antidepressants 2.0 
Narcotics 1.5 
Anti psychotics 0.2 
Anticonvulsants 0.2 
Other central nervous S) stem agents 0 .2 
Vitamins and Minerals 19 4.6 
Musl·uloskelcta l agents 16 3.9 
Nonsteroidal anti-inf1ammatory drugs 1.7 
Acetaminophen 1.2 
Cyclo-oxygenase-2 inhibitors 0.5 
Other Musculoskeletal Agents 0.5 
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Medication class No. % 
Respiratory traer agents 16 3.9 
Antimicrobial agents 15 3.7 
Bcta-Lactam agents 1.0 
Fluoroquinolones 0.7 
Macro! ides 0.5 
Antifungals 0.5 
Other antimicrobial agents 1.0 
Chemotherapy II 2.7 
He1·ba l Agents 1.2 
Others 18 4.4 
Total 409 100.0 
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Discussion 
This study is the first of its kind in NL. and one of the few studies in Canada to 
investigate A DEs among the adult patients presenting to F.Ds. Our study found that A DEs 
accounted for 2.4% of ED visits. of which 29% were considered preventable. Based on 
the findings of this study. we estimate that approximately 2,000 patients were treated for 
drug-related events in EDs in the two St. John's hospitals in 2005. with more than 800 of 
the visits resulting in hospitalization. Few of the A DEs were fatal or life threatening. with 
most considered either serious or significant. Compared with those having no A DEs. 
patients with ADEs/PADEs were older. were prescribed more medications. and had a 
higher nlllllber of comorbidities. 
Comparisons with other studies are challenging since the prevalence of ADE-
related ED visits varied from 2.5% to 35.0% 19.~2 . This variability may be attributed to 
differences in study populations (e.g .. 2:18 years vs. 2::65 years). methodology (e.g. 
retrospective vs. prospective). and inclusion/exclusion criteria. A recent Canadian study 
by Zed et al. 5 reported that 12.0% of ED visits at Vancouver General Hospital over a 12 
week-period period were due to A DEs. of which 68.0% were preventable. A systematic 
review of retrospective and prospective trials found 28% of ED visits were drug-related. 
of \\hich 70% \\ere pre\ entable 1 ·~ A US study using the National Electronic Injury 
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Surveillance System estimated the rate of A DEs to be 2.4 per 1.000 popLllation treated in 
EDs. with the elderly having a higher rate of A DEs (4.9 per I .000 population) 22 Similar 
studies on A DEs in non-EO settings. such as hospital and ambulatory care. reported 
variable ADE rates with the elderly being at greater risk of ADEs J.lQ . .:!-I, l 6·28. The 
prevalence of ADEs!PADEs fOund in our study is at the IO\\er end of previously reported 
ranges. These differences can be explained in part by variations in case definitions {e.g. 
ADE. PADE. medicmion error. etc. ). study designs. patient po pulation. medical practices 
and health systems ' ~Q. '10 . 
Hohl et a!. investigated the freqLlency of A DEs among patients aged ~65 years 
presenting to the ED in Mom real, Quebec and found I 0.6% of ED visits to be the result 
of an ADE 31 . This is comparable to the prevalence of ADE (7.8%) among the elderly in 
our study. Although there is debate in the literature as to whether age itself is a risk factor 
for an ADE-related visit or hospitalization -12• the mechanism relating age to risk for 
ADEs may include administration of multiple drugs in treating multiple comorbidities 
''hich is more common among the elderly 7 While an aging population tends to take a 
higher average number of medications. the people are more likely to be unsure of proper 
administration of drugs and also less likely to tolerate certain medications tOr various 
reasons. as outlined in the Beers Criteria -~-u" . 
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We found that medications such as wartftrin. divalproex. and chemotherapy 
agents with narrow therapeutic index and high risk for toxicity caused about one-third 
(3 1.7%. 13/41) of EO-treated A DEs in patients aged ?:65 years. This tinding supp011s 
findings in a US study that found medications with narrow therapeutic index and high 
risk of overdose or toxicit) (\\arfarin. insulin. and digoxin) caused nearly one third of the 
EO-treated A DEs in patients aged ?:65 years ~2 A similar study based in an ED setting in 
Spain repo11ed that the preventability of A DEs was related to drugs with narrow 
therapeutic index (OR: 9.83. 95% Cl: 5.26-18.40). However. in our study this association 
could not be established due to the small number of naiTO\\ therapeutic inde:•;:.related 
preventable A DEs 55. 
An interesting finding of thi s study was that more serious ADEs/PADEs were 
deemed to be preventable. although the difference was not statistically s ignificant. A US 
study con tined to older outpatients found a similar association between severity and 
preventability of A DEs 25. Consistent with both the hospital and nursing home settings. 
more serious A DEs were more likely to be identified as preventable. 
Information on ADE epidemiology comes mostly from studies carried out in the 
United States. Our study is one of the few carried out within the Canadian context. a 
country that unlike the USA. has a nationwide uni versal health care system. A recent 
review comparing health outcomes between Canada and the US reported that. in general. 
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health outcomes may be superior in patients cared tOr in Canada versus those in the 
United States 311 Although the two countries h.:we looked to each other tOr ways to 
impro\e their respecti'e health care systems. differences still exist. For e:•;ample. the US 
health care system is highly privatized and has higher per capita spending compared to 
Canada 37· 38. The US is the only wealthy industrialized country in the world that Jacks 
some form of universal health care. and thus the relative merits of health care outcomes 
may difter between the two systems 39. TheretOre. our findings add to the existing 
literature by tOcusing on a population with universally funded health care and draw 
attention to the need tOr prevention effOrts that target patients in Canada at high risk tOr 
ADEs. and ultimately add to the discourse to improve patient safety. 
Limitations 
This study had several limitations. Firstly, using a retrospective chart review may 
underestimate the tnte frequency of ED visits as being caused by an ADE. Ideally. a 
prospective design with a large sample would have increased the accuracy of estimates of 
drug-related visits and their preventability. Secondly. compared to patients aged ~65 
years we found fewer A DEs in younger age groups which makes our estimates of ADE 
prevalence more prone to sampl ing error in these age groups. Nevertheless. the 
prevalence of ADE among elderly patients was 7.8% which is relatively close to our pre-
sludy assumption of 10% considered in the study design. Thirdly. we may have missed 
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certain A DEs such as drug induced traflic accidents and suicidality. Inclusion of such 
events. which would be very rare. might have increased the prevalence of ADE obtained 
in our study. Fourthly. we could not extrapolate our data to the entire province. since the 
Health Science Centre and St. Clare·s Mercy Hospital are located in St. John"s. the 
capital of the province. and cannot be considered representati\ e of all hospitals in the 
province. 
Conclusions 
Emergency Department visits as a result at' A DEs are not uncommon. A focus on 
further education along with appropriate tools need to be in place so that physicians and 
phannacists can collaborate more closely to impro\e prescribing practices and 
monitoring. particularly among high·risk patients. and thereby contribute to the reduct ion 
of that subset of A DEs considered preventable. 
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Abstract 
O bjecth'e: To detem1ine the incidence of adverse drug reactions (/\DRs) among elderly 
hospitalized patients; to describe observed A DRs with respect to responsible drug 
classes; and to examine whether comorbid conditions. patient's age and other socio-
demographic factors are associated with recurrent events of A DRs. 
Design: Population-based retrospective cohort study using administrative and patient 
hospital discharge records. 
Setting: All acute care hospitals in the Canadian province of Newfoundland and 
l.abrador. 
Participants: 64.446 patients aged 2:65 years who had at least one hospital admission 
over a period of 12 years (April I. 1995 to March 31. :W07). 
M;l in outcome: Number and incidence density of A DRs. 
Results: 4.056 (6.3%) patients had a total of 4.858 A DRs ranging from I to 8 per 
patient. The incidence of A DRs was 15.2 per I .000 person-years (95% contidence 
interval 14.8 to I 5. 7). The most common drug categories implicated in A DRs were 
cardiovascular agents ( 17.7%). followed by analgesics/antipyretics/anti-inflammatory 
drugs ( 16.1 %). systemic agems ( 11.8%) and agents affecting blood constituents (9.7%). 
A strong dose-response relationship was found bet,,een Charlson comorbidit) index 
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(CCI) and recurrent events of ADR (Rate ratio 1.67. 95% confidence interval 1.41 to 1.98 
for CCJ:2-3: 2.38. 1.98 to 2.87 for 4-5: 3.83. 3.21 to 4.57 for ?:6). Comorbid congestive 
heart failure (1.58. 1.33 to 1.89). connective tissue disorder (1.57. 1.07 to 2.:29). dementia 
(3.91. 2.48 to 6.17). diabetes (with complications) (2.42. 1.64 to 3.56). cancer (3.12. 2.58 
to 3.76). metastatic cancer (1.49. 1.05 to :2.11 ). peptic ulcer diseases {1.8:2. 1.34 to 2.49) 
and renal diseases (2.17. 1.55 to 3.04) were strong predictors. Rural areas ( 1.22. 1.01 to 
1.46) were associated with increased risk for experiencing recurrent /\DRs. whereas 
advancing age and sex had no effect on recurrent A DRs. 
Conclusions: Comorbidity from chronic diseases and the severity of patient"s 
underlying illness. rather than individual characteristics (advancing age and sex). 
increased the likelihood of recurrent events of ADR in elderly hospitalized patients. 
Substantial changes in the organization and delivery ofheahh care that tOcus on the 
monitoring of prescribed drugs in elderly patients with comorbidities could mitigate the 
recurrence of A DRs. 
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Introduction 
Adverse drug reactions (ADRs) are a major public health problem given such 
events arc the most common type of injuries experienced by hospitali7cd patients 1• 
A DRs may lead to hospitalization. or occur during hospi talization and cont ribute to an 
increased length of stay. The rcccn1 focus on patient safety and the conccm about the 
number of negative outcomes resulting from drug use. rather than the underlying 
diseases. has prompted health care professionals to take a critical look at these drug 
responses. A series of studies examined A DRs among hospitaliLed patients in USA and 
Australia 2-b. however. much less infOrmation is available about these events in 
hospita lized patients in Canada. A meta-analysis by Lazarou et al. revealed the incidence 
of serious A DRs in patients during hospitalization and those admitted to hospital in the 
United States as 2. 1% and 4.7%. respectively 6 . The study reported A DRs as being the 
foltrth and sixth leading cause of death. Other stttdies indicated A DRs occurred in 2-20% 
ofhospitali~ed pat i ents"~. Recently. Baker et al. 7 provided the first national estimate of 
the incidence of adverse events among adult patients in Canada (7.5 per 100 hospital 
adm issions). At1er extrapolation. the number of hospital admiss ions attributed to adverse 
events was estimated between I 4 I .250 and 232.250 in 2000. Furthcnnorc. Canadian 
incident reporting data indicated a 35% increase of adverse react ions from 2008 to 2009 
Ill 
Adverse drug reactions are common and can bavt· serious consequences in an 
older population. According to a recent census report. the Canadian population is aging 
rapidly. The gr0\\1h rate in Canadians over the age of65 years \\as more than double 
( 12%) the rate of overall population increase (5%) in the 5-year period from 2001 to 
2006, and. at present. the Canadian senior population represents about 14% of the total 
population. up from abolll 10% in 1981 9· 10• Elderly individuals are vulnerable to ADRs 
because of the multiple drugs they take to manage multiple comorbid conditions and 
because of pharmacokinetics and pharmacodynamics changes II. 11. Furthermore. ADRs 
can be recurrent events. in that an individualnw) experience one or more such e\ ents 
over a period of time. It is important to identitY the magnitude of A DRs in this high risk 
group to aid physicians in their decisions about prescribing. delivering and monitoring of 
drug therapy. If predictive factors can be identified. this would allow providers to identify 
early symptoms of A DRs. and to respond to them quickly 1 ~ . 
Although prior research has identified several risk factors fo r the occurrence of 
A DRs among older adults (e.g .. age. female sex. drug regimen. type of drugs. and 
comorbidities) 11· 1 ~· 1 11• little is known about the risk factors associated with recurrent 
events of ADR. For public-health planning and the evaluation of quality management 
programs. it is important to study recurrent ADRs, rather than only the first event 17. 
Because the risk of both health service utilization and the burden of illness increase with 
each subsequent ADR. the number of A DRs is a more robus1 indicator of risk than a 
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single event18. The objectives of this paper are to: ( l) estimate the incidence of ADR 
among elderly hospitalized patients. (2) characterize observed ADRs with respect to 
responsible drug classes. and (3) examine whether comorbid conditions. patient's age. or 
other socio-demographic factors are associated with recurrent A DRs in elderly 
hospitali?ed patients. 
Methods 
Study design and data sources 
We conducted a population-based retrospective cohort study using province-wide 
administrative data on hospital separations from all community- and teaching-based acute 
care hospitals in Newfoundland and Labrador (NL): a province with 506.000 population 
(2007).lhe study population consisted of all residents aged >65 years (at first hospital 
separation) with at least one hospital admission during the study period from April I. 
1995 to March 31. 2007. The study data were derived through a data linkage system that 
linked live administrative health databases: I) discharge abstract database (DAD). 2) 
health insurance registry database. 3) mortality system. 4) neighborhood socioeconomic 
status (SES) database. and 5) postal code conversion database (Figure 4.1 ). 
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The DAD is the hospital separation database containing the patient health care 
number. care episode number. date of admission. date of separation (i.e .. transfer. 
discharge. or in patient death): nomenclature from the international classitication of 
diseases (lCD) codes for main diagnosis and up to 24 additional diagnoses and up to 10 
medical procedures. Patient's hospital records \vere coded in the DAD using ICD-9 from 
April I. 1995 to March 31 200 I and lCD-I 0-CA ii·om April I. 200 I to March 31. 2007. 
The health insurance registry is a comprehensive plan of medical care insurance tOr the 
residents ofNL. This database contains participants demographic infonnation including. 
health care number. date of birth. sex. postal code of residence. insurance start and end 
date. The mortality system includes data compiled from provincial death notitications 
provided by the provincial Vital Statistics Division. The neighborhood SES database 
contains a measure ofSES for each postal code within NL. This database contains 
participants demographic intOnnation including. health care number. date of bi1 h. sex. 
postal code of residence. insurance start date and end date. The mortality system includes 
data compiled from provincial death notifications provided by provincial vital statistics 
division. The neighborhood SES database contains a measure ofSES for each postal code 
''ithin NL. TheSES score. developed by Audas. Cirtwill. and O'Keefe (2007) 19• is a 
composite value based on a number of measures related to social and economic 
conditions, including employment. education. and income from the 2001 census. The 
overall SES scoring system provides a numerical scale ranging from -24.0 to +24.0. 
where -24.0 indicates .. poorest .. SES and +24.0 is .. richest" SES. 
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Data Linkage S~;stem for Identificat ion of Adnrse Drug Reaction 
~ Unko!'d VJa heahh C2H' mn-ile~ Linked \'ia heahh t:~.re nlni:le~  
Diu:huge ab:s.mc:t diltabaie 
(AD bospnal iepa~atirau for all 
inpatients, 199:5.96 to 2006(17) 
Health in$W2nce regisuy 
(a,!!rnidemsasof31 Updat edd~thsblru; _ 
Mo!UlitySynem 
{Dutb record!. for all pro,'incial 
residenu, 1995 to 2007) Drt 2007) 
1:::! ,3S9 excluded cile 
to h osp!Ul trarufen 
tJ~,ASESda.bbaie 
(A measure ofSESmcie?!; for 
l ~ ... -.............. \ .. -'"' -'-''"'' e:otchposl:::ll codeinNL) 
::0:,-:'03 excludedasth~ ,. ! j 
w~re non-regdenU . 1 T-·-' -·u __ ; .. ..l.., ·-· '-·.1 - .1 ;_ .1... . I Linked \'ia residenual oostcode ______________j 
• -- Link ~d \'ia residenual oostrod~  
'-'---,----,---;---,-;o_-c.:-:-:.;c_::;.---, Postal code conversion daubaie 
(AD postal code nd SGC m NL) 
,&.DR= Adverse drug reactJOn, SES=SOCJ<reconomic status, :\l'L=:\l'ewfoundland and Labrador, 
The shaded boxes md.icate the database usN! for data lmkage and boxes '''1th solid border indJCatc the nwn~ of records extracted 
• ~um~ of~ expenenced by each patient ranged from I to 8, rs:wl_ugg a total of 4858 a.DRs 
Fit!urc -t I. Illustrative flowc ha rt for data linkage system to identify AI)Rs in the ('ldcrly hospitalized pa tien ts 
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Data linkage 
Patient records across all databases. with exception of the neighborhood level SES 
database. were individually linked using patient's health care number as the unique 
identifier. A de-identified study ID was assigned to each patient and identifiable 
information was removed to protect patient privacy. A SES score was assigned to each 
study subject by linking their record to the neighbourhood SES database by residential 
postcode. Ethics approval was obtained from the Human Investigation Committee of 
Memorial University of Newfoundlrmd. 
Definition and identification of ADR 
We studied ADRs that either caused a hospital admission or extended an existing 
patient's hospital stay. We adopted the definition of ADR from Edwards and Aronson 20 : 
··An appreciably hannful or unpleasant reaction. resulting from an intervention related to 
the use of a medicinal product. which predicts hazard from future administration and 
\\arrants prevention or specific treatment. or alteration of the dosage regimen or 
\\ithdrawal of the product .. We have chosen to use the term ·adverse drug reaction· 
rather than ad\erse drug event (ADE) given that according to the definition of these tenns 
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3
·
20
. we believe that ADR is the most appropriate term !Or our data as it does not include 
medication errors. 
Extemal causes of injury associated with the usc of a drug were recorded in the 
DAD using either E-code (E930- E949) for ICD-9 or Y -code (Y40-Y59) for ICD-10-
CA. These codes include any adverse effects caused by correct drugs usc. medicines or 
biological substances properly administered in therapeutic or prophylactic doses. but 
exclude accidental overdoses of a drug. wrong drug given or taken in error. accident in 
technique of administration of drug. and abuse of a dmg. Because a patient might have 
been transferred from one hospital to another betOre discharge. \\e checked all rt::cords tOr 
transfer between hospitals and. if admissions were as a result of transfer. we combined 
them into a single episode tOr analysis to avoid a possible double counting of an ADR. 
We excluded records of hospital separations related to non·residents of NL (0.9%) since. 
unlike residents of NL. they did not have a health care number or any other unique 
identifier to carry out linkage between data sets. 
Primary outcome measure 
Our primary outcome measure was the number of ADRs occurring during the 
study period fOr existing hospital patients or those that resulted in hospital admission. We 
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included patients meeting all inclusion criteria as a cohort and followed them up from the 
fi rst hospital separation (since April I. 1995) until the insurance end date due to death. 
tennination of insurance CO\ erage for another reason (e.g .. moving out of province). or 
end of study (March 31 2007). Dmgs responsible for ADRs were obtained from theE- or 
Y -codes on the hospital separation data. 
O ther va riables 
Patient related t3ctors considered for analysis included baseline age. individual 
comorbidity. severity of illness as measured by Charlson comorbidity index (CCI). sex. 
SES and residential locality (urban/rural). Comorbidity at baseline was estimated using 
the CCI which is a weighted score of 17 comorbiditics that was initially used to predict 
in-hospital and !-year mortality ~ 1 • and subsequently adapted for use with administrative 
data with the ICD-9 and TCD-10-CA :~-~3 . We calculated CCI scores by adding scores 
assigned to each specific diagnosis (Table 4.1 ). To account for patients that did not have 
an illness within the I 7 predefined conditions, a relative weight was given to address the 
issue of missing CCI scores when a patient appeared to have an illness equally severe but 
not related to one of those 17 comorbiditics. The relative weight assigned was based on 
the subjective assessment by a physician and a registered nurse. who reviewed the 
complete list of patients· health conditions. Since the study population consisted of only 
elderly patients \\hO were likely to have many comorbid conditions. assigning such 
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relative weights judged to be more appropriate than modifications of Charlson index 
previously highlighted 2~ . Given that we were interested in non-ADR comorbidity. ADR 
was not included in assigning such weights. Note that comorbidity in this article means 
co-existing health conditions since we considered primary diagnosis and other diagnosis 
lOr health conditions contributing patients to be hospitalized. A higher score on the 
Charlson index indicated a greater burden of co morbid disease. Subjects were grouped 
into tOur CCI categories: 0-1 (least se\ere). ::!- 3. 4- 5 and 2:6 (most st:vere). About 
0.39% ofsrudy subjects had missing SES and therefore values were imputed using 
median value imputation method ~s _ Because SES indicators were not available for 
individuals. a measure of neighborhood level SES score. including continuous values of 
the indexes. \\HS grouped into quintiles. 
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Table 4.1: Charlson comorbidity conditions (with weights) present at baseline in 
hospitalized patients aged 65 years and older, Newfoundland and Labrador, 1995/96 
-2006/07 
Charlson's comorbid conditions + 
AClJte myocardial infarction 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connecti ve tissue disorder 
Peptic ulcer disease 
Mild liver disease 
Diabetes (mi ld to moderate) 
Diabetes with complication 
Paraplegia 
Renal disease 
Cancer : 
Metastatic cancer 
Severe li ver d isease 
Weight 
t although AIDS was one of the eomorbid conditions in the Charlson index. no patients 
were fOund with a diagnosis of AIDS in our study sample. 
! includes any mal ignancy such as lymphoma, leukemia. 
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Statistical Ana lysis 
Descriptive statistics on ADR incidence were calculated by patients· basel ine 
characteristics wi th the d rugs responsible for the ADRs described in percentages. We 
calcu lated incidence density of A DRs per 1,000 person-years for age groups. sex. CCI 
severity scores. residential locality (urban/rural) and SES. Distribution of the drug 
categories (at the three-digit E-codc and two-digit Y-codc level) implicated in the A OR-
related bospitali.wtions and further detail on the drug groups (at the four-digit E-code and 
three-digit Y-codc level) most commonly responsible for A DRs were calculated based on 
the total number of A DRs following a classification system that was a modified version 
of the classification developed by Zhang et al.6 
We tested the overdispersion by using the goodness-of-lit statistical test proposed 
by Bohning u._ To account for the complexity in data characterized by excess zeros and 
overdispersion. we considered several modeling strategies in an effort to lind the most 
appropriate model for this analysis. We fitted Poisson. negative binomial (NB), zero-
innated Poisson. (ZIP) and zero-innated negative binomial (ZINB) regressions models 
(see Appendix F for details about these models) using the number of A DRs experienced 
by a patient as the dependent variable. Age (as a continuous variable). sex. CCI severi ty 
category. sr:s and residential locality were included in the models to adjust for 
differences in case mix of patients. To account for potential biases due to differences in 
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the observation periods we computed the logarithm of follow-up time (measured in 
months) as an offset variab le 21 . The likel ihood ratio test (LRT) was used to test if over-
dispersion was present in the data whi le the Vuong test was used to assess ifzero-
intlation was present:!~. In the final analysis the model that proved to be the most 
appropriate \\as the ZIN B model. 
A separate regression analysis was repeated after replacing the CC I severity 
category by a set of comorbid condi tion indicator variables: acute myocardial infarction. 
congestive heart failure. periphera l vascular disease. cerebrovascular di sease. dementia. 
chronic pulmonary disease. connective ti ssue disorder. peptic ulcer disease. mild liver 
disease. diabetes (mild to moderate). diabetes with complication. paraplegia. renal 
d isease. cancer. metastatic cancer and severe liver disease. RefeiTing it to as a rate ratio 
tRR). the effect of predictor was described us ing the inc idence rate ratio to report an 
incidence of ADR increase using a relative rate. The Wald test 2'l \\as used to assess 
whether the model coefficients were significantly different from zero (a.=O.OS). We used 
SJ\S 9.2 and R 2.8.1 for our analysis. For regression models. we used PROC 
COUNTREG in SAS 9.2 
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Results 
There were a total of308.075 hospital separations. of which 12.389 were 
excluded due to hospital transfers and 2.703 were identified with non-resident patients. 
The final number of separations included in the study was 292.983. 
For the study sample of 6-L~~6 patients (male -l7.9%: female 52.1 %). the total 
person-years of follow-up was 319.207. For the full 12-year study period. 4.056 (6.3%) 
patients were identified having experienced a total of 4.858 A DRs with the number of 
A DRs experienced by each of4.056 patients ranging from I to 8. Table 4.2 presents the 
distribution of the 20 broad categories of drugs impl icated in A OR-related 
hospitalizations. The most common dn1g categories implicated in ADRs were 
cardiovascular agents ( 17.7%). followed by analgesics/antipyretics/anti-inflammatory 
( 16.1 %). systemic ( 11.8%) and blood constituents (9.7%). 
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Tnble -t2: Drug categories· responsible for ad,'c•·se drug reactions (ADRs) in 
hospitalized patients aged 65 years and older, Newfoundland and Labrador, 
1995/96 -2006/07 
lC D- ICD-10- No.(%) of 
l>rug category : CA ADR 
Systemic antibiotics § E930 Y40 310 (6.4) 
Other systemic anti-infcctivcs/ antiparasitics E93 I Y41 89 (18) 
Hormones (including synthetics and antagonists) E932 Y42 368 (7.6) 
Primarily systemic agents E933 Y43 574 (1 1 8) 
Agents primarily affecting blood constituents E934 Y44 -!73 (9.7) 
Analgesics/antipyretics/anti-intlammatory drugs E935 Y45 780 (16.1) 
Antiepileptics/antiparkinsonian drugs E936 Y46 151 (3. 1) 
Sedatives. hypnotics. antianxiety drugs E937 Y47 75 (15) 
Anaesthetics and therapeutic gases E938 Y48 47 (1.0) 
Psychotropic drugs E939 Y49 242 (5.0) 
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lCD- ICD-10- No.(%) of 
Drug cntcgory : CA AOR 
Drugs primarily am~·cting autonomic nervous E941 YSI 153 (3.2) 
system 
Agents primarily affecting cardiovascular system E942 Y52 858( 17.7) 
Agents primarily atlt~cting gastrointestinal syst~m E943 Y5J 34 (0.71 
Agents affecting water balance/minerals/uric acid E944 Y54 233 (4.8) 
Agents affecting muscles/respiratory system E945 Y55 63 (1.3) 
Topical agents atlfcting skin. eyes. ENT. dental E946 Y56 104 (2.1) 
Other and unspecified drugs and medicines E947 Y57 296 (6.1) 
Bacterial vaccines E948 Y58 4 (0.1) 
Other and unspecitied vaccineslbiologicals E949 Y59 4 (0.1) 
Total 4858 ( I 00.0) 
ADR Adverse drug reaction: lCD lnternmional classilication of diseases: ENT ear. 
nose, throat. 
· Drugs responsible tOr A DRs obtained from theE-codes (ICD-9) or Y-codes ([CD-10-
CA) of the diagnosis variable in the hospital separation data: 
+Percent were calculated with respect to 4.858 A DRs. 
:The name of dmg catcgol)' was chosen according to the definition of the corresponding 
Y-eodes in the ICD- 10-CA. 
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§Excludes antineoplastic antibiotics (E930.7) from IC0-9 (,.,.ere added to primaril) 
systemic agents. which include antineoplastics). 
II Excludes benzodiazepines (£939.4) from ICD-9/JC0-9-C~v1 {\\·ere added to group 
sedatives. hypnotics. amianxietv drugs. which includes benzodiazepines in !CO-l 0) . 
.. E:-.:cludes sympathol~ tics (E94l.J) from ICD-9/ICD-9-C\11 {''ere added to agents 
p,rimarily affecting cardio\ascular system. which include these in !CD-I 0). 
E:-.:cludes theoph) lline (£9-t-t.\) from !CD-9 JC0-9-C~ l (was added to agents all~cting 
muscks respirator) s~ stem.'' hich includ ~o·s antiasthmatic::.). 
Specific details on the top 30 drug groups most often implicated with A DRs are 
presented in Table -t.J. The drugs most frequently associated with A DRs were 
antineop!astics or immunosuppressi' e drugs. coronary 'asodilators/cardiac rhythm 
regulators and other antihypertensive drugs. cardiac stimulant glycosides or similar drugs. 
anticoaglllants and NSA!Ds/antirheumatics agents. 
The overall incidence of A DRs was 15.2 per 1.000 person-years (95% CJ. 14.8 to 
15.7). Based on this univariate analysis. the incidence of ADR appeared to be greater 
among those who were older. female. having higher severi ty of illness. higher !eve! of 
SES (-1-(11 and 5(11 quintile) and li\'ing in urban areas (Table -1-.-1- ). These variables "ere then 
included as potential predictors of the number of A DRs. 
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Table ~.3: Top 30 drug groups· most commonly implic:Hcd in :Hivcrsc drug 
re;lctions (A DRs) in hospitalized patients :tgcd 65 yeo1rs a nd older, Newfound land 
and Labrador, 1995/96 -2006/0 7 
lC D- No.(%f 
Drug groups ! IC D-9 10-CA of A])R 
Systematic Antibi01ics 
Other systematic antibiotics E9308 Y408 89 (1.8) 
Unspecified systematic antibiotics E9309 Y409 86 (1.8) 
Penicillins E9300 Y400 44 (0.9) 
Cephalosporin E9305 Y401 43 (0.9) 
Sulfonamides E9310 Y410 38 (0.8) 
Hormones (including synthetics and antagonists) 
Glucocorticoids and synthetics E9320 Y420 197 (4.1) 
lnsulins and oral antidiabetic drugs £9323 Y423 125 (2.6) 
Primarily systematic agent 
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I) rug groups : 
Antineoplastic/immunosuppressive drugs 
Agents primarily affecting blood constituents 
Anticoagulants 
Thrombolytic drugs 
Analgesics/antipyretics/anti-intlammatory drugs 
NSA!Ds and anti rheumatics 
Opioids and related analgesics 
Salicylates adverse effect Rx usc 
Other analgesics/antipyretics 
/antirhcumatoid agents 
-1.-Arninophcnol dcrivmivcs (e.g., 
acetaminophen) 
Anticpilcptics and anti parkinsonian drugs 
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ICD-9 
E933! /E9 
307 
E9342 
E9344 
E9354 
E9350 
E935\ 
E9358-9 
E9352 
lCD- No.(%)t 
10-CA of ADR 
Y431-4 537 (I \.I) 
Y442 377 (7.8) 
Y445 24 (0.5) 
Y452-4 367 (7.6) 
Y450 \59 (3.3) 
Y451 147 (3.0) 
66 (\.4) 
Y458-9 
41 (0.8) 
Y455 
lCD- No.(%)' 
Drug groups! ICD-9 10-CA of ADR 
Hydantoin derivatives E9361 Y462 62 (1.3) 
Other and unspecified antiepileptics E9363 Y466 49 (1.0) 
Antiparkinsonism drugs E9364 Y467 22 (0.5) 
Psychotropic drugs 
Ant ips) choticsl neuroleptics E9391-3 Y493-5 112 (2.3) 
Antidepressants E9390 Y490-2 72 (1.5) 
Benzodiazepines E9394 Y471 72 (1.5) 
Agents primarily atTecting cardiovascular system 
E9420 Y517 504 (10.4) 
Coronary vasodilators/cardiac rhythm 
regulators and other antihypertensive /E9424-6 /Y521-525 
Cardiac stimulant glycosideslsimilar drugs E9421 Y520 415 (8.5) 
Agents affecting water balance. mineral/uric acid 
metabolism 
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l C D- No. (%)' 
Orug grou ps : IC D-9 10-CA of A DR 
Loop and other diuretics E9444 Y544-5 118 (2.4) 
Uric acid metabolism drugs (such as 47 (\.0) 
colchicine) E9447 Y548 
Benzothiadiazine derivatives E9443 Y543 41 (0.8) 
Agents affecting muscles/respiratory systems 
E9441/E9 Y556/Y51 46 (0.9) 
Antiasthmatics (including theophylline) 457 
Topical agents affecting skin. eyes. ENT. dental 
Local an ti-infectives/ anti-inllammatory drugs E9460 Y560 93 (\.9) 
Other and unspecilied drugs and medication 
Other drugs or medicines E9478 Y578 136 (2.8) 
Unspecified dn1gs or medicines E9479 Y579 130 (2.7) 
ADR= Adverse drug reaction: lCD= International classification of diseases: NSA!Ds= 
Non-steroidal anti -inflammatory drugs: ENT- ear. nose. throat. 
·Drugs responsible for A DRs obtained from the E-codcs ( ICD-9) or Y-codcs ( ICD-1 0-
CA) of the d iagnos is \ ariable in the hospital separation datu: 
t Percent were calculated with respect to 4.858 A DRs. 
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:The name of drug category was chosen according to the definition of the corresponding 
Y-codes in the ICD-10-CA. 
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T11ble -t4: Descriptive data on ADR incidence by age, sex, comorbidity and severity 
of illness 
r-v 
follow-up 
64.446 319.207 
All individuals 
Age at baseline (years) 
65-74 33.487 190.976 
75-84 23.552 106.519 
?:85 7,407 21.712 
Male 30.867 14.6084 
f emale 33.579 17.3123 
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No. of 
ADR 
4.858 
2.696 
1.752 
410 
2.166 
2.692 
Incidence/ I ,000 P-Y 
(95%CI) 
15.2 (14.8. 15.7) 
14.1 (13.6. 14.7) 
16.4(15.7.17.2) 
18.9(17.1.20.7) 
14.8 (14.2. 15.5) 
15.5 (15.0. 16.1) 
P-Y Incidence/ 1,000 1)-Y 
No. of 
fo llow-up A llR (95% Cl) 
CCI severity 
0-1 (least severe) 26.570 146.108 1.3:29 9.1 (86.1. 95.9) 
2-3 21.307 106.238 1.523 14.3 (13.6. 15.1) 
4-5 8.131 37.882 872 23.0 (21.5. 24.6) 
>=6 (most severe) 8.437 28.979 1.134 39.1 (36.9. 41.4) 
Socioeconomic status 
I st Quintilc (poorest) 12.836 62.490 859 13.8 (12 .8. 14 .7) 
2nd Quintile 12.7 14 64,058 857 13.4 (12.5. 14.3) 
3rd Quintile 12.363 61.733 810 13. 1 (12.2. 14.0) 
4th Quintile 13.289 66.429 1.283 19.3 (18.3. 20.4) 
5th Quintile (richest) 13.244 64.496 1.049 16.3 ( 15.3. 17.3) 
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P-Y Incidence/ 1,000 P-Y 
No. of 
follow-up ADR (95%CI) 
Residential locality 
Urban 25.280 1'15.277 2.193 17.5 116.8. 18.2) 
Rural 39.166 193.930 2.665 13.7 (13.2. 14.3) 
P-Y= Person-year: ADR=adverse drug reaction: CJ=Confidence interval: CCJ=Charlson 
comorbidity index 
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Model results and comparison 
Out of64.446 patients. 60.390 (93.7%) were found with zero value of ADR 
coum, with the sample variance ( s~ = 0. 1 0) exceeding the sample mean (X= 0.08). 
According to the goodness-of-fit testing. the overdispersion test was statistically 
significant (0=64.14. p<O.OOI ). This indicated that the Poisson model was not 
appropriate for describing the ADR count data. Predicted probabilities of ·null' models 
were compared wi th the observed probability of the ADR counts (Figure 4.2a-b). Due to 
the large proportions of teroes which tends to Hatten the distribution for ADR count 2: 1 
in Fig11re -L2a. the same probabilities excluding those for ADR coum=O were plotted in 
Figure 4.2b. Clearly. the Poisson and ZIP models were a poor fit. Both underestimated 
the probabili ty at AOR count=O and overestimated at ADR count = I. There was 
somewhat under·prediction by the Poisson model and over-prediction by the ZIP model 
for ADR count 2. 2. The NB and ZfNB models made better predictions for the entire 
range of /\OR count values. This important fact suggested exclusion of the Poisson and 
/.IP models due to poor fit. and to do the model comparison between the NB and ZINB 
regr~ssions. 
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Figure -1.2 . Predicted probabilities of intercept-only Poisson, NB, ZIP and ZINB 
models compared with the obsen•e<l probabi lities of ADR l'Oun ts. (a) with zero 
scm·c, (b) without zero scor e. 
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In the regression analysis ofNB model. the test of dispersion parameter. alpha. 
indicated significant over-dispersion (r =21.36. p<O.OO I). When comparing the NB to 
Poisson. the likelihood ratio test gave a highly signi ticant chi-square value (x}· =1548.0. 
p<O.OO l ). These results were consistent with the results of Bohning's over-dispersion test 
\\hich was statistical\) significant. and indicated that NB model is preferred over Poisson 
model. In comparing Zfl> and ZINB models. we found that the ZlNB model was more 
favorable than the ZIP model. given that the LR test statistic was significant (·C =42.0. 
p<O.Ol ). The Vuong test statistics ofV= -1 2.9 (p<O.OOI) indicated that ZIP model tined 
better than Poisson modeL and ZINB model fitted bener than NB model (V=-3.06. 
p<O.OO J ). Additional\). based on the AIC values for the regression models 
(Poisson=36.576: NO=J5.025: ZJP=J4.296: and ZINO=J4.256). the ZINO model appears 
to be fitted slightly better compared to the other models. 
As demonstrated above. our analysis indicated that the ZINB model most 
accurately retlected the data: which means over-dispersion \\ aS as a reSlJlt of Lmobserved 
heterogeneity. temporal dependency. as well as excess zeroes. Therefore. we considered 
results only from the ZJNB regression model when interpreting predictors of A DRs. 
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Identifying llnd interpreting significnnt predictors 
The results of the ZINB regression analysis to the ADR counts with the predictor 
variables are presented in Table 4.5. This model produced two sets of parameter 
estimates. First, a logistic procedure yielded the odds ratios (ORs). given in the right half 
of the table. predicting the odds of··zero·· A DRs. The left side of the table contains the 
rat~ ratios (RRs) for the NB component of ZINB analysis. With a focus on predictors of 
recurrent event of ADR. only RRs have been considered for interpreting significant 
predictors to indicate the relative change in the number of A DRs according to the change 
in the level of a specific predictor variable. Patients with CCI score of2-3 had a 67% 
increase in the number of ADR compared to patients having a CCI score 0-1 (RR=1.67. 
95% confidence interval 1.41 to 1.98). Compared to patients with CCI score 0-1. patients 
with a CCI score 4- 5 \\ere more than twice as likely to experience an ADR (2.38. 1.98 to 
2.87), whereas those with a CCI score ~6 were at 4 times the risk (RR=3.83. 3.2 1 to 
4.57). Similarly. a patient classified in the 4111 quintile of the neighbolll·hood SES class 
had a 50% increase in the number of A DRs compared to a patient classified in the 3rt! 
SES quinti!e ( 1.50. 1.21 to 1.86). No other SES categories \\Cre significant. There was a 
22% percent increase in the number of A DRs for rural patients compared to their urban 
counterparts (1.22. 1.01 to J.-l6). Age and sex were not significant predictors of the 
number of A DRs. 
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T:tblc 4.5: Zcro-inOntcd negative binomial regression predicting the occurrence and 
number of A DRs :tccording to the selected patient-related factors (n=6~A~6) 
Negative binomial Logistic 
component component 
Variable RR 95%CI OR 95%CI 
Age (years) 1.00 0.99 to 1.01 1.01 0.99 to 1.02 
Sex 
:vlale Reference Reference 
Female 0.95 0.85 to 1.07 0.83 0.71 to 0.98 
CCI Severity 
0-1 (least severe) Reference Reference 
2- 3 1.67 1.41 to 1.98 1.09 0.86 to 1.39 
4-5 2.38 1.98 to 2.87 0.90 0.69 to 1.17 
2:6 (most severe) 3.83 3.21 to 4.57 0.88 0.68 to 1.12 
Socioeconomic status 
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Negative binomia l Logistic 
component component 
Variable RR 95%CI OR 95%CI 
lstQuintilc 0.97 0.79to 1.19 0.91 0.69 to 1.20 
2nd Quintile 0.97 0.79 to I 18 0.89 0.67 to I 19 
3rd Quintile Reference Reference 
4th Quintilc \.50 1.21 to 1.86 1.17 0.85 to 1.60 
5th Quintile 1.17 0.96 to 1.41 1.01 0.77 to 1.35 
Residt:ntialloeality 
Urban Reference Reference 
Rural 1.22 1.01 to 1.46 1.39 1.06 to 1.81 
/\OR-adverse drug reaction: CCI-Charlson comorbidity index: RR- Rate ratio 
(indicating relative change in number of A DRs): OR Odds ratio (indicating odds of zero 
ADR): ( !=Confidence Interval 
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Table 4.6 presents the ZINB analysis for individual comorbid conditions. RRs for 
the NB component indicated that patients with congest ive heart failure ( 1.58. 1.33 to 
1.89). connecti ve tissue disorders (I .57. I .07 to 2.29). peptic ulcer di seases ( 1.82. 1.34 to 
2.49) and metastatic cancer { 1.49. 1.05 to 2. 11 ) experienced a significant increase in the 
number of A DRs compared to those patients without these comorbidities. Patients having 
diabetes with complications (2.42. 1.64 to 3.56) or renal diseases (2.17. 1.55 to 3.04) 
were more than twice as likely to experience A DRs. '>vhile those having dementia (3.91. 
2.48 to 6.17) or cancer (3.12. 2.58 to 3. 76) were more than three times at risk compared 
to patients without these conditions. 
141 
Table ..J.6: Zero-inflated negative binomial regression predicting the occurrence and number of A DRs according to the 
C ha rlson comorbiditics · , (n=64,4..J6) 
Charlson ' s comorbid No. (%) No. (%) of Negative binomial Logistk 
conditions t 
of patients 
patients with component 
component 
ADR 
RR 95%C I OR 9S 'Y., C l 
Acute myocardial in farcti on 4 120 (6.4) 318 (7.8) 1.08 0.88 to 1 . 3 ~ 0.76 0.55 to 1.05 
Congestive heart fa il ure 4269 (6.6) 4 13 (10.2) 1.58 1.33 to 1.89 0.74 0.55 to 0.99 
Peripheral vascular d isease 158 1 (2.5) 107 (2.6) 0.9 1 0.64 to 1.29 0.77 0.44 !O 1.37 
Cerebrovasc ul ar disease 35 14 (5.5) 240 (5 .9) 1.07 0.83 to 1.38 0. 70 0.46 to 1.06 
Dementia 1057 (1.6) 55 ( 1.4) 3.91 2.48 to 6. 17 6.2 1 3.59 to 10.7-' 
Chronic pulmonary disease 4452 (6.9) 394 (9.7) 1. 10 0.91 to 1.32 0.6 1 0.44 to 0 .83 
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Charlson's comorbid No.(%) No. (%)of Negative binomial Log istic 
conditions ' patients with com 11onent 
of patients component 
AOR 
RR 95%C I OR 95%CI 
Connective tissue disorder 485 (0.8) 72 (1.8) 1.57 1.07 to 2.29 0.55 0.29 to 1.04 
Peptic ulcer disease 926 (1.4) 116 (2.9) 1.82 1.34 to 2.49 0.82 0.52 to 1.30 
Mi ld liver disease 146 (0.2) 9 (0.2) 0.91 0.33 to 2.51 0.58 0.09 to 3.90 
Diabetes (mild to moderate) 5746 (8.9) 522 ( 12.9) 1.17 0.99 to 1.37 0.68 0.52 to 0.88 
Diabetes with complication 706 (I. I) 66( 1.6) 2.42 1.64 to 3.56 1.28 0.72 lo 2.30 
Paraplegia 293 (0.5) 26 (0.6) 1.49 0. 77 to 2.86 1.06 0.34 to 3.29 
Renal disease 940 ( 1.5) 92 (2.3) 2. 17 1. 55 to 3.04 0.99 0.55 to 1.78 
Cancer : 6882( 10.7) 448 (1 1.0) 3.12 2.58 to 3. 76 2.-t7 1.95 to 3.13 
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C harlson's comorbid No.(%) No. (%)of Ncgatin· binomial Logistic 
conditions t 
of patients 
patients with componcnt 
component 
AOR 
RR 95'% Cl OR 95%CI 
Metastat ic cancer 1782 (2.8) 96 (2.4) 1.49 1.05 to 1. 11 1.30 0.79 to 2.14 
Severe li ver di sease 101 (0.2) 6 (0.1) 1.42 0.38 to 5.26 0.94 0.12 to 7.37 
ADR=adverse drug reac tion: SES Socioeconomic status: RR= Rate rat io (indicating relative change in number of ADRs): 
OR=Odds ratio (indicating odds of zero ADR): CI=Confidcnce Interval 
• Model includes age, sex. SES and residential locality 
t although AIDS was one of the comorbid condi ti ons in the Charlson index. no patients were found with a diagnos is o f AIDS 
in our study sample. 
:includes any mali gnancy such as lymphoma, leukemia. 
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Discussion 
In this population-based cohort of64.446 elderly hospitalized patients. the 
incidence of A DRs was found to be 15.2 per 1.000 person-years over a 12-ycar period. 
The most common drug category implicated in the A DRs was cardiovascular agents. 
while antincoplastics or immunosuppressive. anticoagulants and NSAIDs/antirhcll!natics 
were the specific drug groups most often contributing. Comorbidities from chronic 
diseases. rather than advancing age, were the single-most important factor associated 
with ADR-related hospitalitations. Specifically. congestive heart failure. dementia. 
chronic pulmonary disease. connective tissue disorder. peptic ulcer disease. diabetes with 
complications. renal disease. cancer and metastatic cancer were all strong predictors of 
the number of A DRs experienced. Patients living in mral areas were also associated with 
increased risk for A DRs. 
The contribution of ADRs to hospital admissions or prolonging hospital stays has 
been investigated in several studies 34· 30-33. The proportion of ADR·related 
hospitalizations varied from I% to 35% in patients of all ages 30• and from 3% to 24% in 
an older population l JO . .l1-13. Studies based on meta·analyses estimated the range of ADR 
incidence in Australia from 2.4% to 3.6% ~and in North America from 3.1% to 6.2% ~ . 
As highlighted by Alexopoulou et al. -' 1• A OR-related hospital admissions in European 
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studies varied from a minimum of 1.8% in the Netherlands to a max imum of9.2% in the 
UK. Clearly, the incidence of ADR-related hospitalization in the elderly population that 
\\e observed ( 1.52 per 100 person-years) is at the lower end of previously repm1ed 
research. The low incidence in our study may be explained by two factors. First. because 
our study subjects had ditlt-rent durations of follow-up. '' e calculated incidence rate by 
dividing the number of A DRs by the length of fo llow-up. Although this is the most 
meaningful denominator tOr quantifying risk u . most previous research did not consider 
person-time at risk when est imating incidence rate. which may have contributed to a 
higher-incidence than that of our study. A second factor is that the incidence of drug-
related hospitalizations and ED visits appears to be lower in Canadian population 
compared to other nations 7· ·q . although further work is needed to confirm these findings. 
A major risk factor tOr recurrent events of ADR identified in our study was the 
burden of illness. Since there is a lack of longitudinal data examining predicting factors 
associated with the frequency of A DRs. comparison with other studies is challenging. A 
recent Australian study by Zhang eta!. tl repo11ed that comorbidities. rather than age, 
increased the rate of repeat ADRs among hospitalized patients aged ?:60 years; most of 
the Charlson comorbidity conditions were tOund as predicti\e factors !Or A DRs. 
Although the primary outcome variable of Zhang's study (i.e .. occurrence of a repeat 
admission tOr an ADR) was slightly different from that of our study (i.e .. count of 
frequent occurrences of ADR). our results were consistent with factors that predicted 
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repeat admissions for A DRs in the Australian population. A US study among nursing 
home residents also found that both the number of medical problems and the burden of 
illness {as measured by CCI) were associated with ADEs (which includes A DRs) 12 
Elderly patients are at greater risk of serious injury from adverse events than 
younger patients u~-36 . llowcver. in our analysis of hospitali zed patients aged 65 years 
and older. age was not independently predictive of the number of ADRs. rather we found 
a strong dose-response relationship between severity of illness and the recurrence of 
A DRs. This SL1ggests that within a restricted elderly age range in which multiple 
eomorbidities can be expected. age it.wdfmay not increase the like lihood of an ADR. This 
finding is consistent with other studies confined to older age groups 6· 37.JR. A positive 
re lationship between age and drug related health problems have been tOund in studies 
using all ages 17 • Reasons for an increased risk for rural patients and patients living in 
middle-high class neighborhood (41h quintile ofSES) are not clear. To our knowledge. the 
same ri sk factors tOr recurrent events of A DRs or first-time ADR have not been 
prl.!viously investi gated. 
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Strengths and limitations 
An important limi tation of our study is the absence of drug data in the DAD. It is 
worthwhile to note that our analyses of the relationship between patient-related factors 
and A DRs did not fOcus on iden tifying specific drugs or drug groups that contributed to 
/\DRs. Rather. we presented descriptive data on drug categories found to be primarily 
responsible for A DRs. Hcing unable to include the number of drugs in the list of 
independent variables should not have a significant impact on the observed relationship 
between A DRs and other factors in our study. given that counts of medical conditions 
and number of drugs taken are likely to be correlated. and thus not generally used 
simultaneously in multiple regression modeling 12 . The findings of a disproportionately 
high cont ribution of cardiovascular and systematic agents including antineoplastic or 
immunOSllpprcssivc drugs. NSA lDs. and anticoagulants to A DRs arc similar to those 
from earlier studies of persons aged 2:65 years in hospital setting 37· 31) •• 10. J\ likely 
explanation for this finding is that these were the most common medication groups taken 
by the elderly population 37• and would be the most frequently implicated drugs for A DRs 
In studies that use administrative data. variations in clinical coding may inlluence 
outcomes. While the accuracy of diagnosis is important. we COlJld not perform a 
sensitivity analysis. A va lidation study reviewing the coding practices in Canada found a 
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relatively high sensitivity of82% considering the top 50 most responsible diagnosis ·H. 
However. another study which validated the coding practices for drug-related events. 
''hich is similar to the one used in the present study. found that the AOR identifying 
algorithm had a relatively low sensitivity (56%) and high speciticity (I 00%) 41. The low 
sensitivity indicates that the clinical coding of drug relati' e e'ents is less accurate in the 
DAD compared to disease coding. which may have led us to under-estimate the true 
burden of A DRs in this population. 
Finally. our outcome of interest was the number of A DRs that either caused 
hospit~ll admission or extended an existing patient' s length of stay. whereas most A DRs 
(- 90%) are fairl y minor 41 and occur in the community without admission to hospital. 
Therefore. our tindings of ADR incidence rate shOllld be interpreted just as 'the tip oftht' 
iceberg·, given we only considered hospital admission. which represent only the most 
severe adverse reactions to medication. 
The strength of our study inch1des the cohort design with population-based 
longitudinal administrative data. This design allowed us to identi fy recurrent events of 
A DRs experienced by patients. regardless of changes in the treating hospitals. Having a 
unique health care number is an advantage of the universal health care system in Canada 
that allowed us to link all releva111 administrative data. In fact 99% of hospital records 
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were successfully linked to the other health care data. thus allowing us to overcome 
issues related to selection and recall bias. 
Previous studies experienced an issue of under-ascertaimnent of Charlson 
comorbidity index score because a patient may have an illness beyond the 17 illness used 
for CCI score (•. 4-1. We have overcome this limitation by assigning a relative score for the 
illness that is equi\'alently se' ere to 1 of 17 listed comorbidities. 
Our study demonstrated the usefulness of fairly recent statistical advances that 
allowed us to overcome unique problems associated with the prediction of rare events 
such as A DRs. We felt it important to address complexity in our data (e.g .. over-
dispersion and excess Leroes). by comparing several modeling strategies and considered 
the process as a means to choose the ··most appropriate" model to examine factors 
predictive of A DRs. We believe that the process of choosing statistical approaches to data 
analysis is dependent not only on the research question. but also on the characteristics of 
observed data. To our knowledge. this is the first swdy of its kind in Canada. and one of a 
few studies world\.vidc. investigating predictors of recurrent events of ADR among the 
high risk elderly patients admitted to hospital while illustrating the importance of 
carefully considering appropriate models that best represent the observed data. 
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Our study provides a starting point lOr understanding the recurrent C\'~nts of 
ADRs and the risk factors associated with these events in the elderly hospitalized 
patients. Future research should examine this association beyond the acute care setting 
and include drug doses and multiple drug regimens. Identification of risk ntctors for ADR 
counts in varying study settings is likely to play an important role in providing eft011s to 
improve medication safety. Given that the greatest gains in improving pmient safety are 
bdie\ed to come from modifying the work envi romnent of health professionals 7• 
interventional studies focusing on organization change and delivery of care are the next 
step towards prevention. 
Conclusions 
This study used a population-based cohort design to detennine the incidence of 
ADRs in the elderly hospitalized patients considering a ll events. rather than restricting 
analyses to only first events of ADR. and identify predictors on recurrent events of ADR 
considering the approprimeness of statistical models. Comorbidity from chronic d iseases 
and the severity of the patient' s underlying illness. rather than the characteristic of 
individual patients (advancing age. sex). increased the likelihood of recurrent events of 
A DRs in elderly hospitalized patients. The majority of Charlson comorbidities were 
associated \\ith increased number of A DRs experienced b) the elderly. Substantial 
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changes in the organization and delivery of health care focusing on careful and frequent 
monitoring of prescribed dmgs in elderly patients would mitigate the recurrence of ADR. 
lnterventional studies are recommended to ascertain \\hether recurrent events of ADR in 
this most ndnerable group of patients can be pre\'ented. 
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CHAPTERS 
General Discussion and Summary 
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5.1 General Discussion 
An important focus of the work for this doctoral dissenation was to investigate 
the extent of serious adverse drug events (ADEs) in children and adults presenting to 
Emergency Departments {EDs). and elderly individuals admitted !0 hospitals in 
Newfoundland and Labrador. This research provided a lmique opportunity to utilize three 
datasets: two collected through a retrospective review of ED charts allowing 
characterization of A DEs by patients· demographic and clinical factors: and a third 
obtained from linked administrative data enabling the usc of multiple regression 
modeling techniques to identify patient-related factors that can predict recurrent events of 
AOR. 
This is the most extensive and comprehensive research program of its kind ever 
conducted in Newfoundland and Labrador (NL) to document the serious A DEs. The three 
studies under the program were designed to capture and document a wide range of 
serious A DEs. The studies originated from the idea of gathering baseline infOrmation 
prior to implementing a province-wide Phannacy Network. and later expanded to build 
up benchmark infonnation for risk factors associated with recurrent events of A DRs in 
the high risk group of elderly hospitalized patients. The ultimate intent is to inform and 
provide a better understanding of this negative outcome resulting from drug usc. rather 
161 
than the underlying d iseases. that ted to an increased burden of illness to the individual 
patient and increased burden of health care resources to the health system. 
This final chapter contains a summary discussion of each study, together with 
implication of findings and future directions. The summary discussion of the three studies 
tOcuscs on the simi larity and dissimilarity in methods and measures among the swdics. 
The implication of findings focuses on what the provincial Pharmacy Network can do 
and what could be expected from heal th care professionals to ensure quality of care given 
the findings of the studies included in this research. Future directions include 
recommendations fOr an ongoing analysis of ADE data in other clinical settings and 
vulnerable subgroups of populations to gain a better understating of the patterns of A DEs. 
and their preventability. and suggestions fOr improvement of system factors. education 
and indications for further studies. 
5.2 Summary Discussion of the Th ree Studies 
The magnitude of drug-related adverse incidents and their patient-related factors 
that can predict these incidents were studied in three age groups (children and youth aged 
17 years and younger: adults aged 18 years and older: and elderly aged 65 years and 
o lder) in NL. Drug-related adverse incidents in the elderly were studied in a hospital 
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setting. and the events in the other two subsets were studied in ED setting. The three 
studies differed in their definitions of adverse incidents. outcomes measures. and in their 
study design. including the methods of data collection employed. An introduction to how 
dmg-related adverse events occur. the different terminologies used. and how the data are 
typically collected in observational studies was provided in Chapter I. Although 
providing illustrations of statistical theories used in the analysis of ADE data was not a 
focus of this research. multiple regression modeling fo r analysis of count data (which is 
rarely used for ADE studies) were briefly discussed in Chapter 4. with further details in 
Appendix F. 
5.2.1 Summa ry of Methodological Perspectives of the Three Studies 
The first and second studies (Chapters 2 and 3. respectively) examined the extent 
to which A DEs among pediatric and adult patients resulted in ED visits. how these events 
differed by patients ' demographic nnd clinical characteristics. and what proportion of 
them were classified into severity (significant. serious. life threatening. fatal) and 
preventability (preventable and not preventable) classes. For the fi rst study. the sample 
''as selected using a simple random sampling technique. restricting one visit per patient. 
from a sampling frame which included a previous one-year ED visit by children aged S l 7 
years meeting inclusion criteria. The study sample for the second study was selected with 
the same restriction of one visit per patient. but it used a stratified random sampling 
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technique given that a secondary objective of this study was to detennine age-sex specific 
prevalence of A DEs. In both studies. a nvo-step review of patients' ED charts was 
employed in collecting baseline information prior to implementing the Pharmacy 
Network. Following a retrospective review of ED charts. the reviewers determined 
\\hether an ADE was deemed to be a reason tOr an ED visit. lfit \\as. the reviewer also 
classified the event with respect to severity and preventability. 
The focus of the third study (Chapter 4) was to examine the incidence of A DRs. a 
conservative estimate of A DEs. occurring among elderly hospitalized patients and 
\\hether patients-related factors such as age. sex. chronic diseases. socioeconomic status 
and residential locality can predict recurrent events of ADRs in this population. This was 
a population-based study in which the dataset was developed through a linkage of live 
administrative health databases and ADRs were identitied through the external causes of 
inj ury codes associated ''ith the use of a drug that were recorded in the Discharge 
Abstract Database (Di\D). 
Given that a representative sample of one-year ED visits were reviewed 
retrospectively for each of the first two studies. it was not possible to determine the onset 
of the event. Some people may have developed A DEs during the one-year study period. 
and others may have had the events prior to the study period but presented to EDs. were 
cured or died during the study period. Therefore. the extent of the event was estimated as 
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prevalence of A DEs. as it was deemed to be the most appropriate measure. When the 
word ·prevalence' was used in presenting results of the first two studies it was meant to 
be a period prevalence. which revealed how many people had an ADE at any time during 
the one-year period. The third study included records of all hospitalizations of patients 
aged 65 years and older over a period of 12 years and considered all events. rather than 
the first event only. to determine ADR counts. Using the duration of follow-up for each 
study subject. the incidence densit) was estimated to measure the occurrence of these 
events. Incidence density was reported in terms of the frequency (density) of ADR per 
I .000 person-years. Because of its use of person-time obsen ed as a denominator. the 
incidence density is a composite measure of the number of individuals observed and the 
period of observation COJllributcd by each individual 1 
The tirst two studies which identified and characterized A DEs in an ED setting 
were limited in sample size and number of A DEs. In order to maintain predictive power 
associated with small samples, only bivariate analysis was considered to determine the 
association between prevalence of A DEs and a patient-related fac tor. This means that the 
observed e ffect of a factor (e.g .. agel on A DEs may not be the true etTect due to the 
inability to adjust for con!Ounding. The third stud) \\as population-based and therdOre 
overcame the issue of small sample. The study allowed tOr the use of multiple regression 
analysis that accounted tOr confOunding factors and determined independent predictors 
for ADR counts. 
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5.2.2 Summary of Key Findings from the Three Studies 
In an effort to examine the size and nature of the problem of serious A DEs. and 
therefore, create a basis for targeting preventive strategies to mitigate these unwanted 
events. this research revealed several important findings: ( I) 2.1% of pediatric ED visits 
and 2.4% of ad lilt ED visits were due to ADI::s, of which 20% and 29%, respectively. 
were considered preventable: (2) children with and without ADE·related ED visits were 
similar with respect to mean age and mean number of medications. whereas adults with 
ADE·related ED visits \vere older and were prescribed more medications compared to 
their non-A DE counterparts: (3) the adults with ADF>rclaiCd ED visits had a higher 
number of comorbidities compared to adults without A DEs: (4) the varying distribution 
of A DEs were observed in relation to the types of drugs involved between study 
populations: (5) in a cohort of elderly hospitalized patients. the incidence of ADR was 
15.2 per 1,000 person-years: (6) comorbidity from chronic diseases and the severity of a 
pmient"s underlyi ng illness. rather than the characteristic of individual patients (e.g. 
advancing age. sex). increased the likelihood of recurrent events of ADR in elderly 
hospital ized patients. 
The occurrence (or number) of ADEs/ADRs that either caused ED visits. hospital 
admissions or extended hospital stay was our outcome of interest. whereas most drug· 
rdated adverse events arc fairly minor and occur in the community without ED visits or 
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admission to hospital ~. TherefOre. our findings on magnitude of A DEs should be 
interpreted with caution. since we only considered ADEs resulting in ED visits or 
hospitalizations that may represent the most se\ ere ad\ erse e\ ents of medication use and 
lead to considerable morbidity and linancial burden. Furthermore. the three studies 
included in this disset1ation were designed to describe drug-related events separately in 
each subset of the population. Because of this design. coupled with the variable 
mechanism tOr detection and measures of occurrences. no attempts have been taken to 
compare results among the three studies. However. these tindings are infOrmative in that 
they quanti lied the number of ADEs and characterized them according to the patient-
related factors including health conditions (all three studies) and medications (the first 
and second studies). 
In identifying drug-related adverse incidents in all three studies. we have taken a 
conservative approach that keeps the ADE estimates lo\\ by applying very specilic 
exclusion criteria. The study sample for the two studies in ED setting excluded any visits 
related to drug-induced tratlic accidents. drug abuse and attempted suicide. Similarly. the 
study of elderly hospitalized patients excluded adverse effects caused by accidental 
overdoses of a drug. wrong drug given or taken in etTor. accident in technique of 
administration of drug. and abuse of a drug. Hence. we are probably not over-estimating 
the ADE/ADR estimates despite the fact that the events may include suspected ADE or 
ADR given that (I) the possible A DEs were combined with the confirmed A DEs in 
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estimating prevalence of ADE in the lirst two studies. and (2) conlinnation of each 
individual event of A DRs detected retrospectively using lCD codes in the third study 
may not be realistic-~-~. 
The first two swdies focused on A DEs. which included etTors in administration. 
The findings of these studies arc useful to alert health professionals and policy makers 
about the preventabilit~ of many A DEs. In contrast. the third study on ADRs. which 
excluded medication errors. had a different objective: to demonstrate that there arc a large 
number of A DRs even when dntgs are properly prescribed and administered. Because 
serious ADRs can be a great burden ofhann to a population that is measured in lost lives. 
reduced functionality. and wasted resources. the magnitude of these events is an 
impm1ant clinical issue ~-s. As illustrated in section I .3. A DRs are more difticult to 
prevent than A DEs. However. it is possible to mitigate many ADRs depending on what 
type of events they are. Adverse drug reactions can be classitied into two types: Type A 
(dose-dependent and predictable) and Type 8 (idiosyncratic or bizarre effects that are 
dose-independent and unpredictable) o.q. Although our research did not attempt to 
determine the type of ADRs. a mew-analysis 0 of prospective studies demonstrated that 
the majority of A DRs (over three-fom1hs of t he total events) in a hospital setting \.vere 
attributed to dose dependent causes (i.e .. Type A events). Therefore. we are in agreement 
'' ith the authors· explanation in that health care focusing on careful and frequent 
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monitoring of drugs may lead to a reduction of many of these events. as their occurrences 
are likely due to the use of drugs with unavoidably high toxicity. 
This thesis showed the distribution of A DEs varied in relation to the types of 
drugs involved between study populations. For example. antimicrobial agents (45.0%) 
were the most common drug classes associated with A DEs in children. whereas in adult 
patients cardiovascular agents (37.-t%) were the drug class most often associated with 
A DEs. In the elderly hospitalized patients. the most common drug categories implicated 
in A DRs was cardiovascular agents (17.7%). %). fol lowed by analgesics/antipyretics/ 
anti-inflammatory ( 16.1%). systemic (11.8%) and blood constituents (9.7%. These results 
indicate that much of the variation in the occurrence of A DEs and thei r association with 
patient characteristics and drug types are due to heterogeneity in the populations 
examined in the three different studies. Unlike the first two studies that collected 
infonnation on drug utilization of each study patient prior to the ED visit. the third study 
used the hospital discharge abstract database as the source of patient clinical information 
on '' hich information on drug utilization before or during hospitalization was not 
available. Only drugs that lead to an ADR were identified using diagnosis codes. 
Although the drugs most fi·equently associated" ith A DEs in children and adults ''ere 
identified in the first two studies. only descriptive data on the distribution of ADR-related 
drug classes among elderly hospitalized patients was available in the third study. This 
means that the study of e lderly hospitalized patients was not able to conclude whether the 
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top drugs were more likely to cause A DRs due to the lack of data on the quantity and 
overall types of drugs consumed. The top drugs could just be more commonly prescribed 
drugs among the elderly patients 10. However. from a policy perspective focusing etT011s 
on the drug classes with the greater number of A DRs may have the biggest impact on 
reducing the burden of A DRs in the population. 
The three studies included in this dissertation were limited as noted above by 
retrospective data extraction either through chart review or by using diagnosis fields with 
lCD coding criteria. It is wonhwhile to acknowledge a few additional limitations. Fi rst. 
the small sample sizes !Or the fi rst two studies restricted the analysis to bivariate 
techniques. thus limiting conclusions one can draw from these results. The analysis 
identified factors\\ ith a statistically signiticant associmion '' ith ADE·related ED visits. 
but whether these associations would be independent after considering confounding 
variables is unclear. A multiple regression approach \\ hich would have supponed the 
investigation of predictors of observed A DEs but that requires a large sample or 
population-based study as was caJTied out tOr the stud) of elderly hospitalized patients 
(Chapter 4). Second. sensitivity and specificity are two well-recognized measures of 
validity of a ne" test or tool. However. in order to estimate sensitivity and specificity of 
the trigger assessment tools used in the first two studies. it would require to caJTy out the 
full review of all sampled ED cha11S in the both studies. Because oflimited resources 
available for the studies. a full review was carried Ollt on a sample of charts for visits 
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classitied as having ··no·· probability of being du~ to an ADE. and therefore a ditl'erent 
form of validity assessment has been performed (Chapters 2 and 3). Third. when it was 
intluenced by a context of a situation. the three studies has been referred to with r~thence 
to the three age·related subgroups. although there was a linle overlap in the study 
subjects between 2nd and 3rd studies. Following an investigation we found that. of all 
elderly patients in the 3rd study admitted via EDs. there were I 08 patients incllJded in the 
211..! study. Because this overlapping component is very small (- 7.4% of 2nd study subjects 
and - 0.2% of the 3roJ study subjects). we believe that the impact of this overlap on study 
findings or ans\vering the research questions would be negligible. Fou11h. at the design 
stage of the first two studies. the intent was to gather other types of events such as 
potential ADEs and medication errors (see section 1.3. 1 for de fin itions). which are not 
only a major pan of dmg-related events. but also the extent of such events would likely 
be mitigated by a llt.'\\ in ten ention such as a Pharmacy Network. HO\\ever. necessary 
infonnation was not available in patients' ED charts. Moreover. the data collection plan 
included gathering intOnnation on many other variables such as cause of adverse events. 
who was primarily responsible for the event. and what were the consequences to the 
patient. Ho""ever. these data were not collected comprehensively tOr each event due to 
the unavailability of the information in the patients' ED charts. Thus these factors were 
not considered tOr analysis as to do so wollld introduce high sampling error associated 
with the small number of events and potential bias due to selective recording of t he data 
in the records. These limitations demonstrate the necessity to conduct a well-designed 
prospective cohort study that would be in a better position to investigate the extent of the 
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events beyond what we studied together with the characteristics illustrating their causes 
and consequences for the patients and the health system. A last limitation worthy of note 
was that preventability was assessed using a 4-point Like11 scale. but was subsequent 
collapsed into two categories ("'preventable .. and ··not preventable") resulted in a Joss of 
more detailed information. A larger sample size would have facili tated analysis at the 4-
point scale level. 
While the findi ngs of this research must be viewed with some circumspection. as 
noted above. several factors lend strength to this work. especially the identitication of 
high risk patients requiring close monitoring of their drug consumptions. Apa11 from 
those that have been described separately for each study in the previous chapters. this 
research brings additional strengths to the understanding of the problem of drug satfty 
and contributes to the development of the necessary solutions. Given that this research is 
the first in this province to capture comprehensive infonnation on serious A DEs. the 
tindings can be used as a source of learning and as a basis for preventive action in the 
future. !fan investigation of an event is not conducted locally \\here it occurred. then the 
lessons cannot be learned more widely; the opportunity to generalize the problem is lost 
and the capability to produce powerful and more widely applicable solutions will not be 
realized 11 . The three studies encompassing this dissertation revealed an unrecognized 
burden of serious A DEs in this province. requiring attention to the quality improvement 
of the health system. The three manuscripts and several presentations to intemational and 
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national conterences. academia and provincial special interest groups (e.g. Patient Safety 
Research Aflinity Group). resulting from this work lead to a widespread and ongoing 
dissemination of tindings throughout the course of this doctoral research in order to 
promote the sharing of imponant methodological aspects and research findings among 
the research community and other key stakeholders. 
The observation of the positive correlation between prevalence of ADE and age 
(Chapter 3 ). coupled with an increased risk of ADR associated with certain comorbidities 
and severity of comorbid illness. rather than advancing age (Chapter 4). not only supports 
the fact that older patients experience more A DEs than younger patients, but the higher 
number of A DEs in an older population may be attributed in part to the fact that older 
patients consume more medications and arc likely to have more comorbid illness than 
younger patients. These findings. in conjunction with the dissimi lar drug classes 
associated -.vith (or implicated in) A DEs in the three subgroups. suggests that a 
prevention strategy should be targeted at patient·specilic physiologic and functional 
characteristics. and the high·risk medications to treat coexisting heal th conditions. as 
opposed to being focused on an individual's true chronological age. as noted previously 
in the literature ~ 3 1 ~ 
There have been few ADE studies in the Canadian population 13"15• and they 
focused either on all events including drug and non·dmg related adverse outcomes or 
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were conducted in a single setting. This dissemnion research differs from those reports in 
many respects: (I) we examined the frequency of a wide range of serious A DEs 
experienced by patients in the community setting and resulting in either ED visits. 
hospital admissions. or prolonged hospital stay for an existing pat ient. (2) we separately 
studied the events in three age groups to take into consideration the heterogeneity among 
these groups. and did not attempt to combine them. (3) we studied prevalence ofADEs 
and incidence of A DRs to maintain the appropriateness of study designs. (.t) \\·e detected 
and analyzed A DEs and their severity and pre\·entability followed by a bivariate analysis 
fOr the association of these events with patient-related factors given the small number of 
events and the possibi lity of sampling error (Chapters 2 and 3). (5) we estimated all 
ADR-events in elderly hospitalized patients across the province over a 12-year period. 
and gave special emphasis to choosing an appropriate regression model approach to 
det~::rmine predictors of recurrent ADR events (Chapter .t). The serious ADE events that 
were captured using different detection methods in the hospital and ED settings. in 
conjunction with the separate analysis for each subset of patients. provides guidance in 
tailoring the list of high-risk medications based on age. comorbidities. and setting in 
order to optimize ADE pre\ention. By presenting tindings of the three studies togetht::r. 
this dissertation research provides good intbrmation to advance the planning and 
management of health care improvement so that the impact of a new system such as a 
Phannacy Network can be measured. Subsequent research may lead to understanding of 
the causative reasons for ce11ain medications being more frequently associated \\ith 
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A DEs and new \vays of caring for patients can be designed and implemented to reduce 
these events. 
5.3 Implications of Findings 
5.3.1 Prioritizing Medication Safety Research a nd Intervention 
This research adds to the growing body of literature suggesting \\hich 
medications should be considered as high-alert or high-risk medications for children and 
adults. While identification of such high-risk medications tOr A DRs in the elderly 
hospitalized patients was beyond the scope of this research due to the limitations of the 
administrative data. varying distributions of ADRs in relation to dim~-rent type of drugs 
consumed by them have been provided. This stratified infonnation would likely be useful 
for characterizing a group of high-ale11 patients who have specific clinical attributes that 
present with specific medical problems and place them in a particular risk group fo r 
developing ADEs/ADRs 3 Identification of high-risk patients. high-risk drugs. and top 
drugs (or drug classes) responsible tOr ADEs would help in selecting target groups for 
prewntive strategies. As suggested by Budnitz et at. 11i. because a few drugs that typical!) 
require periodic monitoring accounted for most A DEs. investing resources focusing on 
A DEs associated '' ith these drugs may be one \\ay to prioritize ti.u1her medication safety 
research and intervention. 
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5.3.2 Development of Active Medication Monitoring and ADE 
Surveillance System 
Identification of the importance of high-risk chronic diseases and severity of 
illness was an important step in determining the !actors that render patients at greater risk 
for ADRs. This research provides valuable baseline infonnation for designing or 
evaluating interventions for improving drug safety. Having a complete list of high-risk 
medications along with high-risk illness in a specific subgroup can help to develop active 
medication monitoring systems J . Considering the plannt>d infrastructure of the provincial 
Pharmacy Network. embedded with a computerized decision support system. an active 
medication monitoring system would be desirable to improve medication safety. Another 
implication of these findings of this research that warrants attention is the need for an 
active ADE surveillance system to identify and help prioritize medication safety issues in 
inpatient and outpatient settings through a timely. and jurisdictionally representative 
surveillance system for adverse drug events 16• It is expected that the process and 
methodology followed for these studies. the lessons learned. and the findings presented 
\\ill contribute to future research and drug-related policy initiatives. This work along with 
the establishment of a Phannacy Network \Viii enhance development of an active ADE 
surveillance in the health system which will ultimately provide timely post-marketing 
safety information on specific drugs and thus contribute to improved patient outcomes. 
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5.3.3 Building Research Capacity in Newfoundland and Labrador 
This research was the first assessment of A DEs treated in EDs and in the inpatient 
settings in Newfoundland and Labrador. Our estimates of the occurrences of A DEs will 
help in evaluating the effecti,eness of any future intervention. We found that 20% of 
serious A DEs in pediatric patients and 29% of those in the adults should be preventable. 
Given that one of the expectations of the Newfoundland and Labrador PhannaC) 
Network is improving prescribing and making progress in drug safety. these findings 
offer a measurable goal for the post-Pharmacy Network studies aimed at reducing A DEs 
leading to ED visits of20% and 29%. respectively. Without this research. the health 
system ofNL v.ould not ha' e any data on the burden of A DEs. and thus would have no 
way of measuring the impact of the provincial Pharmacy Network in reducing adverse 
drug-related events. 
Furthennore. there has been a few ADE research carried Ollt in Canada. Our 
analysis provides a basis for identifying issues associated with drug-related serious 
adverse evems. including their measurement and assessment. requiring action for 
therapeutic improvement by health care professionals and leaders of the health system. 
While no funher swdies were conducted previously in the province. this research has 
SllCCessfull y bllilt benchmark infonnation on serious A DEs requiring utilization of health 
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care resources. It is expected that om research. along \\ ith the availability of data from 
the provincial Phannacy Network. will significantly contribute to building research 
capacity in the province of NewfOundland and Labrador in the area of optimal drug 
utilization through enhanced infonnation systems. The findings in this doctoral 
dissertation may trigger an in-depth investigation to identify underlying systems failures 
and lead to efforts to redesign the systems to prevent recurrence. Further ADE studies 
with more well-established ADE identification systems may help us to better understand 
the etiology of adverse drug events through answering questions relating to A DEs and 
identifying patients tOr further studies (e.g .. pharmacogenetic studies) and ultimately lead 
to the adoption of a well-developed patient safety culture. 
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5.3.4 Providing Alert to Health Ca re Professionals 
The drug classes associated with or implicated in A DEs were dissimilar among 
the three age groups. The dmgs that were found to be associated wi th greater risk for 
ADEs. along with patients' underlying health conditions are infonnative for designing 
and implementing interventions for ADE prevention. Given that the majority of A DEs 
are predictable. and therefore potentially avoidable. a new system allowing physicians to 
check medication lists with high-risk patients more carefully (even obsessively) may help 
avoid A DEs and other drug-related adverse incidents. Previous work suggested that good 
communication is pivotal in developing an effective therapeutic partnership with the 
patient and fellow health professionals 17• An intervention program such as a Pharmacy 
Network. consisting of a wcll·dcsigncd informa1ion technology infrastructure and 
offering computeriLed prescribing and monitoring system. can help establish a better 
communication for rationalizing drug therapy while alerting pham1acists and physicians 
to potentially harmful drug-related problems. 
5.3.5 Choosing Medications with Highest Therapeutic Index 
Medications \\ith a narrow therapeutic index (e.g .. ''arfarin. divalproex and 
chemotherapy) were found to cause the majority of EO-treated A DEs in patients aged 65 
)Cars and older. This tinding was supp011ed by earlier studies tS-t'l Provided efticacy is 
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comparable, health care professionals may consider prescribing medications wi th the 
highest therapeutic ratio. fewes t number of poss ible drugs and keeping the dosing 
regimen as simple as possib le 1;· 10 . Close monitoring of these drugs has also been 
advocated as a way of avoiding or mitigating harm from these drugs. As demonstrated by 
Coleman eta!. ~ 1 • if a drug has a narrow therapeutic range. monitoring drug 
concentrations or effects may allo'"v the dose to be adjusted so that the optimal balance of 
efficacy and safety is achieved. 
5.3.6 Addressin g Iss ues Associated with Sea mless Care 
Many health professionals. in particular physicians and phammcists. arc not familiar 
with other areas of practice and not aware of the consequences of the gap between areas 
of care. Seamless care is the desirable continuity of care delivered to a patient in the 
health care system across the spect rum of caregivers and their environments 22 It has 
been recommended to encourage patients towards seamless care by using only one 
primary care physician and one community pharmacy. if possible. and discussing any 
medical prodllCIS to limit p01cntial interactions leading to adverse events. llowevcr. 
providing seamless care is a very challenging task in a population that is large and 
geographica lly wide spread such as in Canada. As has been ini tiated from this research. 
frequent studies may help in establishing a comprehensive list of high-risk dn1gs causing 
adverse even ts. Once this infonnation is built into the provincial Pharmacy Network. all 
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pharmacit!s in the provinct> are connected to that network. and health professionals have 
access to their patient's dispensing history. it is expected that health professionals would 
be able to intervene before and after an adverse event occurs. One benefit might be by 
avoiding ham1ful drug interactions leading to a decrease in the cost associated with 
doctor visits. emergency department visits and hospitalizations through using the patient· 
specific drug information system and an interactive database offering accurate real·time 
prescription profiles within the Pharmacy Network 23 
5.4 Future Directions 
Adverse drug events are an important cause of emergency department visits and 
hospital admissions. resulting in significant economic burden to the health care system 
and threatening the safety of drug therapy. This dissertation research provides baseline 
information with a broad understanding of drug safety and quality of care in a hospital 
and ED setting in Newfoundland and Labrador. Further work is reqllired to help identify 
the burden. severity and preventability of A DEs and medications responsible for them in 
long term care. home care and non-hospital settings. In addition to age·related subgroup 
analyses that were performed in thi s dissertation. futun: analyses should also focus on 
other vulnerable grOllpS such as the poor and Aboriginal populations. This should give 
more insight into the pattems of A DEs. and their preventability. and thereby lead to 
suggestions for improvement of system tUetors and edllcation fOr further swdies. 
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Another area which deserves further attention is the method of gathering 
additional information and analysis. Researchers should include more targeted studies so 
that study revie\\ers can detect A DEs and identify the patient tactors. drug tflctors and 
system factors responsible for each event. Understanding the causative reasons for certain 
drugs being more frequent ly associated with A DEs'' ill be useful in identifying potential 
areas for improvement in the community setting and gaining insights into areas of 
imervention. It is important to consider a problem solving approach that explores what 
could be done differently. and what changes can be made at the individual and 
institutional level to prevent the recurrence of the incidents. 
Other topics not addressed in this dissertation include the consideration ofbenetit-
hann ratio and genet ic tactors. The tindings and the subsequent discussion of this 
dissertation was related to ham1 only. Without consideration of the benefit-harm ratio. it 
is ditlicult to provide conclusive evidence whether the hann of a drug ounveighs the 
benelit 10. The susceptibil ity to serious ADEs may also be linked to genetic factors and 
the idemitication of predisposing genotypes may improve patient management through 
the prospective selection of appropriate candidates for given drugs. Future large-scale 
prospective studies are needed to identify genetic risk t~1ctors tOr serious A DEs. 
particularly Type B reactions (illustrated in section 5.2.2). that could significantly 
decrease hcalthcarc costs and improve the process of drug development 24. 
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There are many measurement issues associated with estimating the magnitude of 
adverse drug events in a manner that permits comparison between populations from 
difterent nationalities \\ hile identifying population-level factors associated v. ith their 
occurrence. As illustrated in the earlier chapters. the rate of drug-related hospitalizations 
or ED visits seems to be lower in the Canadian population compared to other nations. but 
further research with robust study designs aiming to compare Canada with other countries 
is needed to confinn these findings. 
In conclus ion. these findings suggest that the magnitude of serious adverse drug 
events in Canada. while perhaps lower than some other nations. is substantial. This 
analysis was able to discem how predictors of A DEs shifted from demographic factors to 
patient-specific physiologic conditions. To better serve the needs of patients and to 
reduce the pressure on health care resources. a prevention strategy should be targeted at 
patient-specilic phys iologic and functional characteristics. and at high-risk medications. 
as opposed to focusing on individuals' chronological ages. 
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Deer Dr Nebeker, 
My Name Ia Khokan Sikdar. lam a Ph.D. candidate h1 the Faculty or Medicine at Memorial University of 
Newfoundland, St. John's, NL, Canada. I am presenUy wrlbng my doctoral thesis blled, "Serious Adverse Drug 
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of my thesis. I found your artlde on 'Cianfylng adverse drug even!$: a clinidan's guide to terminOlogy, 
documentation. and reporting' pobli&hed In Ann Intern Med 2004; 140:7g5-801 is very Interesting. I have dted 
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Thank you lor your help Jnsdvance 
StnceroJy. 
I<11CI<an C. Slkllllr, MS.:.. MAS 
Ph.D. Carldldate(FacultyoiMedldne) 
~oolll Unl~erslty ol Newro..tndl!tnd 
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Appendix C. I. Pediatric ADE Trigger Assessment Tool 
Study of Adverse Drug Events in Children Presenting to the Janeway Emergency 
Department 
Study Code c=J D:nc of 13inh (dd/mm/yyyy ) 
Gender 0 Male D Female Date of ER visit (dd1mm lyyyy) 
D I . Jomt~\-\elling D ~.Stridor 
DJ.Jaundice D4.UrticariaorEczema 
D 5.Skinrash/ purpura D6.WhceL(' 
D 7. Chest pain or Palpitatton D B.Arrhythmias 
DQ. Pruritus D 10. Respiratory Depression 
D II. Ditlicuhy brc:~thing D 12. Nausea or vomiting 
D IJ.Headache D 14. Abdominal pain 
D IS. Nosebleeds D 16.Seizure 
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D1 7.Diarrhea 
D 19. Const ipation 
D ::!!.Difficult)insleeping 
D 23. Letlmrgy/Sornnolence 
D 25. Hypotension 
D 27. Coagulation Abnormalities 
D 29. Hyperkalemia/Hypokalemia 
D 31. 1ncreasedlivertUnctiontestresults 
D 33. CloS1ridit1m difflcile positive stool 
D35.Anemia 
D 37. Mucous membrane changes 
D 18. Allered level of consciousness 
D 20. Angioedema 
:=J 22. Recc:nt E>.trap)ramidal effect:.. 
Dystonia tremors (not diagnosed due 
to any disease) 
D 24. Hypenension 
D 26. Increased serum creatinine/BUN 
Le\eiS 
D 28. 1-lypoglycemia/llyperglycemia 
J 30. Leukopenia 
D 32. Hypematrcmia! Hyponatremia 
D 34. Neutropenia or thrombocytopenia 
D 36. Tinnitus 
D 38. Other (please specify) 
39 (a) Did rhi.~ el'l!llf happen imenrionai~J'? D Yes D 1\'o 
3 9 (h) 1.\· thert' (I ltl.~tory ofm edimliOII IHe wirflin ptl.\'llwo wel'/.a? D l't·.~ D So 
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39 (c)/.~· if clfl.uijied a.f a poremial ADE? DJ'es D No 
J9(tl) If J'ES, what h'OIIId be the probflbili(l' of being till AD£? 
D Ver:vlow D Low D Motlerate D fligiJ 
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Appendix C.2. Pedia tric ADE Data Collection Form 
Study of Adverse Drug Events in Children Presenting to the Janeway Emergency 
Department 
(Pediatric ED Chat1 Review) 
I. Reviewer 10 Team 1: Team 2: 
(Choose only one to 
identify yourself) 
1:3 . Porter B. Brennan S. Nose worthy 
Tucker 
2. Study 
Code: 
3.1 Pat ient's Age 
~years months(if <2 years) 9 _days(if < lrnonth) 
4. Has the patient been ad mined to the hosp ital ? 
4. 1 If YES. has the patient been admitted to the Critical Care 
Un it ') 
5. What is the chief complaint of the patient? 
6. Patienfs o ther presenting complaims 
3.2 Height 
feet inch 
D 0 "'Yes.2=No) 
E. 
3.3 Weigh t 
lbor 
kg 
7. Is there evidence in chan of any of the following health conditions? Check all rhm app(1 •. 
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l Astllm•l 15 Anllnus 
[[)p<:rdlOicSll"TOlcmiR 
_2 Reacti\e Airwnys _9 Acquired H~Jn Disease 16Seizure Disorder 
10 CardiacArrytllmia l7Substanct"Abuse 
_J Cen::hral Pab) _H Prolonged QT 
ll \eurumu\Cular Di"<!a~e _ Ill H)penen~ion 
_4SpmaBi1ida syndrOilll" 
_12 lnllamm:tWI) Bo11d 19 Migraine 
_5 Down Syndrome Disease 
_6 0therGcnetic 
Syndrt>ml" 
_7Leukemiaormber 
8. Current medication list: 
IJ Diabetl'5 
14 Kidney Disease 
9. Is there a history of new medication use 
w ithin past two weeks? 
9.1 lfYES. 
Please record 
H~adaclle 
_20 P~ychiatric 
Di">lm.kr 
_21 Pulmonal) 
Disease 
10 
_25 Otll~r 
_26Non~ 
D (I=Yes.2=No.3=Unknown) 
Durationofuse<da\S) ~ 
10. History of allergies reactions':' Medication D 
(!=Yes. 2= No.3= Un[.,nown) 
EnvironmcmaiD 
(I"'Yes. 2= No, 3=- UnknO\\n) 
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10.1 lf YES. give detHils of the allergy /reHction Hnd list suspected substHnces 
11. Ad,.erse Drug Event? I ADE 
(choose onl) one) 2 PotentiHI ADE (PADE) 
3 M~dication Error(ME) 
4 E:-.clude 
12. comments 
**CONTINUE only if AD£, PAD£ or ME judged :1s present, othen\•ise STOP 
here*** 
13. Confidence regarding above judgment _ I Little or no evidence 
2 Slight to modest evidence 
3 Less than 50· 50 but close call 
4 More than 50·50 but close call 
5 Strong evidence 
6 Vinuall} cet1ain evidence 
14. Information on medication. dose. freqltency and reaction for each event (i.e .. for 
ADE. PADE or ME) 
14.1 Name of the drug that 
resuhs with the event 
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14.2 Categories of 
complications of the event. 
Check all thai apply 
1-U Was the event caused 
by any of the listed errors? 
Check all !hal app~\' 
14.4 Did the patient have a 
documented previous 
allergy or reaction to the 
drug that caused the event? 
I 
__ 1 Bleeding 
2 CNS 
3 Allergic 
__ 4 Anaphylnxis 
5 Cutnneous 
6 Metabolic 
1 Overdose 
__ 2 Missing dose 
3 Underdose 
_ 4 \V rong dose 
form ordered 
5 Dose omitted 
from order 
6 No dose units 
7 Incorrect 
frequency 
__ 8 Frequency 
omi11ed 
__ 9 Drug-drug 
interaction 
I No 
7 Cardiovasculnr 
8 Gl 
9 Rennl 
10 Respiratory 
11 Marrow Depression 
12 
Other _____ _ 
10 Inappropriate 
drug 
(i ncludes 
duplicate) 
__ 11 Allergy to 
ordered drug 
__ 12 Wrong drug 
ordered 
13 Wrong patient 
14 Illegible order 
15 Preparation error 
16 Other 
2 lntolernnce (e.g. nausea. headache) 
3 Allerg} (reaction not documented) 
4 Allergy. not anaphylaxis (e.g. rash) 
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14.5 What was the result of 
the event? 
14.6 Who is the person 
primarily responsible? <!f 
mullip/e. choose the ,,en·ice 
you feel was the mo.'}t 
re.~ponsible) 
14.7 Did this event result in 
an additional visit? 
14.8 If yes. what type of 
visit? 
(check all thai app~)') 
14.9 Was the event caused 
by a medication that 
required outpatient 
5 Anaphylaxis 
6 Other ______ _ 
I No signs or symptoms 
2 Laboratol') abnormality on I) requiring change 
thcmp) 
3 Up to one day of symptoms 
4 I· 7 days o f symptoms 
5 7 d:~ys-1 month of symptoms 
6 >1 month of symptoms 
7 Other _______ _ 
I Physician 50ther 
2 Pll:lnll:IC)' 6 None 
3 Patient 7 Unkn01111 
4 Parents 
Yes 
No (skip IO qu~stion# 1./.9) 
I Required clinic visit only 
__ 2 Required emergenq room visit 
_ _ 3 Required admission to hospita l 
__ 4 Required admission to long-tenn faci lity 
5 Other ________ _ 
Yes 
No (sk1p to <JIIf!Wion;; /5) 
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Blood monitoring? 
14.10 If yes. ·was there an 
--
I Yes (explain ) 
elevated/ abnonnal level 
with the event? 
2 No 
\4.\1 Was there regular 
--
I Yes 
monitoring of the blood 
I 
1 No level prior to the event? 
15. Record any relevant lab data 
*"'For ADE & PADEs (o nly)*"'* 
\6. Severity of ADE fatal ADE 
(choose 011~r one) Life-threatening AD I:: 
3 Serious 
4 Signiticant ADE 
17. Disability/lnjmy associated with ADE Up to I day of symptoms 
(choose 011~1, one) Laboratory abnormality only 
requiring change in therapy 
More days of symptoms or 
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prolongation of hospitali7ation 
4 Non-pcnnanent d isabil ity at 
d ischarge 
5 Permanent disability 
6 Death 
"""* For ADEs, PADEs & MED ICATION ERRORS ,.."' 
18. Preventability- Implici t I Error intercepted 
(choose on~v one) 2 Definitely preventable 
3 Probably preventable 
Probably not 
preventable 
Definitely not 
preventable 
19. Could the event have been prevented by any of the following checks? Check alii hal 
app~v 
1 Drug-drug check -1 Drug-allergies test 
_ :! Drug-pt. characteristi cs test _5 Guided dose algorit lm1 
_3 Drug-dose check 6 
Othe,,· _________ _ 
20. Describe what failu res occu1Ted. and hu\\ they occurred. 
214 
21. Any other comments: 
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ADE SEVERITY CLASSIFICATION 
ADE is defined as an inj ury due to a drug. Severity of AD£ is classified into four C!llegories: 1= 
Fatal ADE. 2= Life-threatening AOE. 3= Serious and 4= Significam ADE. Definitions/ 
characteristics of them arc given below. 
II. LIFE TIIREATENTNG 
Definition 
An ADE is considered /{fi! 
threalening ilthe e1·em 
causes symptoms flwt ifnol 
treated u·ould pur the 
patient ar risk of demh. 
Life threatening A DEs also 
include laboratory values 
that are either elevated or 
depressed to the point that 
a critical physiologic 
function is at risk of fai lure. 
Ill. SERIOUS 
I Definition 
An ADE is considered to 
be serious if the event 
causes symptoms that are 
associated with a serious 
level of risk that is not high 
enough to be life 
threatening. In addition. an 
ADE is also serious if it 
causes persistent alteration 
oflite function. 
Serious A DEs can also 
include elevated or 
depressed lab values that 
require medical 
intervention. especially if 
they suggest organ system 
dystlmction. 
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IV. SIGNIFICANT 
Defi11ition 
An ADE is considered to 
be significant if the event 
causes symptoms that 
while harmful to the 
patient pose little or no 
threat to the patient"s life 
function. 
Signilicant ADEs can 
include elevated or 
depressed laboratory test 
levels. 
Symptoms/ Lab 
infOrmation•: 
Symptoms l.ab 
ii!/Ormation •· 
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Symptoms! Lab 
infOrmation•: 
POTENTIAL ADE SEVERITY CLASSIFICATION 
A potential AOE (PADE) is a medicat ion error that has the potential to harm the patient. but did 
not do so because it was intercepted or because the patient ''as lucky. Severity of PADE is 
classified into four categories: I= Fatal ADE. 2= Lifc~thrcatcning ADE, J- Serious and -l= 
Significant PADE. Definitions/ characteristics of them are given below. 
II. LifE 
THREATENING 
Definition 
A potelllial AD£ is 
considered l(fe 
rhrearn1ing ifrhe nent 
has the potentia/to cause 
.\ymptoms thar if nO! 
treclfed. would put I he 
pari em a1 risk of demh. 
Symploms! Lab 
i1![ormation *: 
Il l. SERIOUS 
Definition 
A potential ADE is 
considered to be serious if 
the event has the potential 
to cause symptoms that are 
associated with a serious 
level of harm that is not 
high enough to be life 
thn.:atcning. In addition. a 
potential ADE is s~.:rious if 
it has the potential to cause 
persistent alteration of life 
funct ion. 
Symploms! Lab 
information*· 
IV. SIGNif iCANT 
Definirion 
A potential ADE is 
considered to be 
significant if the event has 
the potential to cause 
symptoms that while 
harmful to the patient pose 
little or no threat to the 
patient's lif~ function. 
Symp10ms/Lab 
information* 
*Please mdtcate symplom!. lab w(ormal/011 flulf you considered to class((y the ewnllo a 
se1•eriry carexm:v. 
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APPENDIXD 
Trigger Assessment Tool and Data Collection Tool 
Used to Review of ED Charts for Detecting ADEs 
in Adult Patients 
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Appendix 0.1 . Adult ADE Trigger Assessment Tool 
Study of Adverse Drug Events in Adult Patients Presenting to the Emergency 
Departments of 
Health Science Center and St. Clare's Mercy Hospital 
Study code c=J DateofBirth(ddlmm/yyyy) Ll ______ _j 
Gender D Male D Femflle DateofERvisit(ddlrnmtyyyy) Ll ______ _j 
Trigge rs: 
D I.Fever D :!.Anaphylaxis 
D3. 1ctcr D 4. Urticnria or Eczcmn 
D5.Skinrash/ purpurallesion D 6. Flushing 
D 7. Bradycardia or Tachycardia D 8. Acute chest pain or Palpitation 
D 9.Cough D 10. Dyspnea 
D 11. Respiratory depression D 12. Nausea or vomiting 
D I3.He:~dache D 14. Abdominal pain 
D 15.DiarrhcaorConstipation D 16. Altered level of consciousness 
D 17. HallucinationfDelusion DIS. Angioedema 
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D 19. Acute non-traumatic eye problem 
(notdtK"toOM) D 21. Edema associated with introduction 
a new drug 
D 23.Fa!ls 
D 25. Hypoglycemia/Hyperglycemia 
(>20 or <2.8 mol/L) 
D 27. Hyperkalemia/Hypokalemia 
(>5.5 or <3.5 mmol/L) 
D 29. Coagulation Abnormalities 
{1-'TI> 90 secor li\R> 5 or Platekt < 150.000) 
~ 3 1. LFT (ASTI AL T 1bi l irubin 3 ULN) 
D 20.Seizure 
D 21. Recell! tremor 
(not diagnosed due to :my disease) 
D 24.SBP < 90or > 180mmHg 
D 26. Hypernatrcmia/ Hyponatremia 
(> 150or < IJOmmui!L) 
D 28. Leukocytosis/leukopenia 
(>30000 or <4000fmrn)\ 
D 30. Renal Fuction (Cr> 133 ~unoi / L ) 
D 32. Digoxin serum level >2.5 nmol L 
D 33. Theophylline serum level > 110 ~unoi/L D 34. Phenytoin serum level> 80 ~tmol/ L 
D 35. Clostridium difficile positive stool D 36. Lithium serum level > 1.5 mmo!IL 
D 37. Creatine Kinase (3 x ULN) D 38. Anemia (Hb < 100 giL) 
39 (a) IJ t ften• a lli.~tory• of medication use prior ro ER l'isit? D l'e.< 
39 (b) Is itdtmijietl as tl potemia/ADE? D J'e.,· 
39(c) If )'£5, wlwtwould be tlte probabili(l' of being all ADE? 
D l 'et:J' /ow D Low D illmlemte D High 
Comments: 
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Appendix 0.2. Adult ADE Data Collection Form 
Study of Adverse Drug Events in Adult Patients Presenting to the Emergency 
Departments of 
Health Science Center and St. Clare's Mercy Hospital 
1. Reviewer 10 
(Choose only one to 
identify yourself) 
(Adult ED Chan Review) 
Team I: 
C. Seviour J. Hawboldt 
1. Study 
Code 
c==J 3. Patient'smarital status _ 
4. ll:~s the p:~tient been :~dmitted to the hospital? 
Team 2: 
C. Pollock S. Young 
I Single 
2 Married 
3 Separated 
4 Divorced 
5 WidO\\ed 
6 Unknown 
D (I - Yes.2- No) 
4.1 JfYFS. has the patient been adm1ttc:d to the Critical Care Unit? D ( I .. Yc:~. 2"" No) 
5. What are the complaints of the patient? 
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6. Is there evidence in chan of any of the following health conditions? Check all Th(ll app~l' 
I l>iahetes 5Sei,ureDisorder 9 \ •hgraine l leadache 13 Gl 
DlslurblUlC•.' 
_2 Kidn~~ Oi,e<~se 6 Suh>t<~nce Ahtl'~ 
-
_ tn p,ychi:nricDborder 
I~ Otlwr 
-
J Animus _7 H}pcncnsion II Putmonal"\ Disease 
_~Can!io\ascutar 8 (VA 
-
1:! Chokstcr<>l 15 V•ne 
Dise:~se 
7. Current medicat ion list : 
10 
8. Is there a history of allergies? D ( l=Yes. 2= No. 3= Unknown) 
8. I If YES. what are the drugs that results an 
al lergy/ reaction? 
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9. Adverse Drug Event? 
(choose only one) 
I 0. Any comment at this point? 
I ADE 
Potential ADE (PADE) 
Medication Error (ME) 
Exclude 
9.1 The category of 
event after consensus 
WITHIN Team 
(if applicable) 
**CONTINUE only if AOE, PAOE or ME judged ns present, othen\'ise STOP 
here**"' 
II . Confidence regarding above judgment __ Little or no evidence 
Sl ight to modest evidence 
Less than 50-50 but close call 
4 More than 50-50 but close call 
5 Strong evidence 
6 Virtually certain evidence 
12. Information on medication. dose, frequency and reaction for each event (i .e .. for 
ADE, PADE or ME) 
12.1 Name of the drug that 
results with the event 
12.2 Categories of 
complications of the e\ent. 
Check alii hal app(l' 
I Dlccding 
2 CNS 
__ 3 Allergic/ cutaneous 
4 Metabolic 
5 Cardiovascular 
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6 Gl 
7 Renal 
__ 8 Respiratory 
9 Marrow Depression 
10 
12.3 Was the event caused 
by any of the listed errors? 
Check all rhar apply 
12.4 Did the patient have a 
documented previous 
allerg) or reaction to the 
drug that caused the event? 
12.5 What was the result of 
the event? 
1 Overdose 
_ 2 Miss ing dose 
3 Underdose 
__ 4 Wrong dose 
form ordered 
5 Dose omitted 
from order 
6 No dose units 
7 Incorrect 
frequenc y 
~ 8 Frequency 
omitted 
_ 9 Drug-drug 
interaction 
I No 
Other _____ _ 
_ 10 Inappropriate 
drug (includes duplicate) 
_ II Allergy to 
ordered drug 
__ 12 Wrong drug 
ordered 
13 Wrong patient 
14 Illegible order 
I 5 Preparation 
error 
16 Other 
2 Intolerance (e.g. nausea. headache) 
3 Allerg~ (reaction not documt'nted) 
4 Alkrg.y. not anaphyla:~:is (e.g. rash) 
5 Anaphyl:t:>.i:. 
60ther __ 
I No signs or symptoms 
2 Laboratory abnormality only requiring change 
therapy 
3 Up to one day of symptoms 
4 1-7daysofs~mptoms 
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12.6 Who is the person 
primarily responsible? (if 
mu!njJ!e. choose rhe service 
youfeelwas rhe mosr 
responsible) 
I~. 7 Did this event result in 
an additional visit? 
1:2.8 If yes. \\hat typt' of 
visit? 
(check all rhaF app~v) 
12.9 Was the event caused 
by a medication that 
required outpatient Blood 
monitoring? 
12.10 If yes, was there an 
elevated/ abnormal level 
with the event? 
12.11 Was there rt'gular 
monitoring of the blood 
le\ el prior to the event? 
5 7days-1 monthof symptoms 
6 > I month of symptoms 
7 Other _______ _ 
1 Physician 4 Other _____ _ 
2 Phannacy 5 None 
3 Pmicnt 6 Unknown 
Yes 
No (.,kip ro 'fii<'Srion= I -'- 'h 
I Required clinic visit onl) 
__ 2 Required emergent) room visit 
__ 3 Required :ldmission to hospital 
__ 4 Required admission to long-term facility 
5 Other ________ _ 
Yes 
No (skip 10 quewitmit I 3) 
Yes (explain) 
2 No 
Yes 
No 
\ 3. Patients most recent labs prior to visit 
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13.1 Creatinine (Cr) 
13.2 Bilirubin(BILT) ____ _ 
\3.3 Albumin (ALB) 
**For ADE & PADEs (only)*** 
14. Severity of ADE __ I Fatal ADE 
(choose on~y one) 
ADE 
2 Life-threatening 
3 Serious 
4 Signilicant ADE 
\5. Disability/Injury associaied with ADE 
(choose OI/~J' one) 
date _}_!_ 
dd!mm/yyyy 
date _!_}_ 
dd/mrn!Y))'Y 
date _!_!_ 
dd!m1nlyyyy 
14. 1 The categol)' of severity after 
consensus WITHIN Team 
(if applicable) 
Up to I day of symptoms 
Laboratory abnom1ality only 
requiring change in therapy 
More days of symptoms or 
prolongation of hospitalization 
4 Non-pcnnancnt disability at 
discharge 
5 Pennanent di sability 
6 Deuth 
"'**For A DEs, PAI)Es & ME DI CATI ON ERRORS*** 
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I 6. Preventability- Implicit__ 1 Error 
intercepted 
16.1 The category of 
preventability after consensus 
WITH TN Team 
(choose only one) 2 Dcfinitdy preventable 
(if applicable) 
3 Probably preventable 
4 Probably not 
preventable 
5 Oeiinitely not 
preventable 
17. Could the event have been prevented by any of the following checks? Check o!f thai 
apply 
_ 1 Drug·drug check _ 4 Drug-allergies test 
_ 2 Drug-pt. characteristics test _ 5 Guided dose algorithm 
_ 3 Drug-dose check _ 6 
Other _________ _ 
I 8. Do you feel the Pharmacy Nemork D (I~Yes. 2~ No. 
\\Ould have a\ aided this C\ ent? J=May be. 4=Unknown) 
19. Describe the system stage at which the failures identified above occurred. and the 
way in which they occurred: 
:20. Any other comments? 
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ADE SEVERITY CLASSIFICATION 
ADE is defined as an injury due to a drug. Severity of ADE is classified into four categories: 1-
Fatal ADE. :!= Life·tlueatening ADE. 3= Serious and 4= Sign ificant ADE. Definitions/ 
characteristics of them are given belO\\ . 
II. LIFE II. SERIOUS V. SIGNIFICANT 
HREATENING 
petinition peiinition lpe.finilion 
-In AD£ is co11sidered ~n ADE is considered to be serious i f ~n AD I:: is considered to 
!fe lhreafening ffrhe he event causes symptoms that are [be significant if the event 
vent causes symptoms ~ssociated with a serious level of risk a uses symptoms that 
hal if nor rremed. 1rottld hat is not high enough to be life fwhi le hannful to the 
'Jill/he pariem at risk f?f hreaten ing. In addition, an ADE is Patient pose litt le or no 
Ieath !so serious if it causes persistent hreat to the patient"s life 
.alteration of life function. function . 
ife threatening A DEs 
[so include laboratory ~erious A DEs can also include Signiticant A DEs can 
alues that are either levated or depressed lab values that inclL1de elevated or 
[evated or depressed to equire medical intervention. ~epressed laboratory test 
he point that a critical ~specially if they suggest organ levels. 
~hysiologic function is ystcm dysfunction. 
1 risk of failure. 
229 
ymproms ymptoms ymptom 
• Patient transferred to • A two-unit gastrointestinal bleed • Rash 
ICU 
• Cardiac arrest 
• Respiratory failure I 
requiring intubation 
• Mental status 
change- pt falls and 
gets intracranial 
hemorrhage 
• Anaphylaxis 
• Any use of fresh 
frozen plasma AND 
Vitamin K to reverse 
anticoagulation 
• 7-unit 
gastrointestinal 
bleed 
• Symptom requiring hospitalization • Diarrhea 
• Altered mental status/ excessive 
sedation 
• Allerg ic reaction- shaking chills/ 
fever 
• Angioedema. lip swelling 
• Symptomatic hypoglycemia 
• Bradycardia/dizziness/syncope 
• Jaundice 
• Ot1hostatic hypot~nsion 
• Urinary incontinence 
• Persistent sexual dysfunction 
• Confusion 
• Tardive dyskinesia 
• Clostridium Oifficile colitis 
230 
• Nausea and vomiting 
• Muscle weakness 
• Oral thrush 
• Dyspepsia 
• Cough 
• Dizziness 
• Fatigue 
• Constipation 
• Muscle cramps 
• Insomnia 
• Headaches 
• Pedal edema 
ab A bnomwli(J' 
• Any potassium S 2.5 
mEq/L 
or ~ 7.0 
mEq/L 
• Any phenytoin ~ 139 
~moJ/L 
• Any theophylline ~ 
167 ~mol/L 
• Any glucose < 1.67 
~mol/L 
• Any INR;::: 10 
• Any digoxin level > 
3.0 nglml 
• Lithium >4.0 
mmol/L 
ab Abnormalif) ' 
• Any potassium: 2.62: & <2.7 
mEq/L 
or 6.5 2:. & < 7.0 mEq/L 
• An) phen)toin: 119 2:. & < 139 
~unoi/L 
• Any theophylline: 139 2:. & < 167 
• lJ- 111 01/L 
• Any glucose: 1.67 2:. or < 1.94 
pmoi/L 
• Any JNR: 8 2': or < 10 
• Any digoxin: 2.5 2:. & < 3.0 ng/ml 
• Elevated QTc > 500 mil Iisee 
• Decreased platelet count to < 
20.000 
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ab A buomwlif)' 
• Any potass ium: 2.82:. 
& 2.9 mEq/L 
or 6.0 2: & < 
6.5 mEq/L 
• Any phenytoin: 992:. 
& <119 pmol/L 
• Any theophylline: 
Ill ~ & < 139 
pmoi/L 
• Any glucose: 1.9~2:. 
& <2.21 pmoi/L 
• Any INR: 6 ~ INR < 
8 
• Elevation in SGPT > 
150 U/L (ALT) 
POTENTIAL ADE SEVERITY CLASSIFICATION 
A potential ADE (PADE) is a medication error that has the potential to harm the patient, but did 
not do so because it was intercepted or because the patient was lucky. Severity of PADE is 
classified into four categories: 1= Fatal ADE. 2= Life-threatening ADE. 3= Serious and 4= 
Significant PADE. Definitions/ characteristics of them arc given below. 
II. LIFE 
THREATENING 
Definition 
A porenrial AD£ is 
considered l!fe 
threatening ({!he event 
has the potential ro cause 
symp1oms thai {(no! 
tre(lfed, would pulthe 
patiem at risk of dearh 
• Symptoms/ L<tb 
Abnom1ality 
Ill. SERIOUS IV. SIGNIFICANT 
Definition Definilion 
A potential ADE is A potential ADE is considered 
considered to be serious if to be significant if the event has 
the event has the potential the potential to cause symptoms 
to cause symptoms that that while hannfulto the patient 
are assoc iated with a pose little or no threat to the 
serious level of harm that patient's life function. 
is not high enough to be 
life threatening. In 
addi tion. a potential ADE 
is serious if it has the 
potential to cause 
persistent alteration of life 
function. 
• Symptoms/ Lab 
Abnonnality 
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• Symptoms/ Lab 
I 
Abnormality 
. 
I II. LIFE I Ill. SERIOUS 
THREATENfNG 
• Digoxin level greater • Chronic Indomethacin 
than 2.5 nglml AND use for an older adult 
Potassium level 
greater than 5.0 
mEq/L 
• Patient \.vith a prior 
penicillin-? 
anaphylaxis reaction 
and receiving a 
penicillin and no 
reaction 
• 2 concurrent tylenol 
prt'scriptions \\ ith a 
total daily dose > 15 
grams 
• Concurrent non-
aspirin NSA IDs 
prescribed to an older 
adult 
• Rofecoxib and 
Naproxen prescribed 
together 
• 2 concurrent tylcnol 
prescriptions with a 
total daily dose of> 
10 grams but 5 15 
grams 
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IV. SIGNIFICANT 
• Inappropriate medication for 
elderly 
• Phenobarbital not monitored 
>I year 
• Clozapinc prescribed and 
WBC not monitored > I 
month 
• Digoxin prescri bed and 
Digoxin level not monitored 
> \year 
• Woman taking tinasteride 
• 2 concurrent tylenol 
prescriptions with a total 
daily dose > 4 grams but :5 
10 grams 
• Cyclosporine levels not 
monitored >!year 
• Ketorolac prescribed for 7 
days 
• Divalprocx levels not 
monitored > I year 
• Elevated Lithium level due 
to drug-drug interaction 
between Lithium and 
Indomethacin 
APPENDIXE 
Estimation of ADE/PADE Prevalence in Adults Presenting to 
EDs: Sample Weight Adjustment to Account for the Sampling 
Fraction and Stra tification in the Sampling Design 
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General description on sampling design has been given in chapter 3 tOr steps to 
prepare a sample frame followed by a two·step chart review to determine adverse drug 
events (ADEs) in adults presenting to Emergency Depm1ments (EDs). Given that the 
study employed a stratified random sampling design along with a multistep review of ED 
chm1s. estimation of ADE preHllence was pertOrmed using a sample weight to account 
for the sampling fract ion and stratification in the sampling design. This appendix 
provides a brief description on the sampl ing scheme related to the sample "eight 
selection. and then a detail about the process of selecting sample weight leading to 
calculation of ADE/PADE prevalence. 
Sampling scheme and data collection 
The study population included a total of 82,516 ED visits by patients aged \8 
years and older in the calendar year 2005. After excluding ED visits that were by non-
residents or associated with high probability of not being due to an ADE (e.g .. motor-
vehicle-accident. substance abuse. drug abuse. attempted suicide. cut-or-burn injuries. 
etc.). there \.-vere 67.691 ED visits available for the sample frame. A stratified random 
sample of 1.458 ED charts "ere selected from this sample frame and reviewed tOr this 
study. Although the plan was to review an equal number of ED visits from each of the six 
strata. the number of ED visits actually reviewed ditTcrs slightly (Table E.l ). 
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Table E. I. Samrlling scheme for the first step chart review: Stratum-specific 
num ber of [ I) clutrts in the study SllnlJl lc 
Sample Size 
S tr:Ha 
(Number of E D ch<lrts) 
Stratum I: Male aged 18 - 44 years 241 
Stratlml 2: Male aged 45 -64 years 242 
Stratum 3: Male aged 65+ years 248 
Stratum 4· Female aged 18 - 44 years 241 
Stratum 5: Female aged 45 - 64 years 242 
Stratum 6: Female aged 65+ years 243 
Tota l 1,458 
ED - Emergency Department 
In the first step. the ED summaries of each of the 1.458 charts were reviewed by a 
team consisting of a physician and a regi stered mnsc using a manually enabled Trigger 
Assessment Tool. Following this review of the 1.458 ED visits. 653 were identified as 
having a high (29). moderate ( 135). low (218). or very low (271) probability of being the 
result of an ADE. Because of limited resources available for the swdy we were not able 
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to carry out the s~cond step revie\\ tOr all of these 653 charts. TherefOre. the review by 
the team. consisting two physicians and two pharmacists. at the step-2 was carried out on 
all charts that were classified havi ng a '·high" (n=29) or ··moderate·· (n=l35) probability 
of having A DEs. and only a sample of 170 ED visits classitied as having a "low" or "very 
IO\\ .. probability of having A DEs. Of the 526 ED charts reviewed in step 2. 334 (29 + 
135 + 170) was considered as the main sample and the remaining 192 was reviewed to 
validate the Trigger Assessment Tool. There were 55 (52+ 3=55) char1s detennined to 
have an adverse drug event or a poss ible adverse drug event (ADE/PADE) (Table E.2). 
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Table E.2. Results of the first step chart review followed by the sampling scheme for 
and resulls of the second step chru·t review 
Resulls of step I review by Step 2 review by 
"physiciltn & a nurse 2 EO physicians & 2 clinical pharmacists 
Sample size #of Ell charts with Probability of AilE ! #of [I) duu·ts 
I an ADEIPADE 
High 29 29 
Moderate 135 135 
Low 218 52 
170: 
Very Low 271 
None 805 192 
Total 1,458 526 55 
The matn sample for the second step rev1ew mcluded 334 (1.e .. 29+ \35+ 170-334) ED 
charts and the remaining 192 charts (a sample from the no probability of ADE group) 
were reviewed as part of the validation exercise. 
: included a random sample of 170 ED charts selected from the pool of low and very low 
probability classes consisting 489 charts (i.e .. 218+ 271 =489). 
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Sample weight adjustment and calculation of ADE/PADE 
prevalence 
Given the complexity in sampling design employed in this study. the analysis was 
carried out to calculated the prevalence of ADE/PADE by using: ( I) adjusted numerator 
and denominator to account for sampling frac tion associated with exclusion of ED visits 
in two-step re\ ie\\. and (2) the sample weight variable to account for stratification in the 
sampling design so that the sample estimate of prevalence of ADE/PADE is closer to the 
true prevalence in the study population. 
Numerator 11 nd denominator of prevalence of ADE/PADE to account for sampling 
fraction 
The 2-step review of the sampled ED charts identified 55 ADEs/PADEs. If the 
sample of 1.458 1-:1) charts \VCrc selected from the entire population. and each of these 
charts was reviewed in both steps. the prevalence of ADEIPADE would have been 
calculated by dividing 55 (numerator) by 1.458 (denominator). llowever, in recognizing 
the need to adjust for the excluded ED visits prior to selecting the study sample and for 
not reviewing all eligible charts at step 2. the numerator and denominator counts were 
adjusted to accoun1 for sampling fraction. 
Given that 3 of the 55 ADEs/PADEs were identified a tier reviewing 170 of489 
ED charts classilied as .. low/very lov.•· probability for ADE. we have taken inverse 
probability of the sampling fraction and estimated that there would be 9 evcms ((i.e .. 3 x 
1/( 170/489)=8.6) if all489 charts were reviewed. yielding an estimated count among the 
random sample of 1.458 charts to 52+9=61 ADEs/PADEs (numerator). The denominator 
of the prevalence of ADE/PADE "asset to 1.777 (i.e .. 1458 • 1/(67691 /82516)=1777) to 
account for the excluded ED vis its prior to the chart review. working with the ass umption 
that none of the excluded visits were attributed to an ADE/PADE. 
1n order to include- the 6 additional numerator counts (61-55=6) and the 319 
denominator coun ts (I. 777-1.458=319) in calculating the prevalence of ADE/PADE. we 
estimated the age group and sex for these additional patients. The age group and sex for 
the 6 patients with ADE/PADE were ass igned in proportion to the actual number of 
ADEIPA DE (55) whi le the 319 were assigned in proportion to the study sample (1.458). 
\\ ith rounding to the nearest whole number (Table E.J). 
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Table E .. 3 .. Distribution of 6 numerator and 319 denominator counts into six str.-ta with reference to actual AllE/ I)ADE 
counts (55) and study s:tnljllc {1,458) 
x::'!h = X 3; = 
n 2h = nl , * 
n 3h = 
Stl·ata xl" XI II * XI ; + nl h 3 19 / I ,458 ni h+ 
6 / 55 X 1; n 1h 
Male aged 18 - 44 years 2-l l 53 294 
Male aged 45 - 6-l )Cars 2-l2 53 295 
Male aged 65i years 19 2 1 2-lS 53 301 
Female aged 18 - 44 years 2-t2 53 295 
Female aged 45-64 years 2-t2 53 295 
Female aged 65t years 22 25 2-G 54 297 
24 1 
Total 55 61 1458 31'J 1777 
X 1 = Number o f A LJ EIPALJE dctcm1ined through chart rcviC\\. X 2 additional counts to the numerator following the 
adjustment tOr the sampling fraction. X 3 =Adjusted numerator coun ts. 11 1 = Size o f the study sample. n 2 additional 
counts to the denominator following the adjustment for the sampling fraction, and J1 3 =Adjusted denominator counts. The 
subscript h indicates h rh stratum. where h = I ,2 , ..... , 6 . 
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Sample weight va riable to account for stratification in sampling design 
The sample weight variable was derived to adjust for stratification in the sampling 
design so that each ED visit in the study sample represents the stratum.specific number of 
visits in the study population (Table E.4). 
Table EA. Derivation of sample weight to account for stratification in sampling 
design 
Adjusted 
Population 
Strata denominator Site Sample weight 
Male aged ! 8 - 44 years 294 20.! 13 1/(294/20.113)-68.41 
Male aged 45 - 64 years 295 11.827 1 /(295/1 1.827)~40.09 
Male aged 65+ years 301 7.035 I /(30 117.035 1~23.3 7 
Female aged ! 8- 44 years 295 23.027 1 /(295/23.027)~78.06 
Female aged 45 - 64 years 295 11.813 1/(295/ 11.81 3)~40.05 
Female aged 65+ years 297 8.701 1/(297/8.701 )~29.29 
Total 1,777 82,516 
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Ca lculation of preva lence of ADE/PADE and its 95'Yo confidence interva l 
In calculati ng prevalence or ADEs/PADEs. we used (1) adjusted numerator (61 
ADEs/PADr:s) and denominator (n=1.777) to account for sampling fraction. and (2) the 
sample weight variable to account for strati tication in the sampling design. 
The prevalence of ADE/PADE was calculated as 
where h indicates strata . h=l. 2. 3. 4. 5. 6. 
Nh is the number of ED visits in the h1h stratum ofthc study population. 
N= ~Nh is the total number of ED vis its in the study population 
Ph= xh/nh is the estimated proportion or ADE/PADE in stratum h 
xh is the adjlJStcd number ofADE/PADE in stratum h 
llh is the number of ED visit in denominator (adjusted sample size) stratum h 
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To determine the confidence interval for a prevalence or proportion estimated from 
stratified random sampling. the standard error (SE) of the proportion was derived using 
the follO\\ing equation: 
The 95% conlidenec interval for prevalence of ADE!PADE was calculated as 
The fonnulae "ith the notations given above have been taken ti·om Lohr_ SL ( 1999) 1 
Tahlt.· E.5 presents a worksheet us~d to calculat~ the o,·erall pn.:vatencc of ADE/PADE. 
After a sample weight adjustment to account for the sampling fraction and stratification 
in this study, the overall prevalence of ADEs/PADEs was dctcnnincd to be 2.4%. the 
standard error of the prevalence estimate was 0.003206042. and the 95% Cl was 1.8 • 3.0. 
The prevalence of ADEsfPADEs and its 95% Cis for males, females, and for three age 
groups \\ ere calculated using a similar approach. 
Note that we only used the adjusted ADE number of 61 to calculate prevalence 
and for extrapolation. Information related to those 55 ADEsfPADEs identified through 
the chart review were used for additional analysis given severity. preventability and drug 
related information was not available for these estimated 6 ADEs (6 1·55=6). 
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Table E.S. Worksheet to calcu late the weighted pre,•alcnee of ADE/PAOE is gh•en below. 
Strata Strata Nh " h :Xh ph ( 1-nt>fNh)* (N1,/N)"2 (Nh/N) p <,[,-1.96 P slr-1.96 
Name 
*P,h(I-P h)/(nh-1) *P.h *SE(P~~tr) (h) *SE(P ~~,) 
M 18-44 20.1 13 294 0 0.0000 0 0.000 
M -!5-64 11.827 295 3 0.0102 6.85829E-07 0.001 
M 65+ 7.035 301 21 0.0698 1.50516E-06 0.006 
F 18-44 23.027 295 4 0.0 136 3.49752E-06 0.00-! 
F 45-64 11.8 13 295 8 0.027 1 1.79325E-06 0.00-! 
F 65+ 8.701 297 25 0.0842 2.79694E-06 0.009 
Total 82,516 1,777 61 0.003206042 0.024 0.018 0.030 
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SE(pAstrj~ ~( 1 - P"'str=~(Nh!N) 95% Con lidcnce 
nh!Nh) ' *P"h =2.-J% interva l = (1.8, 3.0) 
(NhJNjA2' PAh (1-
PAh)/(nh-1 ) 
~0.003206042 
Nh is the number of ED visits in the h111 stratum o ft he study population: N= ~N11 is the total number of ED visits in the study 
population; P 11 = x1/ nh is the estimated proportion o r i\ DE/ I'ADE in stratum h: xh is the adjusted number of ADE/PADE in 
stratum h: nh is the num ber of ED visi t in denominator (adj us ted sample s ize) stratum h: P"str = prevalence o f A DE/PA DE 
after account ing or sampling fraction and stra tification: SE(P"'str)= Standard error of prevalence esti mate 
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APPENDIXF 
Multiple Regression Models for Analysis 
of ADR Count Data 
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The background infonnation and theoretic<JI aspects concerning the fOur models (Poisson. 
negative binomial. zero-inflated Poisson, and zero-inflated negative binomial) used in the 
analysis of the recurrent events of adverse drug reaction (ADR) in Chapter 4 are brielly 
described below. 
Background 
The data analyzed in Chapter 4 were from a population-based. retrospective. 
cohort study using administrative and patient hospital discharge records over a period of 
12 years. The study identified recurrent events of adverse drug reactions (ADRs). rather 
than only the first event. Frequencies of A DRs experienced by a patient in a given 
interval of time can be referred to as .. count data". These count data consist of on ly non-
negative integers. and its typical distribution is highly positively skewed. consisting of a 
high proportion of zero scores; this is because ADR incidents are relatively rare. and 
most will not sustain a serious ADR if they do experience minor reactions of medication 
use 1• This type of data can be modeled by a number of different probability distributions. 
depending on how the variance compares to the mean and whether there are a 
disproportionate number of zero counts. It is important to explicitly account for zeroes in 
analysis given that. similar to positive counts. they are outcome values. Proper statistical 
modeling is needed to generate accurate and reliable estimates in predicting number of 
ADRs. taking into account the large prop011ion of zero counts and the possibility of 
recurrent ADRs. As highlighted by Robertson et al. ~and Ullah et al. 3, several studies 
250 
have incorrectly assumed that count data followed a normal distribution and subsequently 
used inappropriate statistical models. Other studies used a transformation to induce 
nonnality .... although this can be problematic gi\en that transfonnations often do not 
yield normally d istributed data and can make the interpretation of regression coetliciems 
cumbersome as they are not estimated on the original scale. 
A potential solution to the afOrementioned problem is to use Poisson regression. 
Poisson regression is a commonly used statistical technique to model count data 5. For 
such coums. the Poisson regression model is better suited to explain the relationship 
between the outcome variable and a set of explanatory variables. However. count data 
often exhibit greater variability than allowed by the Poisson model- a condition called 
over-dispersion. If unaccounted. over-dispersion may have undue consequences such as 
biasing estimates. A common statistical method used to account for over-dispersion is 
negative binomial (NB) regression. In modeling the NB regression, the variance and 
mean are not assumed to be equal and the assumption of independence of observations is 
lifted 6. The NB model can also be appropriate when count data arc recurrent 3· 7. 
Rose and Marlin 8 have demonstrated three pOicrllial reasons for over-dispersion: 
unobserved heterogeneity. temporal dependency and/or excess zeroes in the data. 
Unobserved heterogeneity may be an issue when a population consists of several sub-
populations resulting from the fac t that the participants enrolled in the study sample are 
disti nct with respect to their socio-dcmographic or heal th-related factors. bllt the sub-
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population membership has not been observed in the data. Temporal dependency 
associated with multiple comorbidities diagnosed over time for each panicipant may be 
an issue resulting in over-dispersion. Although NB regression is able to model the data 
with over-dispersion. it is possible that this modeling approach st ill could fail to fit a set 
of data with many zero counts because ofzero-intlation. over-dispersion. or both 9 For 
thi s type of data. more zeroes are observed than would be predicted by a standard Poisson 
or NB models. As an alternative means. zero-intlated regression models such as zero-
inflated Poisson (ZIP) and zero-inflated negative binomial (ZIN B) address the issue of 
excess zeroes in their own rights of handling count data 10• 
In the analysis ofzero-intlated models, it is assumed that there are two latent or 
unobserved groups that could contribute to the excess zeroes. These two categories of 
excess zeroes are also referred to as structural or sampling zeroes H. For example. a 
subpopulation of patients may be from the zero state as they are not at risk of 
experiencing an ADR requiring hospitalization due to their personal characteristics 
(structural zeroes) and anot her subpopulation of patients may be susceptible to serious 
ADR requiring hospitalization in which occurrence of zero would be due to chance 
(sampling zeroes). ZIP and ZINB are the two models that recognize the existence of these 
two groups. and also allow for covariate adjustments in each group 11 For patient safety 
studies. the zero-inllated pot1ion can be thought of as the odds of moving from the non-
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risk to the at-risk group. Once in the at-risk grOllp we can detennine the expected number 
of events or the risk of an event for one group versus another group H_ 
The modeling considerations raised above have significant implications for the 
description of ADR data. When determining predicting factors of a rare event outcome 
such as ADR. and their directionality and magnitttde of association. correctly spcci fying 
the statistical models is of the utmost importance in getting proper inferences. Count data 
with an excess of zero counts have been analy7cd in several areas of research including 
manufacturing defects 10• road safety JJ_ agriculture and horticulture 13• species abundance 
14
• medical consultation 1 ~ . sexual behavior 16 and injury 17. However. to our knowledge, 
there have been no studies to date that focused on risk factors associated with recurrent 
events of ADR taking into consideration the complexity in data charactcri7cd by excess 
Lero and over-dispersion. An appropriate statistical model ma) allow for a better 
understanding of the relationship bcn.vcen patient-related factors and recurrent A DRs. 
and help identify potential risk factors that provide accurate and reliable information to 
guide policy decisions in relation of priority setting and intervention investments to tackle 
these unwanted events. 
The counts of ADRs in elderly hospitalized patients were modeled using the 
Poisson. NB. ZIP and ZINB. The basic regression equations directing how ADR counts 
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were modeled using the four targ~t regression models deserve methodological elaboration 
given in the following section. 
Theoretical Concepts of the Fou•· Regression Models 
The Poisson regression model is the most basic model that explicitly takes into 
account the non-negative integer-valued aspect of the dependent count variable. Because 
the Poisson distribution is usually appropriate to model the number of events. this 
regression model can be used in the prediction of likelihood or frequency of A DRs. In a 
study of A DRs. kt ) ~ be the random variable that reprcscms the munbcr of A DRs 
experienced by the patient i over the study period. and y , is a value of>~ . The mean of>~ 
is J.1 i . which is also a random variable with values p, . In this situation. the Poisson 
probability distribution of an ADR count )~ is 
P(Y ; ,. · J1 ) ; e-" 1',' 
I .- 1' I _\',! (I) 
where y, is a non-negative integer. that is. y, =0. 1, 2. 3 .. 
i indicates the number of cases or study patients with the data. 
that is. i = I.::!. J ... ... .... n: 
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It is usually assumed that the number of events >: follows a Poisson distribution with a 
conditional mean ( p , ) depending upon a set of regressors 
(x,0 ,x,1.x,2 , ... , x,k , where xw = 1) and corresponding parameters (/)0 ./)1./)2 • ... [Jk) for 
participants' linear predictor. Using a log link. the expected number of even ts for 
participant i can be written as 
Jl , = E(y , I x , ) = e' 'P,,,, 
Where xiJ is the ij'n element of the regressor X J . where i =I. 2. 3 ........... n. 
and }=0. I. 2. 3. . . ... k: 
/)0 is the intercept term: and 
jJ1• fl: .... {:J1. are the coefficients for k covariates/predictors. 
Because of the property of the Poisson distribution having equal mean and variance. the 
variance of Y, is 
V(y , l.r , ) = !1 , 
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The mean J.l, is always a positive value given that it represents the average number of 
A DRs of a specific patient i in the sllldy. Taking the exponential of I 1fi1 xl) ensure that 
the mean parameter J.l , is non-negative. 
The Poisson regression model is also referred to as the log-linear model since the 
logarithm of the conditional mean is linear in the parameters: 
ln[p, J=In[E(y,[ x, )J=l: , fJ,x ,, 
As noted earlier. the Poisson regression has been criticized due to its restrictive property 
that the conditional variance equals the condi ti onal mean. Real-life data arc often 
characteriLed by over-dispersion- that is. the variance exceeds the mean. l f over-
dispers ion is an issue, the estimated parameter based on Poisson regression will be 
inefficient 5• 
The equality of\ariance assumption of Poisson can be relaxed by using the 
negative binomial model. The NB regression model is a generalization of the Poisson 
regression model that allows for over-dispersion by introducing an unobserved 
heterogeneity tenn for study participants. In N[3 model. study subjects are assumed to 
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differ randomly in a manner that is not fully accounted for by the observed covariates. 
The probJbility distribution of an ADR count } ~ is giH~n by 
p y- ' - r(y, + Ji ll) (11!1, ) '• 
( , -.) ,)-r(y,+ I)r(J t ii)(J+IIp, ) '· · ' ' (2) 
where tl, . 0 and r ( •) arc the expected number of events. the NB dispersion parameter. 
and the gamma function. respectively. The conditional mean parameter p , can be 
expressed as f../1 = £(y, I X 1 ) = e~ ,Prr,, and the condit ional variance of.\', is 
l "(y, I x, ) = tl, (I+ Bp, ). Here. 8 is a dispersion in the NB model that represents over-
dispersion resulting from unobserved heterogeneity and/or temporal dependency. As 
8approaches zero. y becomes a Poisson distribution. and as 8 becomes larger. the 
distribution of y becomes more dispersed. 
Zero-inflated J>oisson and zero-inflated negative binomial models can be used to 
fit a set of data with many t:ero counts because ofzero-in!lation. over-dispersion or both 
Q 18' 19 The ZIP model for an ADR count >; can be delined as a mixture of two 
distributions incorporating extra zeroes: 
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!", +(1-;r,)e''' P(>~ = y,) = e''' p,'' (1-;r,)--
y,! 
Y, =0 
Y, > 0 
(3) 
where lr, is the probability of being an extra ?era that is often modeled by using 
logistic regression. II ere for ?cro inflated portion of ZIP and ZrNB regressions. we used 
the logistic model to estimate n, . and hence the ff , is estimated by llSing 
"=---/ I +e-"'' 
where. '7,1 = L ,P,x,1 is a linear predictor of explanatory variables (x). Zero- inflated 
models put more weight on the probability of observing a 7Cro by using a mixing 
distribution. Hence. for ZIP model (3) the probability of observing a zero is given by the 
sum of observing an excess zero plus the probability of observing a zero in the Poisson 
mode!. Clearly. the ZIP models allows for two separate processes. As a first step. it 
models the structural 7crocs (e.g .. logistic regression) and the second step models the 
Poisson distribution conditional on the e.xcess .:::eroes. i.e .. the Poisson regression models 
the sampling zeroes and counts 8. The mean and variance of the ZIP model are given by 
F:(y, I x , ) = (\- Jr , )p , 
l '(y, x , ) = 11, (\- If, )(I+ !I ,JT,) 
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It can be seen here that when ;r , equals zero the ZTP model reduces to the standard 
Poisson model, but when ;r , approaches one the variance increases and the data exhibit 
greater overdispersion. The over-d ispersion accounted for in the ZIP model is 
conceptually a result of the strucwral zeroes. Interpretation of the ZIP model depends 
upon what is being modeled. For patient safety studies. the zero-intlated portion can be 
thought of as the odds of moving from the non-risk to the at-risk group. Once in the at-
risk group we can determine the expected number of events or the risk of an event for one 
group versus another group. 
Zero-intlated negative binomial models are sometimes preferred because they 
aiiO\\ tOr more flexibility in the variance. The ZINB takes care of both over-dispersion 
and zero-inflated issues. The zero part performs analysis of dichotomous outcome and 
takes care of the zero-inllation (e.g .. no ADR ' s. ADR). and the negative binomial part 
carry out analysis of continuous outcome (e.g .. number of ADRs). The ZINB is 
" . 
tOrmulated as equation (3). replacing the Poisson distribution ~with the negative 
y ,! 
binomial d istribution in equation (:2). Therefore. the ZINB model fOr }; can be written as 
fOllow. 
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l;r+(l-;r-1 ' , )(\ +lip , )'' PO: = Y, ) = f( . + 1/ IJ) (II ) , I tr .J , 'J.i, 
( - , ) f (y, + l)f(l / 11) (I +ll11, ) ' _, 
v , =0 
(4) 
y , >0 
The mean ofZrNB model is same as the mean for ZIP model but the variance is 
given by J' (,I', I x , ) = p , (I - ;r , )[I + 11, (;r , +II, )]. It should be noted that the 
variance depends on 1r , and the dispersion parameter 0, . The ZTNB model takes into 
account that the non-zero counts might be correlated ~ The added flexibility of ZINB 
model is that it allows for over-dispersion arising from excess zeroes and heterogeneity. 
whereas the ZIP model only accommodates over-dispersion from excess zeroes. 
Model selection is one of the fundamental tasks of scientilic inquiry that choose 
the best model from a set of potential models. While several criteria can be used to 
compare and contrast the models given above. nested models can be tested using a 
likelihood rmio test (LRT). Since the Poisson model is nested within the NB model. and 
accordingly the ZIP model is nested with the ZINB model. a LRT can be used !Or this 
comparison. A maximum likelihood ratio 20 p~ is given by 
, _ 1_ L(Pl 
p - L(O) (O~p' ~ I) (5) 
where L(p) is the log likelihood function 
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and L(O) is restricted log likelihood. 
Of the tOur models. the Poisson model is not nested within the ZIP. and the NB 
model is not nested within the ZINB model. TherefOre. tOr the purpose of the comparison 
between non·nested models. the test proposed by Vuong ( 1989) can be used. If 
~(.v, I xn) and P~(.v, I x,1) are opposing predicted probability distributions. the Vuong 
statistic is computed as fo llows lUU 
(6) 
(7) 
In comparing the non-nested models given above. F; (v, I x,1 ) represents ZIP (or. 
ZINB) model and P~ (y, I x,1 ) represents the standard Poisson (or. NB) model. r or a 
sample of si7e n. the statistic m has a mean Iii and standard deviation S111 • The Vuong 
stat istic //asymptotically 10\lows standard nonnal distribution. If fl > 1.96 then it favors 
the 7ero intlated model and r'< -1. 96 favors the standard Poisson or NB model. 
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In addition to above two tests. the multiple regression models for the ADR study 
data leading to chapter 4 were compared by using the Bohning's 21 goodness-of-fit 
statistical test. the Wald test ~ 2 • and the Pearson' s chi-square test. A graphical 
presentation of predicted probabilities and Aaike information criteria (AI C) were also 
used to compare models. 
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